[go: up one dir, main page]

WO2018190643A1 - An isoxazole derivatives as nuclear receptor agonists and used thereof - Google Patents

An isoxazole derivatives as nuclear receptor agonists and used thereof Download PDF

Info

Publication number
WO2018190643A1
WO2018190643A1 PCT/KR2018/004277 KR2018004277W WO2018190643A1 WO 2018190643 A1 WO2018190643 A1 WO 2018190643A1 KR 2018004277 W KR2018004277 W KR 2018004277W WO 2018190643 A1 WO2018190643 A1 WO 2018190643A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclopropyl
phenyl
chloro
ethynyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/004277
Other languages
French (fr)
Inventor
Jae-Hoon Kang
Hong-Sub Lee
Yoon-Suk Lee
Jin-Ah Jeong
Sung-Wook Kwon
Jeong-Guen KIM
Kyung-Sun Kim
Dong-Keun Song
Sun-Young Park
Kyeo-Jin KIM
Ji-Hye Choi
Hey-Min HWANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IL Dong Pharmaceutical Co Ltd
Original Assignee
IL Dong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HRP20220026TT priority Critical patent/HRP20220026T1/en
Priority to PL18785171T priority patent/PL3612520T3/en
Priority to AU2018252880A priority patent/AU2018252880B2/en
Priority to ES18785171T priority patent/ES2904294T3/en
Priority to SG11201908235R priority patent/SG11201908235RA/en
Priority to US16/604,180 priority patent/US10988449B2/en
Priority to CA3059869A priority patent/CA3059869C/en
Priority to LTEPPCT/KR2018/004277T priority patent/LT3612520T/en
Application filed by IL Dong Pharmaceutical Co Ltd filed Critical IL Dong Pharmaceutical Co Ltd
Priority to RS20211546A priority patent/RS62711B1/en
Priority to SI201830504T priority patent/SI3612520T1/en
Priority to CN201880024769.3A priority patent/CN110678450B/en
Priority to JP2020506694A priority patent/JP6886074B2/en
Priority to EP18785171.2A priority patent/EP3612520B1/en
Priority to DK18785171.2T priority patent/DK3612520T3/en
Priority to IL269896A priority patent/IL269896B/en
Priority to MX2019012167A priority patent/MX394743B/en
Priority to BR112019021320-1A priority patent/BR112019021320B1/en
Priority to SM20220175T priority patent/SMT202200175T1/en
Priority to MYPI2019006047A priority patent/MY198265A/en
Priority to RU2019132135A priority patent/RU2741306C1/en
Priority to NZ758117A priority patent/NZ758117A/en
Priority to PE2019002025A priority patent/PE20191792A1/en
Priority claimed from KR1020180042545A external-priority patent/KR102168543B1/en
Publication of WO2018190643A1 publication Critical patent/WO2018190643A1/en
Priority to ZA2019/06541A priority patent/ZA201906541B/en
Priority to PH12019502326A priority patent/PH12019502326A1/en
Anticipated expiration legal-status Critical
Priority to US17/191,806 priority patent/US11912674B2/en
Priority to CY20221100082T priority patent/CY1124936T1/en
Priority to US18/420,478 priority patent/US20240262799A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to compounds useful as agonists for Farnesoid X receptor(FXR, NR1H4), pharmaceutical formulation comprising such compounds and its study for medicinal uses.
  • Farnesoid X receptor (FXR, NR1H4)is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. FXR is highly expressed in the liver, intestine, kidney, adrenal glands, white adipose tissue and in induced during adipocyte differentiation in vitro . (Cariu B. et al., J. Biol. Chem., 2006, 16, 11039-11049).
  • FXR regulates various physiological processed such as modulates regulrated of bile acid(BA) regulation, lipids/glucose metabolism, inflammation/fibrosis, but recently it has also been linked to the pathology of FXR receptors.
  • This nuclear receptor is the intracellular bile acid ⁇ “sensor” and its major physiological role is to protect liver cells from the deleterious effect of bile acids(BA) overload.
  • Intestine is the tissue expressing the first FXR target gene identified. Indeed IBAB-P is expressed in enterocytes and binds bile acids, thus limiting the free concentration of BA intracellularly and consequently their toxicity.(Makishima M, et al., Science, 1999, 284(5418), 1362-1365).
  • FXR is highly expressed in the liver and regulates key genes involved in BA synthesis, metabolism and transport including CYP7A1, UGT2B4, BSEP, MDR3, MRP2, ASBT, NTCP, OST ⁇ and OST ⁇ in humans.
  • FXR activation is down regulation of CYP7A1 and thus bile acid synthesis; this is accomplished through induction of SHP(Small Heterodimer Partner) which then represses CYP7A1 transcription(Claude T, et al., Arterioscler. Thromb. Vasc. Biol., 2005, 25, 2020-2031). Altered expression or malfunction of these genes has been described in patients with cholestatic liver disease.
  • FXR agonist 6-ethyl-chenodeoxycholic acid (6EtCDCA) was found to fully reverse the impairment of bile flow and to protect the hepatocytes against liver cell injury caused by the cytotoxic lithocholic acid.(Pelliciari R, et al., J. Med. Chem., 2002, 45(17), 3569-3572).
  • FXR also induces expression of SHP which represses transcription of the apical sodium dependent bile acid transporter(ASBT, SLC10A2) gene which encodes the hight affinity apical sodium dependent bile acid transporter that mouse bile acids from the intestinal lumen into the enterocyte as part of the enterohepatic recycling of bile acids.
  • ASBT apical sodium dependent bile acid transporter
  • SLC10A2 apical sodium dependent bile acid transporter
  • IBABP Ileal bile acid binding protein
  • FXR Fibroblast Growth Factor 15(rodents) or 19(monkeys, humans).
  • FXR activation has also been described to downregulate proinflammatory enzymes iNOS and COX-2, as well as migration of vascular smooth muscle cell migration.(Li YTY, et al., Arterioscler Thromb Vasc Biol., 2007, 27(12), 2606-2611). FXR is also expressed in hepatic stellate cells(HSC) which play a role in deposition of extracellular matrix during the fibrotic process. Treatment of cultured HSCs with the FXR agonist 6-ethyl-chenodeoxycholic acid(6EtCDCA) results in decreased expression of fibrotic markers such as ⁇ -smooth muscle actin and ⁇ 1(I)collagen.
  • HSC hepatic stellate cells
  • 6EtCDCA has also been reported to precent development and promote resolution of hepatic fibrosis in multiple rodent models of this disease.(Fiorucci S, et al., Gastroenterology, 2004, 127(5), 1497-1512; Fiorucci S, et al., J. Pharmacol. Exp. Ther., 2005, 314(2), 584-595).
  • bile acid(BA) are secreted with nile into the lumen of the small intestine to aid in the digestion and absorption of fat and fat-soluble vitamins,
  • the ratio of different BA determines the hydrophilicity of the bile acid pool and its ability to solubilize cholesterol.
  • FXR activation increases the hydrophilicity of the pool, decreasing the intestinal solubilization of cholesterol, effectively blocking its absorption.
  • FXR activation affects Triglyceride(TG) metabolism via several pathways such as Sterol regulatory element-binding transcription factor 1 (SREBF1), apoC-III, apoC-II, syndecan-1 and the VLDL receptor.
  • SREBF1 Sterol regulatory element-binding transcription factor 1
  • apoC-III apoC-III
  • apoC-II syndecan-1
  • VLDL receptor VLDL receptor
  • FXR agonist GW4064 or cholic acid treatment reduced plasma glucose levels and improved insulin sensitivity in three diabetic models(db/db, ob/ob and KK-A(y)mice)(Cariu B,et al., J. Biol. Chem., 2006, 281(16), 11039-11049 Zhang Y, et al., Proc. Natl. Acad. Sci., 2006, 103(4), 1006-1011; Ma K, et al., J. Clin. Invest., 2006, 116, 1102-1109). This demonstrates that FXR is involved in glucose metabolism.
  • FXR activity has been implicated in variety of diseases, including, but not limited to disorder of bile acid homeostasis, inflammation/fibrosis and hight levels of plasma triglyceride(TG)/ cholesterol.
  • FXR agonists INT-747(OCA) and EDP-305 are modified bile acid(BA),developed for the treatment of diseases caused by disorder of bile acid homeostasis such as Nonalcoholic fatty liver disease(NASH), Alcoholic disorders, Primary biliary cirrhosis(PBC), Primary sclerosing cholangitis(PSC) and caused clinical side effects for the accumulation of substances in the body.
  • diseases caused by disorder of bile acid homeostasis such as Nonalcoholic fatty liver disease(NASH), Alcoholic disorders, Primary biliary cirrhosis(PBC), Primary sclerosing cholangitis(PSC) and caused clinical side effects for the accumulation of substances in the body.
  • NASH Nonalcoholic fatty liver disease
  • PBC Primary biliary cirrhosis
  • PSC Primary sclerosing cholangitis
  • small molecule compounds such as FXR agonist were derived form GW4064, PX-102(GS-9674)/PX-104 and Global Pharmaceutical Company published various patent with various derivatives(WO2000037077, WO2003015771, WO2004048349, WO2009012125, WO2009149795, WO2011020615, WO2013037482 and WO2016097933).
  • FXR agonist is development as target for variety treatment of diseases, including, but not limited to disorder of bile acid homeostasis, inflammation/fibrosis and hight levels of plasma triglyceride(TG)/ cholesterol so that worldwide attention is focused.
  • the present invention is expected that patients with metabolic diseases, including, but not limited to cholestatic Liver Diseases, Organ Fibrosis and Liver Fibrosis, will be able to open a therapeutic field of new mechanism.
  • the present invention is related to compounds of excellent activity as FXR agonist. Particularly, the present invention relates to derivatives and processes for the preparation thereof.
  • the object of the present invention is to provide medical use for useful treatment of diseases, for modulating the activity as FXR receptors and for the treatment, prevention or amelioration of one or more symptoms of disease or disorder related to the activity of the receptors, including, but not limited to hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, dyslipidemia, lipodystrophy, cholestasis/fibrosis, cholesterol gallstone disease, gastrointestinal disease or condition, hyperglycemia, diabetes, insulin resistance, metabolic inflexibility, nephropathy, liver diseases, atherosclerosis, cancer, inflammatory disorders, osteoporosis and skin aging.
  • diseases for modulating the activity as FXR receptors and for the treatment, prevention or amelioration of one or more symptoms of disease or disorder related to the activity of the receptors, including, but not limited to hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, dyslipidemia, lipodystrophy, cholestasis/fibrosis, cholesterol gallstone disease, gastrointestinal
  • the present invention provides a compound represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
  • Y is carbon or nitrogen
  • R 1 and R 2 are each independently hydrogen, halo or trifluoromethyl
  • n 0, 1 or 2
  • X 1 , X 2 and X 3 are each independently carbon or nitrogen
  • R 3 and R 4 are each independently hydrogen, halo, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , , CONR a1 R a2 , NR a1 R a2 , CH 2 NR a1 R a2 , CH 2 R c3 , COR a3 , OR a3 , NR a4 COR a3 , NR a4 CO 2 R a3 , NHCONHR a3 , NHSO 2 R a3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • n 1 or 2
  • R a1 and R a2 are each independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a3 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a4 is hydrogen or C 1-6 alkyl
  • R 5 is hydrogen, , , , , or ,
  • R 6 and R 7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
  • R c3 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl,
  • W 1 , W 2 and W 3 are each independently oxygen, nitrogen, CHR w1 , CR w1 , NR w1 or CO,
  • R w1 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, C 1-6 alkylamine, C 1-6 alkyl alcohol, , (CH 2 ) p heteroaryl or (CH 2 ) p aryl, wherein, p is 1, 2 or 3.
  • the present invention provides a compound represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
  • the present invention provides a pharmaceutical composition for the treatment, prevention, or amelioration of metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis comprising the compound represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
  • the present invention provides a use for the treatment, prevention, or amelioration of metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis comprising the compound represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
  • the present invention provides a method for the treatment, prevention, or amelioration of metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis in a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof to the subject(including human).
  • the compounds of the present invention are highly active as FXR agonist, and according to its pharmaceutical compositions are expected to be useful for therapeutic applications which are improved by FXR agonist, such as metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis.
  • the present invention provides a compound represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.:
  • Y is carbon or nitrogen
  • R 1 and R 2 are each independently hydrogen, halo or trifluoromethyl
  • n 0, 1 or 2
  • X 1 , X 2 and X 3 are each independently carbon or nitrogen
  • R 3 and R 4 are each independently hydrogen, halo, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , , CONR a1 R a2 , NR a1 R a2 , CH 2 NR a1 R a2 , CH 2 R c3 , COR a3 , OR a3 , NR a4 COR a3 , NR a4 CO 2 R a3 , NHCONHR a3 , NHSO 2 R a3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • n 1 or 2
  • R a1 and R a2 are each independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a3 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a4 is hydrogen or C 1-6 alkyl
  • R 5 is hydrogen, , , , , or ,
  • R 6 and R 7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
  • R c3 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl,
  • W 1 , W 2 and W 3 are each independently oxygen, nitrogen, CHR w1 , CR w1 , NR w1 or CO,
  • R w1 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, C 1-6 alkylamine, C 1-6 alkyl alcohol, , (CH 2 ) p heteroaryl or (CH 2 ) p aryl, wherein, p is 1, 2 or 3.
  • the compound of Formula I is preferably selected form i) or iv) disclosed below:
  • R 3 and R 4 are each independently hydrogen, halo, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, trifluoromethyl, , , , , NR a1 R a2 , CH 2 NR a1 R a2 , OR a3 , , NR a4 CO 2 R a3 , , or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein, wherein, m is 1 or 2, R a1 and R a2 are each independently hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, trifluoromethyl, , azetidine or piperidine, R a3 is hydrogen, methyl, ethyl, propyl, tert-butyl, cyclopropyl, trifluoromethyl, , , , azet
  • Z is , R c3 is hydrogen or methyl, R w1 is hydrogen, methyl, ethyl, propyl, cyclopropyl, , , , , , or .
  • R 1 and R 2 are each independently hydrogen, chloro or trifluoromethyl
  • R 3 and R 4 are each independently hydrogen, chloro, fluoro, iodo, cyano, methyl, ethyl, isopropyl, cyclopropyl, trifluoromethyl, , , , , NR a1 R a2 , CH 2 NR a1 R a2 , NR a4 CO 2 R a3 , azetidine, piperazine or pyrrolidine
  • R a1 and R a2 are each independently hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, trifluoroethyl, , azetidine, piperidine or oxetane
  • R a3 is hydrogen, methyl, ethyl, tert-butyl, cyclopropyl, triflu
  • Z is , R 1 and R 2 are each independently hydrogen, chloro or fluoro, n is 0 or 1, R 5 is , W 1 , W 2 and W 3 are each independently oxygen, nitrogen, CR w1 or NR w1 , wherein, R w1 is hydrogen, methyl, ethyl, isopropyl, cyclopropyl, , , , , or .
  • C 1-6 alkyl is a saturated hydrocarbonyl amine with linear or branched chains of 1-6 carbon atoms.
  • exemplary alkyl include, but are not limited, to methyl, ethyl, propyl, butyl, pentyl, hexyl, 1-methylethyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 1-methylbutyl, 1,1-dimethylpropyl, 1-methylpentyl or 1,1-dimethylbutyl.
  • C 3-6 cycloalkyl is intended as a saturated hydrocarbonyl ring with 3-6 carbon atoms.
  • exemplary cycloalkyl include, but are not limited, to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • C 1-6 alkylamine is a saturated hydrocarbonyl amine with linear or branched chains of 1 ⁇ 6 carbon atoms.
  • exemplary alkylamines include, but are not limited, to methylamine, ethylamine, propylamine, butylamine, 1-methylethylamine, diethylamine or dimethylamine.
  • C 1-6 alkyl alcohol is an R-OH group with R as defined above.
  • exemplary alkyl alcohol with 1-6 carbon atoms include, but are not limited, to methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol or n-butyl alcohol.
  • halo is intended as bromine, fluorine, or chlorine atom.
  • halo C 1-6 alkyl is intended as a C 1-6 alkyl radical having one or more hydrogen atoms replaced by a halogen atom as defined above.
  • exemplary haloalkyl include, but are not limited, to difluoromethyl or trifluoromethyl.
  • aryl is intended as aromatic ring with single ring and substituted a halogen.
  • exemplary aryl include, but are not limited, to phenyl or halo phenyl.
  • heteroaryl is intended as a monocyclic ring with at least one nitrogen, oxygen or sulfur atom.
  • exemplary heteroaryl include, but are not limited pyridinyl, quinolyl, furanyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, imidazolyl, pyrimidinyl, indolyl, pyrazinyl or indazolyl.
  • heterocycle is intended as a saturated or partially unsaturated hydrocarbonyl mono-tricyclic ring with at least one nitrogen atom.
  • exemplary mono heterocycles with 5-6 atoms include, but are not limited, to pyrrolidinyl, piperidinyl, piperazinyl pyrollyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, triazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl.
  • exemplary bicyclic aromatic ring include, but are not limited, to benzothiazolyl, benzoxazolyl, benzoxazinone, benzoxadiazolyl, 1,3-benzodioxolyl, benzofuryl, benzopyrazinyl, indolyl, indazolyl, benzimidazolyl, benzopyranyl, pyrolopyridanyl, furopyridinyl, or imidazothiazolyl.
  • pharmaceutically acceptable when referring to a component of a pharmaceutical composition means that the component, when administered to an animal, does not have undue adverse effects such as excessive toxicity, irritation, or allergic response commensurate with a reasonable benefit/risk ratio.
  • treatment covers any treatment of a disease in a mammal, particularly a human, and includes inhibiting the disease, i.e., arresting its development; or relieving the disease, i.e. causing regression of the disease and/or its symptoms or conditions and slowing disease progression.
  • terapéuticaally effective amount means an amount of a compound of the present invention that ameliorates, attenuates or eliminates a particular disease or condition or prevents or delays the onset of a particular disease or condition.
  • the compounds of the invention may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention.
  • a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
  • a 50:50 mixture of enantiomers is referred to as a racemic-mixture or a racemate.
  • Diastereomer refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
  • Enantiomers refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
  • phrases "pharmaceutically acceptable salt” as used herein, refers to pharmaceutically acceptable organic or inorganic salts of a compound of the invention.
  • Exemplary salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate "mesylate", ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate(i.e., 1,1'-methylene-bis-(
  • a pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counter ion.
  • the counter ion may be any organic or inorganic moiety that stabilizes the charge on the parent compound.
  • a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counter ion.
  • the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid
  • an inorganic acid such as hydro
  • the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine(primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like.
  • suitable salts include, but are not limited to, organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
  • the present invention provides a method of preparing the compound represented by Formula I or a pharmaceutically approved salt thereof.
  • the compound of Formula A8, which is a compound of the present invention, may be prepared by series of steps from the compound of Formula A2 as shown in Scheme 1.
  • R 6 and R 7 of Formula A8, A2 and A7, illustrated in Scheme 1, are defined as below.
  • R 6 and R 7 is each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy.
  • the preparation method of the Formula A8 according to the present invention comprise:
  • a compound of Formula A2 may be converted to Formula A3 by reductive amination under conditions of hydroxyl amine and sodium hydroxide in ethanol and distilled water at 90°C for 24 hours.
  • a compound of Formula A3, prepared as described in step 1 may be converted to Formula A4 by chlorination carried out in the presence of chlorination reagents in one or more of N,N -dimethylformamide, or chloroform at room temperature for 1 hour.
  • Example of preparing the compound of Formula A4 from the compound of Formula A3 by chlorination in the above Step 2 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula A4 prepared as described in step 2 may be converted to Formula A6 by cyclization with Formula A5 under basic condition at room temperature for 24 hours.
  • Example of preparing the compound of Formula A6 from the compound of Formula A4 and A5 by cyclization in the above Step 3 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula A6, prepared as described in step 3 may be converted to Formula A7 by reduction carried out in the presence of reducing reagent in THF at room temperature for 7 hours.
  • Example of preparing the compound of Formula A7 from the compound of Formula A6 by reduction in the above Step 4 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula A7 prepared as described in step 4 may be converted to Formula A8 by bromination carried out in the presence of bromination reagent in dichloromethane at room temperature for 4 hours.
  • Example of preparing the compound of Formula A8 from the compound of Formula A7 by bromination in the above Step 5 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula I which is a compound of the present invention, may be prepared by series of steps from the compound of Formula B2 as shown in Scheme 2.
  • Y is carbon or nitrogen
  • R 1 and R 2 are each independently hydrogen, halo or trifluoromethyl
  • n 0, 1 or 2
  • X 1 , X 2 and X 3 are each independently carbon or nitrogen
  • R 3 and R 4 are each independently hydrogen, halo, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , , CONR a1 R a2 , NR a1 R a2 , CH 2 NR a1 R a2 , CH 2 R c3 , COR a3 , OR a3 , NR a4 COR a3 , NR a4 CO 2 R a3 , NHCONHR a3 , NHSO 2 R a3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • n 1 or 2
  • R a1 and R a2 are each independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a3 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a4 is hydrogen or C 1-6 alkyl
  • R 5 is hydrogen, , , , , or ,
  • R 6 and R 7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
  • R c3 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl,
  • W 1 , W 2 and W 3 are each independently oxygen, nitrogen, CHR w1 , CR w1 , NR w1 or CO,
  • R w1 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, C 1-6 alkylamine, C 1-6 alkyl alcohol, , (CH 2 ) p heteroaryl or (CH 2 ) p aryl, wherein, p is 1, 2 or 3.
  • the preparation method of the Formula I according to the present invention comprise:
  • the compound of Formula B3 may be prepared by protection of hydroxyl group of Formula B2 using tert-Butyldimethylsilyl chloride(TBSCl) and imidazole in N,N -dimethylformamide at room temperature for 6-24 hours.
  • TBSCl tert-Butyldimethylsilyl chloride
  • the compound of Formula B3, prepared as described in step 1 may be converted to Formula B4 by Sonogashira reaction using catalytic amount of tetrakis(triphenylphosphine)palladium(0)(Pd(PPh 3 ) 4 ) or bis(triphenylphosphine)palladium(II) dichloride(PdCl 2 (PPh 3 ) 2 ) in one or more of N,N -dimethylformamide or methanol at 70-100°C for 3-24 hour.
  • Example of preparing the compound of Formula B4 from the compound of Formula B3 by Sonogashira reaction in the above Step 2 of the preparing method of the present invention is in the following reaction scheme
  • the compound of Formula B4 may be converted to Formula B5 by deprotection of tert-butyldimethyloxy( ) using either Potassium fluoride in one or more of tetrahydrofuran or methanol or Tetrabutylammonium fluoride solution at 0°C to room temperature for 1-6 hours.
  • Example of preparing the compound of Formula B5 from the compound of Formula B4 by deprotection reaction in the above Step 3 of the preparing method of the present invention is in the following reaction scheme.
  • the compound of Formula B5, prepared as described in step 3 may be converted to Formula B6 by substitution of with A8 under basic conditions in one or more of THF or N,N -dimethylformamide at room temperature for 5-24 hours.
  • Example of preparing the compound of Formula B6 from the compound of Formula B5 with A8 by substitution in the above Step 4 of the preparing method of the present invention is in the following reaction scheme.
  • the compound of Formula B6, prepared as described in step 4 may be converted to Formula I by Sonogashira reaction with B7 using catalytic amount of tetrakis(triphenylphosphine)palladium(0)(Pd(PPh 3 ) 4 ) or bis(triphenylphosphine)palladium(II) dichloride(PdCl 2 (PPH 3 ) 2 ) and Copper(I)iodide under basic condition in one or more of tetrahydrofuran or N,N -dimethylformamide at 70-100°C for 3-24 hour.
  • the compound of Formula I can be prepared from Formula B6 with B7 by Sonogashira reaction with hydrolysis using lithium hydroxide in one or more of tetrahydrofuran, 1,4-dioxane or water at 80°C for 4-48 hours.
  • Example of preparing the compound of Formula I from the compound of Formula B6 with B7 by Sonogashira reaction or hydrolysis after Sonogashira reaction from in the above Step 5 of the preparing method of the present invention is illustrated below.
  • the compound of Formula I which is a compound of the present invention, may be prepared by series of steps from the compound of Formula B6 as shown in Scheme 3.
  • R 1 , R 2 , R 6 , R 7 , Y and Z of Formula I, B2 and B7, illustrated in Scheme 3, are defined as below.
  • Y is carbon or nitrogen
  • R 1 and R 2 are each independently hydrogen, halo or trifluoromethyl
  • n 0, 1 or 2
  • X 1 , X 2 and X 3 are each independently carbon or nitrogen
  • R 3 and R 4 are each independently hydrogen, halo, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , , CONR a1 R a2 , NR a1 R a2 , CH 2 NR a1 R a2 , CH 2 R c3 , COR a3 , OR a3 , NR a4 COR a3 , NR a4 CO 2 R a3 , NHCONHR a3 , NHSO 2 R a3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • n 1 or 2
  • R a1 and R a2 are each independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a3 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a4 is hydrogen or C 1-6 alkyl
  • R 5 is hydrogen, , , , , or ,
  • R 6 and R 7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
  • R c3 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl,
  • W 1 , W 2 and W 3 are each independently oxygen, nitrogen, CHR w1 , CR w1 , NR w1 or CO,
  • R w1 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, C 1-6 alkylamine, C 1-6 alkyl alcohol, , (CH 2 ) p heteroaryl or (CH 2 ) p aryl, wherein, p is 1, 2 or 3.
  • the preparation method of the Formula I according to the present invention comprise:
  • the compound of Formula B6, prepared as described in step 4 in scheme 2 may be converted to Formula D2 by Sonogashira reaction with Formula D1 using catalytic amount of tetrakis(triphenylphosphine)palladium(0)(Pd(PPh 3 ) 4 ) or bis(triphenyl phosphine)palladium(II) dichloride(PdCl 2 (PPH 3 ) 2 ) and Copper(I)iodide under basic condition in one or more of tetrahydrofuran or N,N -dimethylformamide at 70-100°C for 3-24 hour
  • Example of preparing the compound of Formula D2 from the compound of Formula B6 with D1 by Sonogashira reaction in the above Step 1 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula D2 prepared as described in step 1 may be converted to Formula I by hydrolysis using lithium hydroxide in one or more of tetahydrofuran, 1,4-dioxane or water at rt-80°C for 4-48 hours followed by deprotection in the presence of boron tribromide solution or hydrogen chloride solution in dichloromethane or tetahydrofuran(THF) at 0-80°C for 2-24 hours.
  • Example of preparing the compound of Formula I from the compound of Formula D2 by hydrolysis and deprotection reaction in the above Step 2 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula I which is a compound of the present invention, may be prepared by series of steps from the compound of Formula B6 as shown in Scheme 4.
  • R 1 , R 2 , R 6 , R 7 , R e1 , R e2 , Y and Z of Formula I, B6 and E3, illustrated in Scheme 4, are defined as below:
  • Y is carbon or nitrogen
  • R 1 and R 2 are each independently hydrogen, halo or trifluoromethyl
  • n 0, 1 or 2
  • X 1 , X 2 and X 3 are each independently carbon or nitrogen
  • R 3 and R 4 are each independently hydrogen, halo, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , , CONR a1 R a2 , NR a1 R a2 , CH 2 NR a1 R a2 , CH 2 R c3 , COR a3 , OR a3 , NR a4 COR a3 , NR a4 CO 2 R a3 , NHCONHR a3 , NHSO 2 R a3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • n 1 or 2
  • R a1 and R a2 are each independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a3 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a4 is hydrogen or C 1-6 alkyl
  • R 5 is hydrogen, , , , , or ,
  • R 6 and R 7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
  • R c3 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl,
  • W 1 , W 2 and W 3 are each independently oxygen, nitrogen, CHR w1 , CR w1 , NR w1 or CO,
  • R w1 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, C 1-6 alkylamine, C 1-6 alkyl alcohol, , (CH 2 ) p heteroaryl or (CH 2 ) p aryl, wherein, p is 1, 2 or 3.
  • the preparation method of the Formula I according to the present invention comprise:
  • the compound of Formula B6, prepared as described in step 4 in scheme 2 may be converted to Formula E2 by Sonogashira reaction with Formula E1 using catalytic amount of tetrakis(triphenylphosphine) palladium(0)(Pd(PPh 3 ) 4 ) or bis(triphenylphosphine)palladium(II) dichloride (PdCl 2 (PPh 3 ) 2 ) and Copper(I) iodide under basic condition in one or more of tetrahydrofuran or N,N -dimethylformamide at 70-100°C for 3-24 hour.
  • Example of preparing the compound of Formula E2 from the compound of Formula B6 with E1 by Sonogashira reaction in the above Step 1 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula E2 prepared as described in step 1 may be converted to Formula E3 by reduction or reductive amination depending on the type of the substituent R e1 .
  • the desired compound of Formula E3 may be prepared by reduction or reductive amination.
  • the above reduction reaction may be carried out by Tin(II) chloride dehydrate in ethyl acetate or ethanol with the compound of Formula E2(When R e2 is nitro in the above Formula) at room temperature for one day and it is illustrated in the following reaction scheme.
  • the compound of Formula E2 (When R e1 is aldehyde in the above Formula) also may be converted to Formula E3(A substituent maybe introduced in the presence of sodium carbonate and R c4 -I in N,N -dimethylformamide) by reductive amination in the presence of sodiumtriacetoxyborohydride(NaBH(OAc) 3 ) or acetic acid in one or more of dichloromethane or 1,2-dichloroethane at room temperature for overnight and it is illustrated in the following reaction scheme.
  • the compound of Formula E3, prepared as described in step 2 may be converted to Formula I by hydrolysis using lithium hydroxide in one or more of tetrahydrofuran, 1,4-dioxane or water at rt - 80°C for 4-48 hours.
  • Example of preparing the compound of Formula I from the compound of Formula E3 by hydrolysis in the above Step 3 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula I which is a compound of the present invention, may be prepared by series of steps from the compound of Formula B6 as shown in Scheme 5.
  • R 1 , R 2 , R 3 , R 6 , R 7 , Y and Z of Formula I, B6 and G4, illustrated in Scheme 5, are defined as below:
  • Y is carbon or nitrogen
  • R 1 and R 2 are each independently hydrogen, halo or trifluoromethyl
  • n 0, 1 or 2
  • X 1 , X 2 and X 3 are each independently carbon or nitrogen
  • R 3 and R 4 are each independently hydrogen, halo, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , , CONR a1 R a2 , NR a1 R a2 , CH 2 NR a1 R a2 , CH 2 R c3 , COR a3 , OR a3 , NR a4 COR a3 , NR a4 CO 2 R a3 , NHCONHR a3 , NHSO 2 R a3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • n 1 or 2
  • R a1 and R a2 are each independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a3 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a4 is hydrogen or C 1-6 alkyl
  • R 5 is hydrogen, , , , , or ,
  • R 6 and R 7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
  • R c3 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl,
  • W 1 , W 2 and W 3 are each independently oxygen, nitrogen, CHR w1 , CR w1 , NR w1 or CO,
  • R w1 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, C 1-6 alkylamine, C 1-6 alkyl alcohol, , (CH 2 ) p heteroaryl or (CH 2 ) p aryl, wherein, p is 1, 2 or 3.
  • the preparation method of the Formula I according to the present invention comprise:
  • the compound of Formula B6, prepared as described in step 4 in scheme 2 may be converted to Formula G2 by Sonogashira reaction with Formula G1 using catalytic amount of tetrakis(triphenylphosphine)palladium(0)(Pd(PPh 3 ) 4 ) or bis(triphenyl phosphine)palladium(II) dichloride(PdCl 2 (PPh 3 ) 2 ) and Copper(I) iodide under basic condition in one or more of tetrahydrofuran or N,N -dimethylformamide at 70-100°C for 3-24 hour.
  • Example of preparing the compound of Formula G2 from the compound of Formula B6 with G1 by Sonogashira reaction in the above Step 1 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula G2 prepared as described in step 1 may be converted to Formula G3 using Tin(II) chloride dehydrate in ethyl acetate or ethanol at room temperature for one day and it is illustrated in the following reaction scheme.
  • the compound of Formula G3 prepared as described in step 2 may be converted to Formula G4 by substitution or addition.
  • the desired compound of Formula G4 may be prepared by substitution or addition.
  • the compound of Formula G3 may be converted to Formula G4 by the above substitution in the presence of tert-butylnitrile with iodine in toluene at room temperature for 3 hours or by iodo substitution followed by substitution with amine compound using L-proline, cesium carbonate, copper(I) iodide in dimethylsulfoxide.
  • Example of preparing the compound of Formula G4 from the compound of Formula G3 by substitution or iodo substitution followed by amine substitution in the above Step 3 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula G4 may be prepared by addition reaction which is carried out with the compound of Formula G3 and , or (R c3 in the Formula is same as that defined in the above Formula I) in dichloromethane or N,N -dimethylformamide at room temperature for 3-6 hours and it is illustrated in the following reaction scheme.
  • the compound of Formula G3 may be converted to Formula G4 by another method of the addition reaction which is carried out with (R c3 in the Formula is same as that defined in the above Formula I) in the presence of triphosgene or 1,1'-carbonyldiimiazole in dichloromethane or tetrahydrofuran(THF) at room temperature for 2-6 hours and it is illustrated in the following reaction scheme.
  • the compound of Formula G4 prepared as described in step 3 may be converted to Formula I by hydrolysis using lithium hydroxide in one or more of tetrahydrofuran, 1,4-dioxane or water at rt-80°C for 4-48 hours.
  • Example of preparing the compound of Formula I from Formula G4 by hydrolysis in the above Step 4 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula I which is a compound of the present invention, may be prepared by series of steps from the compound of Formula B6 as shown in Scheme 6.
  • R 1 , R 2 , R 3 , R 6 , R 7 , R j1 , Y and Z of Formula I, B6 and J3, illustrated in Scheme 6, are defined as below:
  • Y is carbon or nitrogen
  • R 1 and R 2 are each independently hydrogen, halo or trifluoromethyl
  • n 0, 1 or 2
  • X 1 , X 2 and X 3 are each independently carbon or nitrogen
  • R 3 and R 4 are each independently hydrogen, halo, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , , CONR a1 R a2 , NR a1 R a2 , CH 2 NR a1 R a2 , CH 2 R c3 , COR a3 , OR a3 , NR a4 COR a3 , NR a4 CO 2 R a3 , NHCONHR a3 , NHSO 2 R a3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • n 1 or 2
  • R a1 and R a2 are each independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a3 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, , , or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
  • R a4 is hydrogen or C 1-6 alkyl
  • R 5 is hydrogen, , , , , or ,
  • R 6 and R 7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
  • R c3 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl,
  • W 1 , W 2 and W 3 are each independently oxygen, nitrogen, CHR w1 , CR w1 , NR w1 or CO,
  • R w1 is hydrogen, halo, C 1-6 alkyl, C 3-6 cycloalkyl, halo C 1-6 alkyl, C 1-6 alkylamine, C 1-6 alkyl alcohol, , (CH 2 ) p heteroaryl or (CH 2 ) p aryl, wherein, p is 1, 2 or 3.
  • the preparation method of the Formula I according to the present invention comprise:
  • the compound of Formula B6, prepared as described in step 4 in scheme 2 may be converted to Formula J2 by Sonogashira reaction with Formula J1 using catalytic amount of tetrakis(triphenylphosphine) palladium(0)(Pd(PPh 3 ) 4 ) or bis(triphenyl phosphine)palladium(II)dichloride (PdCl 2 (PPh 3 ) 2 ) and Copper(I)iodide under basic condition in one or more of tetrahydrofuran or N,N -dimethylformamide at 70-100°C for 3-24 hour.
  • Example of preparing the compound of Formula J2 from the compound of Formula B6 with J1 by Sonogashira reaction in the above Step 1 of the preparing method of the present invention is illustrated in the following reaction scheme.
  • the compound of Formula J2 prepared as described in step 1 may be converted to Formula J3 by reduction reaction with Tin(II) chloride dehydrate in ethyl acetate or ethanol at room temperature for one day and it is illustrated in the following reaction scheme.
  • the compound of Formula J3, prepared as described in step 2 may be converted to Formula I by hydrolysis or addition reaction.
  • the desired compound of Formula I may be prepared by hydrolysis or addition reaction.
  • the compound of Formula J3 may be converted to Formula I by above hydrolysis reaction under the condition of lithium hydroxide in one or more of tetrahydrofuran, 1,4-dioxane or water at rt-80°C for 4-48 hours and it is illustrated in the following reaction scheme.
  • the compound of Formula I may be prepared by addition reaction with Formula J3 under basic condition in N,N -dimethylformamide or tetrahydrofuran at room temperature or heating condition for 3 or 24 hours in the present invention and it is illustrated in the following reaction scheme.
  • the present invention provides a pharmaceutical compostion for the treatment, prevention, or amelioration of the metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis comprising the compound of Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
  • the metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis may be caused by FXR receptor activity.
  • Exemplary diseases include hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, dyslipidemia, lipodystrophy, cholestasis/fibrosis, cholesterol gallstone disease, gastrointestinal disease or condition, hyperglycemia, diabetes, insulin resistance, metabolic inflexibility, nephropathy, liver diseases, atherosclerosis, cancer, inflammatory disorders, osteoporosis and skin aging.
  • the present invention provides a method of the treatment, prevention, or amelioration of metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis in a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition to the subject.
  • the dosage of pharmaceutical composition of the present invention may vary depending on the patient's weight, age, gender, physical condition, diet, the time and mode of administration, excretion rates, and the severity of illness. Mammals(including human) are desirable for the individual without limit.
  • compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition(Mack Publishing Company, 1995).
  • the compounds of the invention may be administered orally.
  • Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
  • Formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solid and liquid(including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids, emulsions or powders; lozenges(including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
  • Liquid(including multiple phases and dispersed systems) formulations include emulsions, suspensions, solutions, syrups and elixirs.
  • Such formulations may be presented as fillers in soft or hard capsules(made, for example, from gelatin or hydroxypropyl methyl cellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methyl cellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents.
  • a carrier for example, water, ethanol, polyethylene glycol, propylene glycol, methyl cellulose, or a suitable oil
  • emulsifying agents and/or suspending agents may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • the compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001)
  • the immediate release portion may comprise a disintegrant.
  • disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, powdered cellulose, loweralkyl-substituted hydroxypropyl cellulose, polacrilin potassium, starch, pregelatinizedstarch, sodium alginate, and mixtures thereof.
  • the disintegrant will comprise from 1 wt% to 80 wt%, preferably from 5 wt% to 60 wt% of the layer.
  • matrix materials, fillers, or diluents include lactose, mannitol, xylitol, dextrose, sucrose, sorbitol, compressible sugar, microcrystalline cellulose, powdered cellulose, starch, pregelatinized starch, dextrates, dextran, dextrin, dextrose, maltodextrin, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, magnesium carbonate, magnesium oxide, poloxamers, polyethylene oxide, hydroxypropyl methyl cellulose and mixtures thereof.
  • the compounds may also be blended with conventional excipients such as binders, including gelatin, pregelatinized starch, and the like; lubricants, such as hydrogenated vegetable oil, stearic acid, and the like; diluents, such as lactose, mannose, and sucrose; disintegrants, such as carboxymethyl cellulose and sodium starch glycolate; suspending agents, such as povidone, polyvinyl alcohol, and the like; absorbants, such as silicon dioxide; preservatives, such as methylparaben, propylparaben, and sodium benzoate; surfactants; such as sodium lauryl sulfate, polysorbate 80, and the like; flavorants; and sweeteners.
  • binders including gelatin, pregelatinized starch, and the like
  • lubricants such as hydrogenated vegetable oil, stearic acid, and the like
  • diluents such as lactose, mannose, and sucrose
  • disintegrants such as carboxymethyl
  • the surfactants would comprise of 0.2 wt% to 5 wt% and the absorbants would comprise from 0.2 wt% to 1 wt%.
  • Another excipients include one or more of: anti-oxidants, colorant, flavouring agents, preservatives and taste-masking agents.
  • Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting.
  • the final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.
  • Solid formulations for oral administration may be formulated to be immediate and/or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release
  • the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ.
  • Suitable means for parenteral administration include intravenous, intra-arterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
  • Suitable devices for parenteral administration includes needle(including micro needle) injectors, needle-free injectors and infusion techniques.
  • needle free injection is Powderject TM .
  • Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents(preferably, to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non aqueous solution or as a powdered, dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • excipients such as salts, carbohydrates and buffering agents(preferably, to a pH of from 3 to 9)
  • a suitable vehicle such as sterile, pyrogen-free water.
  • parenteral formulations under sterile conditions may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
  • a proper dosage form such as combination with solubility enhancer can increase solubility of compound of formula I used in non-oral solution.
  • Formulations for parenteral administration may be formulated to be immediate and/or modified/controlled release.
  • Controlled/modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and pro-grammed release.
  • compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and PGLA microspheres.
  • the compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally.
  • Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions.
  • Li-posomes may also be used.
  • the precise daily dose administered depends on various factors such as the age, sex, weight and condition of the patient being treated.
  • the amount of dose can be selected within the bounds of goal achieving treatment effect without harmful or serious adverse effect.
  • the dosage of the compound of invention may be administered in an effective amount raging from 0.05 to 1000mg daily on patients.
  • the following dosage levels and other dosage levels herein are for the average human subject having a weight range of about 65 to 70kg. The skilled person will readily be able to determine the dosage levels required for a subject whose weight falls outside this range, such as children and the elderly.
  • Step 1 Preparation of 2,6- dichlorobenzaldehyde oxime
  • N -chlorosuccinimide(NCS, 18.4g, 140mmol) was added to a solution of the intermediate compound(Step 1)(25.9g, 140mmol) in chloroform(1000ml) and stirred for 4 hours at room temperature.
  • the reaction mixture was evaporated in vacuum, diluted with dicholrometane and washed with water.
  • the combined organic layers were dried over MgSO 4 , filtered, evaporated in vacuum and purified using silica chromatography to afford the intermediate compound 2,6-dichloro-N-hydroxybenzimidoyl chloride(29g) without any further purification.
  • Step 3 Preparation of ethyl 5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole -4- carboxylate
  • the intermediate compound(Step 2)(29g, 129mmol) was added to ethyl 3-cyclopropyl-3-oxopropanate(25ml, 194mmol) in triethylamine(150ml)and stirred for 24 hours at room temperature.
  • the reaction mixture was diluted with ethyl acetate and washed with water.
  • the combined organic layers were dried over MgSO 4 , filtered, evaporated in vacuum and purified using silica chromatography to afford the intermediate compound ethyl 5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate (22.37g, 56%).
  • Step 4 (5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl )methanol
  • Step 5 Preparation of 4-( bromomethyl )-5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole
  • Triphenylphosphine(TPP, 16.9g, 64.53mmol) and tetrabromomethane(21.4g, 64.53mmol) was slowlly added to the intermediate compound(Step 4)(12.2g, 43.02mmol) in dichloromethane(158ml) at 0 o C and stirred for 4 hours at room temperature.
  • the reaction mixture was evaporated in vacuum and purified using silica chromatography to afford the title compound(13.44g, 90%).
  • Example 1 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl ) methoxy)phenyl)ethynyl)benzoic acid; ( I-1)
  • Step 1 Preparation of tert - butyl(4-iodophenoxy)dimethylsilane
  • tert-Butyldimethylsilyl chloride (TBSCl, 2.1g, 13.6mmol) and imidazole (1.2g, 18.2mmol) were added to a solution of 4-Iodophenol(2g, 9.1mmol) in N,N -dimethylformamide (45ml) and stirred for 12 hours at room temperature.
  • the reaction mixture was diluted with ethyl acetate and washed with water.
  • the combined organic layers were dried over MgSO 4 , filtered, evaporated in vacuum and purified using silica chromatography to afford the intermediate compound tert-butyl(4-iodophenoxy)dimethylsilane(2.8g, 93%).
  • Step 2 Preparation of tert -butyl(4-((trimethylsilyl)ethyl)phenoxy)silane
  • Trimethylsilylacetylene(2.4ml, 17mmol), bis(triphenylphosphine)palladium(ii) dichloride (PdCl 2 (PPh 3 ) 2 , 0.6g, 0.85mmol), Copper(I) iodide(0.16g, 0.85mmol), and triethylamine(0.6ml, 4.25mmol) were added to a solution of the intermediate compound(Step 1)(2.8g, 8.5mmol) in N,N -dimethylformamide (50ml) and stirred for 12 hours at 80°C.
  • the reaction mixture was diluted with Ethyl acetate and washed with water.
  • Potassium fluoride (KF, 3.8g, 65mmol) was added to a solution of the intermediate compound(Step 2)( 1.99g, 6.5mmol) in methanol (65ml) at 0°C and stirred for 1 hour.
  • the reaction mixture was diluted with dichloromethane and washed with water.
  • the combined organic layers were dried over MgSO 4 , filtered, and evaporated in vacuum.
  • the resulting 4-((trimethylsilly)ethyl)phenol was used for next step without any further purification.
  • Step 4 Preparation of 5- cyclopropyl -3-(2,6- dichlorophenyl )-4-((4- ethynylphenoxy)methyl)isoxazole
  • Step 5 Preparation of methyl 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate
  • Step 6 Preparation of 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
  • Step 1 Preparation of methyl 3-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate
  • This compound was made using the procedure described for example 2(Step 5).
  • this intermediate compound(Step 4 of Example 1)(100mg, 0.26mmol) was reacted with 3-bromobenzoate (56mg, 0.26mmol), bis(triphenylphosphine) palladium(II) dichloride (PdCl 2 (PPh 3 ) 2 , 21mg, 0.03mmol), Copper(I) iodide(5.7mg, 0.03mmol), and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.2ml, 1.3mmol) to afford the intermediate compound methyl 3-((4-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(40mg, 30%).
  • Step 2 Preparation of 3-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol - 4-yl)methoxy)phenyl)ethynyl)benzoic acid
  • Step 1 Preparation of tert -butyl(4- iodo -3-( trifluoromethyl ) phenoxy ) dimethylsilane
  • Step 2 Preparation of tert - butyldimethyl(3- ( trifluoromethyl )-4-(( trimethylsilyl ) ethynyl)phenoxy)silane
  • This compound was made using the procedure described for example 1(Step 2).
  • this intermediate compound(Step 1)(52mg, 0.13mmol) was reacted with Trimethylsilylacetylene(0.036ml, 0.26mmol), bis(triphenylphosphine)palladium(ii) dichloride (PdCl 2 (PPh 3 ) 2 , 9.1mg, 0.013mmol), Copper(I) iodide(2.4mg, 0.013mmol) and triethylamine(0.095ml, 0.65mmol) to afford the intermediate compound tert-butyldimethyl(3-(trifluoromethyl)-4-((trimethylsilyl)ethynyl) phenoxy)silane(41.1mg, 88%).
  • Step 3 Preparation of 3-( trifluoromethyl )-4-(( trimethylsilyl ) ethynyl )phenol
  • This compound was made using the procedure described for example 1(Step 3).
  • this intermediate compound(Step 2)(41.1mg, 0.16mmol) was reacted with Potassium fluoride (KF, 93mg, 1.6mmol) to afford the intermediate compound 3-(trifluoromethyl)-4-((trimethylsilyl)ethynyl)phenol.
  • KF Potassium fluoride
  • Step 4 Preparation of 5- cyclopropyl -3-(2,6- dichlorophenyl )-4-((4- ethynyl -3 -(trifluoromethyl)phenoxy)methyl)isoxazole
  • This compound was made using the procedure described for example 1(Step 4).
  • this intermediate compound(Step 3)(0.16mmol) was reacted with 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxlazole(Intermediate 1)(50mg, 0.144mmol), and potassium carbonate (26.6mg, 0.192mmol) to afford the intermediate compound 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-((4- ethynyl-3-(trifluoromethyl)phenoxy)methyl)isoxazole(36mg, 50%).
  • Step 5 Preparation of methyl 3-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)-2-(trifluoromethyl)phenyl)ethynyl)benzoate
  • This compound was made using the procedure described for example 1(Step 5).
  • this intermediate compound(Step 4)(36mg, 0.080mmol) was reacted with methyl 3-iodobenzoate(21mg, 0.080mmol), bis(triphenylphosphine)palladium(II) dichloride (PdCl 2 (PPh 3 ) 2 , 5.6mg, 0.008mmol), Copper(I) iodide(1.5mg, 0.008mmol) and triethylamine(0.013ml, 0.096mmol)to afford the intermediate compound methyl 3-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)-2-(trifluoromethyl)phenyl)ethynyl)benzoate(3mg, 75%).
  • Step 6 Preparation of 3-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol - 4- yl ) methoxy )-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid
  • Example 4 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl ) methoxy )-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid; (I-4)
  • Step 1 Preparation of methyl 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl ) methoxy )-2-(trifluoromethyl)phenyl)ethynyl)benzoate
  • Step 2 Preparation of 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl ) methoxy )-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid
  • Example 5 4-((3- chloro -4- ethynylphenoxy )methyl)-5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole ; (I-5)
  • Step 1 Preparation of tert-butyl(3-chloro-4-iodophenoxy)dimethylsilane
  • Step 2 Preparation of tert-butyl(3-chloro-4-((trimethylsilyl)ethynyl)phenoxy) dimethylsilane
  • Step 4 Preparation of 4-((3- chloro -4- ethyntlphenoxy ) metehyl )-5- cyclopropyl -3-(2,6- dichlorophenyl)isoxazole
  • Step 1 Preparation of 4-((3- chloro -4-( phenylethynyl ) phenoxy )methyl)-5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazole
  • Step 1 Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate
  • Step 1 Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-nitrobenzoate
  • Step 2 Preparation of methyl 3-amino-5-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
  • the intermediate compound(step 1) was dissolved in ethyl acetate(70ml) and ethanol(35ml) and tin(II) chloride dihydrate(15.5g, 68.7mmol) were added. The reaction was stirred at room temperature for 1 day. The reaction mixture was extracted with ethyl acetate and washed with water.
  • Step 3 Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoate
  • the intermediate compound(step 2) was dissolved in N,N -dimethylform amide(8.8ml) and ethylchloroformate(250ul, 2.64mmol), triethylamine(369ul, 2.64mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene(DBU, 13 ul, 0.0881mmol) were added.
  • the reaction was stirred at room temperature for 4 hours.
  • the reaction mixture was extracted with ethyl acetate and washed with water.
  • the combined organic phase was dried over MgSO 4 , filtered, concentrated and purified by column chromatography on silica to give the title compound(254mg, 65%).
  • Step 1 Preparation of methyl 3-( tert - butoxycarbonyl )amino)-5-((2- chloro -4- (( cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
  • Step 1 Preparation of methyl 3-( tert - butoxycarbonyl )amino)-5-((2- chloro -4- (( cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)(methyl)amino)benzoate
  • Step 1 Preparation of 4-((3- chloro -4-((3- nitrophenyl ) ethynyl ) phenoxy ) methyl)-5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazole
  • Step 2 Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)aniline
  • This compound was made using the procedure described for example 8(Step 2).
  • this intermediate compound(Step 1) (100mg, 0.19mmol) was reacted with tin(II) chloride dihydrate(208.9mg, 0.93mmol) to afford the intermediate compound 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4- yl)methoxy)phenyl)ethynyl)aniline(60mg, 62%).
  • Step 3 Preparation of ethyl(3-((2-chloro-4-( (5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)phenyl)carbamate
  • Triethylamine(12.3ul, 0.08mmol) and ethylchloroformate(8.3ul, 0.08mmol) was added to a suspension of the intermediate compound(Step 2)(30mg, 0.06mmol) in dichloromethane and stirred for 7 hours at room temperature. Water was added to the reaction mixture and the product was extracted into dichloromethane. The combined organic layers were dried over MgSO 4 , filtered, evaporated in vacuum and purified using silica chromatography to give the title compound(25mg, 72%).
  • Step 1 Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzenesulfonamide
  • Step 1 Preparation of N -(3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)phenyl)methanesulfonamide
  • Methanesulfonyl chloride(2drops) was added to a solution of 3-((2-chloro-4- ((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)aniline(Step 2 of example 11)(35mg, 0.0686mmol) in tetrahydrofuran(1ml) and triethylamine(0.05ml, 0.343mmol) was added to the reaction mixture and stirred for 8 hours. The reaction mixture was concentrated in vacuum, added 1N HCl(aq) and extracted into ethyl acetate. The combined organic layers were dried over MgSO 4 , filtered, evaporated in vacuum and purified using silica chromatography to afford the title compound(27mg, 67%).
  • Step 1 Preparation of N -(3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)phenyl)sulfamide
  • Step 1 Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
  • Step 1 Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate
  • Step 2 Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
  • Example 17 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)nicotinic acid; (I-17)
  • Step 1 Preparation of methyl 6-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)nicotinate
  • Step 2 Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)nicotinic acid
  • Step 1 Preparation of methyl 2-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)isonicotinate
  • Step 2 Preparation of 2-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)isonicotinic acid
  • Step 1 Preparation of methyl 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)picolinate
  • Step 2 Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)picolinic acid
  • Step 1 Preparation of methyl5 -((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)nicotinate
  • Step 2 Preparation of 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)nicotinic acid
  • Step 1 Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(dimethylamino)benzoate
  • Step 2 Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(dimethylamino)benzoic acid
  • Step 1 Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-3-(dimethylamino)benzoate
  • Step 2 Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)picolinic acid
  • Step 1 Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-(dimethylamino)benzoate
  • Step 2 Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-(dimethylamino)benzoic acid
  • Step 1 Preparation of Methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(diethylamino)benzoate
  • Step 2 Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(diethylamino)benzoic acid
  • Step 1 Preparation of 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
  • Step 1 Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-(dimethylamino)benzoate
  • Step 2 Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-(dimethylamino)benzoic acid
  • Step 1 Preparation of methyl 3- chloro -5-((2- chloro -4-((5- cyclopropyl - 3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
  • Step 2 Preparation of 3- chloro -5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
  • Example 28 4- chloro -3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-28)
  • Step 1 Preparation of methyl 4- chloro -3-((2- chloro -4-((5- cyclopropyl - 3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
  • Step 2 Preparation of 4- chloro -3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
  • Step 1 Preparation of methyl 2- chloro -5-((2- chloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
  • Step 2 Preparation of 2- chloro -5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
  • Step 1 Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-fluorobenzoate
  • Step 2 Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-fluorobenzoic acid
  • Step 1 Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethyl)benzoate
  • Step 2 Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethyl)benzoic acid
  • Step 1 Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-ethynylbenzoate
  • Step 2 Preparation of 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-ethynylbenzoic acid
  • Step 1 Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-cyanobenzoate
  • Step 2 Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-cyanobenzoic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor(FXR, NR1H4).

Description

AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF
The present application claims priority to Korean Patent Application No. 10-2017-0047393 filed on April 12, 2017 and Korean Patent Application No. 10-2018-0042545 filed April 12, 2018, the disclosures of which are incorporated herein by reference.
The present invention relates to compounds useful as agonists for Farnesoid X receptor(FXR, NR1H4), pharmaceutical formulation comprising such compounds and its study for medicinal uses.
Farnesoid X receptor(FXR, NR1H4)is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. FXR is highly expressed in the liver, intestine, kidney, adrenal glands, white adipose tissue and in induced during adipocyte differentiation in vitro. (Cariu B. et al., J. Biol. Chem., 2006, 16, 11039-11049).
Not only FXR regulates various physiological processed such as modulates regulrated of bile acid(BA) regulation, lipids/glucose metabolism, inflammation/fibrosis, but recently it has also been linked to the pathology of FXR receptors.
This nuclear receptor is the intracellular bile acid ¡“sensor” and its major physiological role is to protect liver cells from the deleterious effect of bile acids(BA) overload. Intestine is the tissue expressing the first FXR target gene identified. Indeed IBAB-P is expressed in enterocytes and binds bile acids, thus limiting the free concentration of BA intracellularly and consequently their toxicity.(Makishima M, et al., Science, 1999, 284(5418), 1362-1365). FXR is highly expressed in the liver and regulates key genes involved in BA synthesis, metabolism and transport including CYP7A1, UGT2B4, BSEP, MDR3, MRP2, ASBT, NTCP, OST α and OST β in humans. One effect of FXR activation is down regulation of CYP7A1 and thus bile acid synthesis; this is accomplished through induction of SHP(Small Heterodimer Partner) which then represses CYP7A1 transcription(Claude T, et al., Arterioscler. Thromb. Vasc. Biol., 2005, 25, 2020-2031). Altered expression or malfunction of these genes has been described in patients with cholestatic liver disease. FXR agonist 6-ethyl-chenodeoxycholic acid(6EtCDCA)was found to fully reverse the impairment of bile flow and to protect the hepatocytes against liver cell injury caused by the cytotoxic lithocholic acid.(Pelliciari R, et al., J. Med. Chem., 2002, 45(17), 3569-3572).
In the intestine, FXR also induces expression of SHP which represses transcription of the apical sodium dependent bile acid transporter(ASBT, SLC10A2) gene which encodes the hight affinity apical sodium dependent bile acid transporter that mouse bile acids from the intestinal lumen into the enterocyte as part of the enterohepatic recycling of bile acids.(Li H, et al., Am. J. Physiol. Gastrointest.Liver Physiol., 2005, 288, G60-G66). Ileal bile acid binding protein (IBABP) gene expression is also induced by FXR agonists in the enterocyte.(Grober J, et al.,J. Biol. Chem., 1999, 274(42), 29759-29754). FXR seems to be also involved in paracrine and endocrine signaling by upregulation the expression of the cytokine Fibroblast Growth Factor 15(rodents) or 19(monkeys, humans).(Holt J, et al., Genes Dev., 2003, 17(13), 1581-1591; Inagaki T,et al., Cell Metab., 2005, 2(4), 217-225).
FXR activation has also been described to downregulate proinflammatory enzymes iNOS and COX-2, as well as migration of vascular smooth muscle cell migration.(Li YTY, et al., Arterioscler Thromb Vasc Biol., 2007, 27(12), 2606-2611). FXR is also expressed in hepatic stellate cells(HSC) which play a role in deposition of extracellular matrix during the fibrotic process. Treatment of cultured HSCs with the FXR agonist 6-ethyl-chenodeoxycholic acid(6EtCDCA) results in decreased expression of fibrotic markers such as α-smooth muscle actin and α1(I)collagen. 6EtCDCA has also been reported to precent development and promote resolution of hepatic fibrosis in multiple rodent models of this disease.(Fiorucci S, et al., Gastroenterology, 2004, 127(5), 1497-1512; Fiorucci S, et al., J. Pharmacol. Exp. Ther., 2005, 314(2), 584-595).
The process of enterohepatic circulation of bile acids is also a major regulator of serum cholesterol homeostasis. After biosynthesis from cholesterol in the liver, bile acid(BA) are secreted with nile into the lumen of the small intestine to aid in the digestion and absorption of fat and fat-soluble vitamins, The ratio of different BA determines the hydrophilicity of the bile acid pool and its ability to solubilize cholesterol. FXR activation increases the hydrophilicity of the pool, decreasing the intestinal solubilization of cholesterol, effectively blocking its absorption. Recent report have shown that FXR opposed this effect in part by directly repressing the expression of HMGCoA reductase via a pathway involving SHP(Small Heterodimer Partner) 및 LRH1.(Datta S, et al., J. Biol. Chem., 2006, 281(2), 807-812).
According to subsequent studies, FXR activation affects Triglyceride(TG) metabolism via several pathways such as Sterol regulatory element-binding transcription factor 1 (SREBF1), apoC-III, apoC-II, syndecan-1 and the VLDL receptor. Recently new FXR modulator compounds show the ability to reduce both plasma triglyceride(TG) and cholesterol levels in normal and hyperlipidemic animal models(WO2007070796).
In addition, FXR agonist GW4064 or cholic acid treatment reduced plasma glucose levels and improved insulin sensitivity in three diabetic models(db/db, ob/ob and KK-A(y)mice)(Cariu B,et al., J. Biol. Chem., 2006, 281(16), 11039-11049 Zhang Y, et al., Proc. Natl. Acad. Sci., 2006, 103(4), 1006-1011; Ma K, et al., J. Clin. Invest., 2006, 116, 1102-1109). This demonstrates that FXR is involved in glucose metabolism.
Therefore, FXR activity has been implicated in variety of diseases, including, but not limited to disorder of bile acid homeostasis, inflammation/fibrosis and hight levels of plasma triglyceride(TG)/ cholesterol.
Conventionally known FXR agonists INT-747(OCA) and EDP-305 are modified bile acid(BA),developed for the treatment of diseases caused by disorder of bile acid homeostasis such as Nonalcoholic fatty liver disease(NASH), Alcoholic disorders, Primary biliary cirrhosis(PBC), Primary sclerosing cholangitis(PSC) and caused clinical side effects for the accumulation of substances in the body.
Following, small molecule compounds such as FXR agonist were derived form GW4064, PX-102(GS-9674)/PX-104 and Global Pharmaceutical Company published various patent with various derivatives(WO2000037077, WO2003015771, WO2004048349, WO2009012125, WO2009149795, WO2011020615, WO2013037482 and WO2016097933).
As FXR agonist has been progressed with respect to the prior published clinical literature, has a new mechanism of action for the treatment.
FXR agonist is development as target for variety treatment of diseases, including, but not limited to disorder of bile acid homeostasis, inflammation/fibrosis and hight levels of plasma triglyceride(TG)/ cholesterol so that worldwide attention is focused.
So The present invention is expected that patients with metabolic diseases, including, but not limited to cholestatic Liver Diseases, Organ Fibrosis and Liver Fibrosis, will be able to open a therapeutic field of new mechanism.
The present invention is related to compounds of excellent activity as FXR agonist. Particularly, the present invention relates to derivatives and processes for the preparation thereof.
In addition, the object of the present invention is to provide medical use for useful treatment of diseases, for modulating the activity as FXR receptors and for the treatment, prevention or amelioration of one or more symptoms of disease or disorder related to the activity of the receptors, including, but not limited to hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, dyslipidemia, lipodystrophy, cholestasis/fibrosis, cholesterol gallstone disease, gastrointestinal disease or condition, hyperglycemia, diabetes, insulin resistance, metabolic inflexibility, nephropathy, liver diseases, atherosclerosis, cancer, inflammatory disorders, osteoporosis and skin aging.
However, the technical objects to be achieved in the present invention are not limited to those stated above and other objects may be clearly understood to those skilled in the art from the following description.
To solve the problem described above, the present invention provides a compound represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
[Formula I]
Figure PCTKR2018004277-appb-I000001
In the present Formula I,
Y is carbon or nitrogen,
R1 and R2 are each independently hydrogen, halo or trifluoromethyl,
Z is
Figure PCTKR2018004277-appb-I000002
or
Figure PCTKR2018004277-appb-I000003
,
n is 0, 1 or 2,
X1, X2 and X3 are each independently carbon or nitrogen,
R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000004
,
Figure PCTKR2018004277-appb-I000005
,
Figure PCTKR2018004277-appb-I000006
,
Figure PCTKR2018004277-appb-I000007
, CONRa1Ra2, NRa1Ra2, CH2NRa1Ra2, CH2Rc3, CORa3, ORa3, NRa4CORa3, NRa4CO2Ra3, NHCONHRa3, NHSO2Ra3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
wherein, m is 1 or 2,
Ra1 and Ra2 are each independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000008
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra3 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000009
,
Figure PCTKR2018004277-appb-I000010
,
Figure PCTKR2018004277-appb-I000011
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra4 is hydrogen or C1-6 alkyl,
R5 is hydrogen,
Figure PCTKR2018004277-appb-I000012
,
Figure PCTKR2018004277-appb-I000013
,
Figure PCTKR2018004277-appb-I000014
,
Figure PCTKR2018004277-appb-I000015
,
Figure PCTKR2018004277-appb-I000016
or
Figure PCTKR2018004277-appb-I000017
,
R6 and R7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
Rc3 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl,
W1, W2 and W3 are each independently oxygen, nitrogen, CHRw1, CRw1, NRw1 or CO,
wherein, Rw1 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl, C1-6 alkylamine, C1-6 alkyl alcohol,
Figure PCTKR2018004277-appb-I000018
,
Figure PCTKR2018004277-appb-I000019
(CH2)p heteroaryl or (CH2)p aryl, wherein, p is 1, 2 or 3.
The present invention provides a compound represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
The present invention provides a pharmaceutical composition for the treatment, prevention, or amelioration of metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis comprising the compound represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
The present invention provides a use for the treatment, prevention, or amelioration of metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis comprising the compound represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
The present invention provides a method for the treatment, prevention, or amelioration of metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis in a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof to the subject(including human).
The compounds of the present invention are highly active as FXR agonist, and according to its pharmaceutical compositions are expected to be useful for therapeutic applications which are improved by FXR agonist, such as metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis.
Hereinafter, the present invention will be described in detail.
The present invention provides a compound represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.:
[Formula I]
Figure PCTKR2018004277-appb-I000020
In the present Formula I,
Y is carbon or nitrogen,
R1 and R2 are each independently hydrogen, halo or trifluoromethyl,
Z is
Figure PCTKR2018004277-appb-I000021
or
Figure PCTKR2018004277-appb-I000022
,
n is 0, 1 or 2,
X1, X2 and X3 are each independently carbon or nitrogen,
R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000023
,
Figure PCTKR2018004277-appb-I000024
,
Figure PCTKR2018004277-appb-I000025
,
Figure PCTKR2018004277-appb-I000026
, CONRa1Ra2, NRa1Ra2, CH2NRa1Ra2, CH2Rc3, CORa3, ORa3, NRa4CORa3, NRa4CO2Ra3, NHCONHRa3, NHSO2Ra3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
wherein, m is 1 or 2,
Ra1 and Ra2 are each independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000027
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra3 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000028
,
Figure PCTKR2018004277-appb-I000029
,
Figure PCTKR2018004277-appb-I000030
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra4 is hydrogen or C1-6 alkyl,
R5 is hydrogen,
Figure PCTKR2018004277-appb-I000031
,
Figure PCTKR2018004277-appb-I000032
,
Figure PCTKR2018004277-appb-I000033
,
Figure PCTKR2018004277-appb-I000034
,
Figure PCTKR2018004277-appb-I000035
or
Figure PCTKR2018004277-appb-I000036
,
R6 and R7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
Rc3 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl,
W1, W2 and W3 are each independently oxygen, nitrogen, CHRw1, CRw1, NRw1 or CO,
wherein, Rw1 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl, C1-6 alkylamine, C1-6 alkyl alcohol,
Figure PCTKR2018004277-appb-I000037
,
Figure PCTKR2018004277-appb-I000038
(CH2)p heteroaryl or (CH2)p aryl, wherein, p is 1, 2 or 3.
In the present invention, the compound of Formula I is preferably selected form i) or iv) disclosed below:
i) In case, Z is
Figure PCTKR2018004277-appb-I000039
, R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, trifluoromethyl,
Figure PCTKR2018004277-appb-I000040
,
Figure PCTKR2018004277-appb-I000041
,
Figure PCTKR2018004277-appb-I000042
,
Figure PCTKR2018004277-appb-I000043
, NRa1Ra2, CH2NRa1Ra2, ORa3,
Figure PCTKR2018004277-appb-I000044
, NRa4CO2Ra3,
Figure PCTKR2018004277-appb-I000045
,
Figure PCTKR2018004277-appb-I000046
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein, wherein, m is 1 or 2, Ra1 and Ra2 are each independently hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, trifluoromethyl,
Figure PCTKR2018004277-appb-I000047
, azetidine or piperidine, Ra3 is hydrogen, methyl, ethyl, propyl, tert-butyl, cyclopropyl, trifluoromethyl,
Figure PCTKR2018004277-appb-I000048
,
Figure PCTKR2018004277-appb-I000049
,
Figure PCTKR2018004277-appb-I000050
, azetidine, piperidine, piperazine or morpholine, Ra4 is hydrogen or methyl.
ii) In case, Z is
Figure PCTKR2018004277-appb-I000051
, Rc3 is hydrogen or methyl, Rw1 is hydrogen, methyl, ethyl, propyl, cyclopropyl,
Figure PCTKR2018004277-appb-I000052
,
Figure PCTKR2018004277-appb-I000053
,
Figure PCTKR2018004277-appb-I000054
,
Figure PCTKR2018004277-appb-I000055
,
Figure PCTKR2018004277-appb-I000056
,
Figure PCTKR2018004277-appb-I000057
,
Figure PCTKR2018004277-appb-I000058
or
Figure PCTKR2018004277-appb-I000059
.
iii) In case, Z is
Figure PCTKR2018004277-appb-I000060
, R1 and R2 are each independently hydrogen, chloro or trifluoromethyl, R3 and R4 are each independently hydrogen, chloro, fluoro, iodo, cyano, methyl, ethyl, isopropyl, cyclopropyl, trifluoromethyl,
Figure PCTKR2018004277-appb-I000061
,
Figure PCTKR2018004277-appb-I000062
,
Figure PCTKR2018004277-appb-I000063
,
Figure PCTKR2018004277-appb-I000064
, NRa1Ra2, CH2NRa1Ra2, NRa4CO2Ra3, azetidine, piperazine or pyrrolidine, wherein, Ra1 and Ra2 are each independently hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, trifluoroethyl,
Figure PCTKR2018004277-appb-I000065
, azetidine, piperidine or oxetane, Ra3 is hydrogen, methyl, ethyl, tert-butyl, cyclopropyl, trifluoromethyl,
Figure PCTKR2018004277-appb-I000066
,
Figure PCTKR2018004277-appb-I000067
,
Figure PCTKR2018004277-appb-I000068
, azetidine, piperidine, piperazine or morpholine, Ra4 is hydrogen, methyl or ethyl.
iv) In case, Z is
Figure PCTKR2018004277-appb-I000069
, R1 and R2are each independently hydrogen, chloro or fluoro, n is 0 or 1, R5 is
Figure PCTKR2018004277-appb-I000070
, W1, W2 and W3 are each independently oxygen, nitrogen, CRw1 or NRw1, wherein, Rw1 is hydrogen, methyl, ethyl, isopropyl, cyclopropyl,
Figure PCTKR2018004277-appb-I000071
,
Figure PCTKR2018004277-appb-I000072
,
Figure PCTKR2018004277-appb-I000073
,
Figure PCTKR2018004277-appb-I000074
,
Figure PCTKR2018004277-appb-I000075
or
Figure PCTKR2018004277-appb-I000076
.
Particularly proferred examples of the compound of Formula I according to the present invention comprise the followings:
4-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-1)
3-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-2)
3-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid; (I-3)
4-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid; (I-4)
4-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid; (I-5)
4-((3-chloro-4-(phenylethynyl)phenoxy)methyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole; (I-6)
methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)phenyl)ethynyl)benzoate; (I-7)
methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoate; (I-8)
methyl 3-((tert-butoxycarbonyl)amino)-5-((2-chloro-4-((5-cyclopropyl- 3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate; (I-9)
methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)(methyl)amino)benzoate; (I-10)
ethyl (3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)phenyl)ethynyl)phenyl)carbamate; (I-11)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzenesulfonamide; (I-12)
N-(3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)phenyl)methanesulfonamide; (I-13)
N-(3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)phenyl)sulfamide; (I-14)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-15)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-16)
6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)nicotinic acid; (I-17)
2-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)isonicotinic acid; (I-18)
6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)picolinic acid; (I-19)
5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)nicotinic acid; (I-20)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(dimethylamino)benzoic acid; (I-21)
6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)picolinic acid; (I-22)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-(dimethylamino)benzoic acid; (I-23)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(diethylamino)benzoic acid; (I-24)
3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-25)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-(dimethylamino)benzoic acid; (I-26)
3-chloro-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-27)
4-chloro-3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-28)
2-chloro-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-29)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-fluorobenzoic acid; (I-30)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethyl)benzoic acid; (I-31)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-ethynylbenzoic acid; (I-32)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-cyanobenzoic acid; (I-33)
3-((2,6-dichloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-34)
2-chloro-3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-35)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoic acid; (I-36)
5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoic acid; (I-37)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-fluorobenzoic acid; (I-38)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethoxy)benzoic acid; (I-39)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-methoxybenzoic acid; (I-40)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoic acid; (I-41)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropylamino)methyl)benzoic acid; (I-42)
3-(azetidin-1-ylmethyl)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-43)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((methylamino)methyl)benzoic acid; (I-44)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((ethylamino)methyl)benzoic acid; (I-45)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(((2,2,2-trifluoroethyl)amino)methyl)benzoic acid; (I-46)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((isopropylamino)methyl)benzoic acid; (I-47)
3-((tert-butylamino)methyl)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-48)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((dimethylamino)methyl)benzoic acid; (I-49)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(morpholinomethyl)benzoic acid; (I-50)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((oxetan-3-ylamino)methyl)benzoic acid; (I-51)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methylamino)benzoic acid; (I-52)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(ethylamino)benzoic acid; (I-53)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(isopropylamino)benzoic acid; (I-54)
3-(azetidin-1-yl)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-55)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(pyrrolidin-1-yl)benzoic acid; (I-56)
3-(azetidin-3-ylamino)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid hydrochloride; (I-57)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(piperidin-4-ylamino)benzoic acid hydrochloride; (I-58)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(piperazin-1-yl)benzoic acid hydrochloride; (I-59)
3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-methylbenzoic acid; (I-60)
3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-methoxybenzoic acid; (I-61)
3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methoxybenzoic acid; (I-62)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-methylbenzoic acid; (I-63)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-cyclopropylbenzoic acid; (I-64)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-ethylbenzoic acid; (I-65)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-isopropylbenzoic acid; (I-66)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-iodobenzoic acid; (I-67)
3-((2,5-dichloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-68)
3-((2,3-dichloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-69)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-6-fluorophenyl)ethynyl)benzoic acid; (I-70)
3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methylbenzoic acid; (I-71)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(3-ethylureido)benzoic acid; (I-72)
3-acetamido-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-73)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoic acid; (I-74)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)(methyl)amino)benzoic acid; (I-75)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropoxycarbonyl)amino)benzoic acid; (I-76)
3-((tert-butoxycarbonyl)amino)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-77)
3-((tert-butoxycarbonyl)(methyl)amino)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-78)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(((cyclopropylmethoxy)carbonyl)amino)benzoic acid; (I-79)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(((2-cyclopropylethoxy)carbonyl)amino)benzoic acid; (I-80)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(((2-hydroxyethoxy)carbonyl)amino)benzoic acid; (I-81)
3-(((azetidin-3-yloxy)carbonyl)amino)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-82)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(2-oxooxazolidin-3-yl)benzoic acid; (I-83)
5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)isophthalic acid; (I-84)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(piperazine-1-carbonyl)benzoic acid hydrochloride; (I-85)
3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methylsulfonamido)benzoic acid; (I-86)
3-((2-chloro-4-((5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-87)
3-((2-chloro-4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-88)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indazole-6-carboxylic acid; (I-89)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-benzo[d]imidazole-6-carboxylic acid; (I-90)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indole-6-carboxylic acid; (I-91)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-(dimethylamino)ethyl)-1H-indole-6-carboxylic acid; (I-92)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(3-(isopropylamino)propyl)-1H-indole-6-carboxylic acid; (I-93)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(pyridin-4-ylmethyl)-1H-indole-6-carboxylic acid; (I-94)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-morpholinoethyl)-1H-indole-6-carboxylic acid hydrochloride; (I-95)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2,2-dimethoxyethyl)-1H-indole-6-carboxylic acid; (I-96)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxyethyl)-1H-indole-6-carboxylic acid; (I-97)
4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxy-2-methylpropyl)-1H-indole-6-carboxylic acid; (I-98)
6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indazole-4-carboxylic acid; (I-99)
6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indazole-4-carboxylic acid; (I-100)
6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indole-4-carboxylic acid; (I-101)
5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylic acid; (I-102)
5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-7-carboxylic acid; (I-103)
5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-7-carboxylic acid; (I-104)
5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-propylbenzo[d]oxazole-7-carboxylic acid; (I-105)
5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-isopropylbenzo[d]oxazole-7-carboxylic acid; (I-106)
5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-(hydroxymethyl)benzo[d]oxazole-7-carboxylic acid; (I-107)
7-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)quinoxaline-5-carboxylic acid; (I-108)
7-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2,3-dimethylquinoxaline-5-carboxylic acid; (I-109)
5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-cyclopropylbenzo[d]oxazole-7-carboxylic acid; (I-110)
2-butyl-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylic acid; (I-111)
6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-4-carboxylic acid; (I-112)
6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-4-carboxylic acid; (I-113)
6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-propylbenzo[d]oxazole-4-carboxylic acid; (I-114) and
6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-isopropylbenzo[d]oxazole-4-carboxylic acid. (I-115)
In the present invention, "C1-6 alkyl" is a saturated hydrocarbonyl amine with linear or branched chains of 1-6 carbon atoms. Exemplary alkyl include, but are not limited, to methyl, ethyl, propyl, butyl, pentyl, hexyl, 1-methylethyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 1-methylbutyl, 1,1-dimethylpropyl, 1-methylpentyl or 1,1-dimethylbutyl.
In the present invention, "C3-6 cycloalkyl" is intended as a saturated hydrocarbonyl ring with 3-6 carbon atoms. Exemplary cycloalkyl include, but are not limited, to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
In the present invention, "C1-6 alkylamine" is a saturated hydrocarbonyl amine with linear or branched chains of 1~6 carbon atoms. Exemplary alkylamines include, but are not limited, to methylamine, ethylamine, propylamine, butylamine, 1-methylethylamine, diethylamine or dimethylamine.
In the present invention, "C1-6 alkyl alcohol" is an R-OH group with R as defined above. Exemplary alkyl alcohol with 1-6 carbon atoms include, but are not limited, to methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol or n-butyl alcohol.
In the present invention, "halo" is intended as bromine, fluorine, or chlorine atom.
In the present invention, "halo C1-6 alkyl" is intended as a C1-6 alkyl radical having one or more hydrogen atoms replaced by a halogen atom as defined above. Exemplary haloalkyl include, but are not limited, to difluoromethyl or trifluoromethyl.
In the present invention, "aryl" is intended as aromatic ring with single ring and substituted a halogen. Exemplary aryl include, but are not limited, to phenyl or halo phenyl.
In the present invention, "heteroaryl" is intended as a monocyclic ring with at least one nitrogen, oxygen or sulfur atom. Exemplary heteroaryl include, but are not limited pyridinyl, quinolyl, furanyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, imidazolyl, pyrimidinyl, indolyl, pyrazinyl or indazolyl.
In the present invention, "heterocycle" is intended as a saturated or partially unsaturated hydrocarbonyl mono-tricyclic ring with at least one nitrogen atom. Exemplary mono heterocycles with 5-6 atoms include, but are not limited, to pyrrolidinyl, piperidinyl, piperazinyl pyrollyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, triazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl. Also, exemplary bicyclic aromatic ring include, but are not limited, to benzothiazolyl, benzoxazolyl, benzoxazinone, benzoxadiazolyl, 1,3-benzodioxolyl, benzofuryl, benzopyrazinyl, indolyl, indazolyl, benzimidazolyl, benzopyranyl, pyrolopyridanyl, furopyridinyl, or imidazothiazolyl.
The term "pharmaceutically acceptable," as used herein, when referring to a component of a pharmaceutical composition means that the component, when administered to an animal, does not have undue adverse effects such as excessive toxicity, irritation, or allergic response commensurate with a reasonable benefit/risk ratio.
The term "treatment" as used herein covers any treatment of a disease in a mammal, particularly a human, and includes inhibiting the disease, i.e., arresting its development; or relieving the disease, i.e. causing regression of the disease and/or its symptoms or conditions and slowing disease progression.
The term "therapeutically effective amount" means an amount of a compound of the present invention that ameliorates, attenuates or eliminates a particular disease or condition or prevents or delays the onset of a particular disease or condition.
The compounds of the invention may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic-mixture or a racemate.
"Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
"Enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
The phrase "pharmaceutically acceptable salt" as used herein, refers to pharmaceutically acceptable organic or inorganic salts of a compound of the invention. Exemplary salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate "mesylate", ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate(i.e., 1,1'-methylene-bis-(2-hydroxy-3- naphthoate)) salts. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counter ion. The counter ion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counter ion.
If the compound of the invention is a base, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
If the compound of the invention is an acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine(primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like. Illustrative examples of suitable salts include, but are not limited to, organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
In another aspect, the present invention provides a method of preparing the compound represented by Formula I or a pharmaceutically approved salt thereof.
The method for preparing the compound of Formula A8 according to the present invention is shown in the following scheme 1.
[Scheme 1]
Figure PCTKR2018004277-appb-I000077
The compound of Formula A8, which is a compound of the present invention, may be prepared by series of steps from the compound of Formula A2 as shown in Scheme 1.
R6 and R7 of Formula A8, A2 and A7, illustrated in Scheme 1, are defined as below.
Wherein,
R6 and R7is each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy.
The preparation method of the Formula A8 according to the present invention comprise:
Preparing the compound of Formula A3 by reductive amination of Formula A2 (Step 1);
Preparing the compound of Formula A4 by chlorination of Formula A3 (Step 2);
Preparing the compound of Formula A6 by cyclization of Formula A4 with compound of Formula A5 (Step 3);
Preparing the compound of Formula A7 by reduction of Formula A6 (Step 4);
Preparing the compound of Formula A8 by bromination of Formula A7 (Step 5).
Each step in the above preparation method of scheme 1 is described in more detail as follows.
i) In the first step, a compound of Formula A2 may be converted to Formula A3 by reductive amination under conditions of hydroxyl amine and sodium hydroxide in ethanol and distilled water at 90℃ for 24 hours.
The example of preparing the compound of Formula A3 from the Formula A2 by reductive amination in the above Step 1 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000078
ii) In the second step, a compound of Formula A3, prepared as described in step 1, may be converted to Formula A4 by chlorination carried out in the presence of chlorination reagents in one or more of N,N-dimethylformamide, or chloroform at room temperature for 1 hour.
Example of preparing the compound of Formula A4 from the compound of Formula A3 by chlorination in the above Step 2 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000079
iii) In the third step, the compound of Formula A4, prepared as described in step 2, may be converted to Formula A6 by cyclization with Formula A5 under basic condition at room temperature for 24 hours.
Example of preparing the compound of Formula A6 from the compound of Formula A4 and A5 by cyclization in the above Step 3 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000080
iv) In the fourth step, the compound of Formula A6, prepared as described in step 3, may be converted to Formula A7 by reduction carried out in the presence of reducing reagent in THF at room temperature for 7 hours.
Example of preparing the compound of Formula A7 from the compound of Formula A6 by reduction in the above Step 4 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000081
v) In the fifth step, the compound of Formula A7, prepared as described in step 4, may be converted to Formula A8 by bromination carried out in the presence of bromination reagent in dichloromethane at room temperature for 4 hours.
Example of preparing the compound of Formula A8 from the compound of Formula A7 by bromination in the above Step 5 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000082
Besides, another preparation method of the compound of Formula I according to the present invention is shown in the following reaction scheme 2.
[Scheme 2]
Figure PCTKR2018004277-appb-I000083
The compound of Formula I, which is a compound of the present invention, may be prepared by series of steps from the compound of Formula B2 as shown in Scheme 2.
Y, R1, R2, R6, R7 and Z of Formula I, B2 and B7, illustrated in Scheme 2, are defined as below:
In the present Formula I,
Y is carbon or nitrogen,
R1 and R2 are each independently hydrogen, halo or trifluoromethyl,
Z is
Figure PCTKR2018004277-appb-I000084
or
Figure PCTKR2018004277-appb-I000085
,
n is 0, 1 or 2,
X1, X2 and X3 are each independently carbon or nitrogen,
R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000086
,
Figure PCTKR2018004277-appb-I000087
,
Figure PCTKR2018004277-appb-I000088
,
Figure PCTKR2018004277-appb-I000089
, CONRa1Ra2, NRa1Ra2, CH2NRa1Ra2, CH2Rc3, CORa3, ORa3, NRa4CORa3, NRa4CO2Ra3, NHCONHRa3, NHSO2Ra3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
wherein, m is 1 or 2,
Ra1 and Ra2 are each independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000090
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra3 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000091
,
Figure PCTKR2018004277-appb-I000092
,
Figure PCTKR2018004277-appb-I000093
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra4 is hydrogen or C1-6 alkyl,
R5 is hydrogen,
Figure PCTKR2018004277-appb-I000094
,
Figure PCTKR2018004277-appb-I000095
,
Figure PCTKR2018004277-appb-I000096
,
Figure PCTKR2018004277-appb-I000097
,
Figure PCTKR2018004277-appb-I000098
or
Figure PCTKR2018004277-appb-I000099
,
R6 and R7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
Rc3 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl,
W1, W2 and W3 are each independently oxygen, nitrogen, CHRw1, CRw1, NRw1 or CO,
wherein, Rw1 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl, C1-6 alkylamine, C1-6 alkyl alcohol,
Figure PCTKR2018004277-appb-I000100
,
Figure PCTKR2018004277-appb-I000101
(CH2)p heteroaryl or (CH2)p aryl, wherein, p is 1, 2 or 3.
The preparation method of the Formula I according to the present invention comprise:
Preparing the compound of Formula B3 by protection of hydroxyl group of Formula B2 (Step 1);
Preparing the compound of Formula B4 by Sonogashira reaction of Formula B3 (Step 2);
Preparing the compound of Formula B5 by deprotection of tert-butyldimethyloxy(
Figure PCTKR2018004277-appb-I000102
) of Formula B4 (Step 3);
Preparing the compound of Formula B6 by substitution of Formula B5 with A8(Step 4);
Preparing the compound of Formula I by Sonogashira reaction or hydrolysis after Sonogashira reaction of Formula B6 and B7 (Step 5).
Each step in the above preparation method of scheme 2 is described in more detail as follows.
i) In the first step, the compound of Formula B3 may be prepared by protection of hydroxyl group of Formula B2 using tert-Butyldimethylsilyl chloride(TBSCl) and imidazole in N,N-dimethylformamide at room temperature for 6-24 hours.
The example of preparing the compound of Formula B3 from the Formula B2 by protection of hydroxyl group in the above Step 1 of the preparing method of the present invention is in the following reaction scheme.
Figure PCTKR2018004277-appb-I000103
ii) In the second step, the compound of Formula B3, prepared as described in step 1, may be converted to Formula B4 by Sonogashira reaction using catalytic amount of tetrakis(triphenylphosphine)palladium(0)(Pd(PPh3)4) or bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2) in one or more of N,N-dimethylformamide or methanol at 70-100℃ for 3-24 hour.
Example of preparing the compound of Formula B4 from the compound of Formula B3 by Sonogashira reaction in the above Step 2 of the preparing method of the present invention is in the following reaction scheme
Figure PCTKR2018004277-appb-I000104
iii) In the third step, the compound of Formula B4, prepared as described in step 2, may be converted to Formula B5 by deprotection of tert-butyldimethyloxy(
Figure PCTKR2018004277-appb-I000105
) using either Potassium fluoride in one or more of tetrahydrofuran or methanol or Tetrabutylammonium fluoride solution at 0℃ to room temperature for 1-6 hours.
Example of preparing the compound of Formula B5 from the compound of Formula B4 by deprotection reaction in the above Step 3 of the preparing method of the present invention is in the following reaction scheme.
Figure PCTKR2018004277-appb-I000106
iv) In the fourth step, the compound of Formula B5, prepared as described in step 3, may be converted to Formula B6 by substitution of with A8 under basic conditions in one or more of THF or N,N-dimethylformamide at room temperature for 5-24 hours.
Example of preparing the compound of Formula B6 from the compound of Formula B5 with A8 by substitution in the above Step 4 of the preparing method of the present invention is in the following reaction scheme.
Figure PCTKR2018004277-appb-I000107
v) In the fifth step, the compound of Formula B6, prepared as described in step 4, may be converted to Formula I by Sonogashira reaction with B7 using catalytic amount of tetrakis(triphenylphosphine)palladium(0)(Pd(PPh3)4) or bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPH3)2) and Copper(I)iodide under basic condition in one or more of tetrahydrofuran or N,N-dimethylformamide at 70-100℃ for 3-24 hour. Besides, the compound of Formula I can be prepared from Formula B6 with B7 by Sonogashira reaction with hydrolysis using lithium hydroxide in one or more of tetrahydrofuran, 1,4-dioxane or water at 80℃ for 4-48 hours.
Example of preparing the compound of Formula I from the compound of Formula B6 with B7 by Sonogashira reaction or hydrolysis after Sonogashira reaction from in the above Step 5 of the preparing method of the present invention is illustrated below.
Figure PCTKR2018004277-appb-I000108
Besides, another preparation method of the compound of Formula I according to the present invention is shown in the following reaction scheme 3.
[Scheme 3]
Figure PCTKR2018004277-appb-I000109
The compound of Formula I, which is a compound of the present invention, may be prepared by series of steps from the compound of Formula B6 as shown in Scheme 3.
R1, R2, R6, R7, Y and Z of Formula I, B2 and B7, illustrated in Scheme 3, are defined as below.
In the present Formula I,
Y is carbon or nitrogen,
R1 and R2 are each independently hydrogen, halo or trifluoromethyl,
Z is
Figure PCTKR2018004277-appb-I000110
or
Figure PCTKR2018004277-appb-I000111
,
n is 0, 1 or 2,
X1, X2 and X3 are each independently carbon or nitrogen,
R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000112
,
Figure PCTKR2018004277-appb-I000113
,
Figure PCTKR2018004277-appb-I000114
,
Figure PCTKR2018004277-appb-I000115
, CONRa1Ra2, NRa1Ra2, CH2NRa1Ra2, CH2Rc3, CORa3, ORa3, NRa4CORa3, NRa4CO2Ra3, NHCONHRa3, NHSO2Ra3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
wherein, m is 1 or 2,
Ra1 and Ra2 are each independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000116
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra3 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000117
,
Figure PCTKR2018004277-appb-I000118
,
Figure PCTKR2018004277-appb-I000119
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra4 is hydrogen or C1-6 alkyl,
R5 is hydrogen,
Figure PCTKR2018004277-appb-I000120
,
Figure PCTKR2018004277-appb-I000121
,
Figure PCTKR2018004277-appb-I000122
,
Figure PCTKR2018004277-appb-I000123
,
Figure PCTKR2018004277-appb-I000124
or
Figure PCTKR2018004277-appb-I000125
,
R6 and R7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
Rc3 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl,
W1, W2 and W3 are each independently oxygen, nitrogen, CHRw1, CRw1, NRw1 or CO,
wherein, Rw1 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl, C1-6 alkylamine, C1-6 alkyl alcohol,
Figure PCTKR2018004277-appb-I000126
,
Figure PCTKR2018004277-appb-I000127
(CH2)p heteroaryl or (CH2)p aryl, wherein, p is 1, 2 or 3.
The preparation method of the Formula I according to the present invention comprise:
Preparing the compound of Formula D2 by Sonogashira reaction of Formula B6 and D1 (Step 1);
Preparing the compound of Formula I by deprotection of tert-butyloxycarbonyl(
Figure PCTKR2018004277-appb-I000128
) or tert-butyldimethyloxy(
Figure PCTKR2018004277-appb-I000129
) and hydrolysis of Formula D2(Step 2);
Each step in the above preparation method of scheme 3 is described in more detail as follows.
i) In the first step, the compound of Formula B6, prepared as described in step 4 in scheme 2, may be converted to Formula D2 by Sonogashira reaction with Formula D1 using catalytic amount of tetrakis(triphenylphosphine)palladium(0)(Pd(PPh3)4) or bis(triphenyl phosphine)palladium(II) dichloride(PdCl2(PPH3)2) and Copper(I)iodide under basic condition in one or more of tetrahydrofuran or N,N-dimethylformamide at 70-100℃ for 3-24 hour
Example of preparing the compound of Formula D2 from the compound of Formula B6 with D1 by Sonogashira reaction in the above Step 1 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000130
ii) In the second step, the compound of Formula D2, prepared as described in step 1, may be converted to Formula I by hydrolysis using lithium hydroxide in one or more of tetahydrofuran, 1,4-dioxane or water at rt-80℃ for 4-48 hours followed by deprotection in the presence of boron tribromide solution or hydrogen chloride solution in dichloromethane or tetahydrofuran(THF) at 0-80℃ for 2-24 hours.
Example of preparing the compound of Formula I from the compound of Formula D2 by hydrolysis and deprotection reaction in the above Step 2 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000131
Besides, another preparation method of the compound of Formula I according to the present invention is shown in the following reaction scheme 4.
[Scheme 4]
Figure PCTKR2018004277-appb-I000132
The compound of Formula I, which is a compound of the present invention, may be prepared by series of steps from the compound of Formula B6 as shown in Scheme 4.
R1, R2, R6, R7, Re1, Re2, Y and Z of Formula I, B6 and E3, illustrated in Scheme 4, are defined as below:
In the present Formula I,
Y is carbon or nitrogen,
R1 and R2 are each independently hydrogen, halo or trifluoromethyl,
Z is
Figure PCTKR2018004277-appb-I000133
or
Figure PCTKR2018004277-appb-I000134
,
n is 0, 1 or 2,
X1, X2 and X3 are each independently carbon or nitrogen,
R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000135
,
Figure PCTKR2018004277-appb-I000136
,
Figure PCTKR2018004277-appb-I000137
,
Figure PCTKR2018004277-appb-I000138
, CONRa1Ra2, NRa1Ra2, CH2NRa1Ra2, CH2Rc3, CORa3, ORa3, NRa4CORa3, NRa4CO2Ra3, NHCONHRa3, NHSO2Ra3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
wherein, m is 1 or 2,
Ra1 and Ra2 are each independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000139
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra3 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000140
,
Figure PCTKR2018004277-appb-I000141
,
Figure PCTKR2018004277-appb-I000142
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra4 is hydrogen or C1-6 alkyl,
R5 is hydrogen,
Figure PCTKR2018004277-appb-I000143
,
Figure PCTKR2018004277-appb-I000144
,
Figure PCTKR2018004277-appb-I000145
,
Figure PCTKR2018004277-appb-I000146
,
Figure PCTKR2018004277-appb-I000147
or
Figure PCTKR2018004277-appb-I000148
,
R6 and R7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
Rc3 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl,
W1, W2 and W3 are each independently oxygen, nitrogen, CHRw1, CRw1, NRw1 or CO,
wherein, Rw1 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl, C1-6 alkylamine, C1-6 alkyl alcohol,
Figure PCTKR2018004277-appb-I000149
,
Figure PCTKR2018004277-appb-I000150
(CH2)p heteroaryl or (CH2)p aryl, wherein, p is 1, 2 or 3.
The preparation method of the Formula I according to the present invention comprise:
Preparing the compound of Formula E2 by Sonogashira reaction of Formula B6 and E1 (Step 1);
Preparing the compound of Formula E3 by reduction or reductive amination of Formula E2 (Step 2);
Preparing the compound of Formula I by hydrolysis of Formula E3 (Step 3).
Each step in the above preparation method of scheme 4 is described in more detail as follows.
i) In the first step, the compound of Formula B6, prepared as described in step 4 in scheme 2, may be converted to Formula E2 by Sonogashira reaction with Formula E1 using catalytic amount of tetrakis(triphenylphosphine) palladium(0)(Pd(PPh3)4) or bis(triphenylphosphine)palladium(II) dichloride (PdCl2(PPh3)2) and Copper(I) iodide under basic condition in one or more of tetrahydrofuran or N,N-dimethylformamide at 70-100℃ for 3-24 hour.
Example of preparing the compound of Formula E2 from the compound of Formula B6 with E1 by Sonogashira reaction in the above Step 1 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000151
ii) In the second step, the compound of Formula E2, prepared as described in step 1, may be converted to Formula E3 by reduction or reductive amination depending on the type of the substituent Re1.
The second step in the above preparation method of scheme 4 is described in more detail as follows.
In the second step of the preparation method, the desired compound of Formula E3 may be prepared by reduction or reductive amination.
The above reduction reaction may be carried out by Tin(II) chloride dehydrate in ethyl acetate or ethanol with the compound of Formula E2(When Re2 is nitro in the above Formula) at room temperature for one day and it is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000152
In the present invention, the compound of Formula E2(When Re1 is aldehyde in the above Formula)also may be converted to Formula E3(A substituent maybe introduced in the presence of sodium carbonate and Rc4-I in N,N-dimethylformamide) by reductive amination in the presence of sodiumtriacetoxyborohydride(NaBH(OAc)3) or acetic acid in one or more of dichloromethane or 1,2-dichloroethane at room temperature for overnight and it is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000153
iii) In the third step, the compound of Formula E3, prepared as described in step 2, may be converted to Formula I by hydrolysis using lithium hydroxide in one or more of tetrahydrofuran, 1,4-dioxane or water at rt - 80℃ for 4-48 hours.
Example of preparing the compound of Formula I from the compound of Formula E3 by hydrolysis in the above Step 3 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000154
Besides, another preparation method of the compound of Formula I according to the present invention is shown in the following reaction scheme 5.
[Scheme 5]
Figure PCTKR2018004277-appb-I000155
The compound of Formula I, which is a compound of the present invention, may be prepared by series of steps from the compound of Formula B6 as shown in Scheme 5.
R1, R2, R3, R6, R7, Y and Z of Formula I, B6 and G4, illustrated in Scheme 5, are defined as below:
In the present Formula I,
Y is carbon or nitrogen,
R1 and R2 are each independently hydrogen, halo or trifluoromethyl,
Z is
Figure PCTKR2018004277-appb-I000156
or
Figure PCTKR2018004277-appb-I000157
,
n is 0, 1 or 2,
X1, X2 and X3 are each independently carbon or nitrogen,
R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000158
,
Figure PCTKR2018004277-appb-I000159
,
Figure PCTKR2018004277-appb-I000160
,
Figure PCTKR2018004277-appb-I000161
, CONRa1Ra2, NRa1Ra2, CH2NRa1Ra2, CH2Rc3, CORa3, ORa3, NRa4CORa3, NRa4CO2Ra3, NHCONHRa3, NHSO2Ra3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
wherein, m is 1 or 2,
Ra1 and Ra2 are each independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000162
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra3 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000163
,
Figure PCTKR2018004277-appb-I000164
,
Figure PCTKR2018004277-appb-I000165
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra4 is hydrogen or C1-6 alkyl,
R5 is hydrogen,
Figure PCTKR2018004277-appb-I000166
,
Figure PCTKR2018004277-appb-I000167
,
Figure PCTKR2018004277-appb-I000168
,
Figure PCTKR2018004277-appb-I000169
,
Figure PCTKR2018004277-appb-I000170
or
Figure PCTKR2018004277-appb-I000171
,
R6 and R7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
Rc3 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl,
W1, W2 and W3 are each independently oxygen, nitrogen, CHRw1, CRw1, NRw1 or CO,
wherein, Rw1 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl, C1-6 alkylamine, C1-6 alkyl alcohol,
Figure PCTKR2018004277-appb-I000172
,
Figure PCTKR2018004277-appb-I000173
(CH2)p heteroaryl or (CH2)p aryl, wherein, p is 1, 2 or 3.
The preparation method of the Formula I according to the present invention comprise:
Preparing the compound of Formula G2 by Sonogashira reaction of Formula B6 and G1 (Step 1);
Preparing the compound of Formula G3 by reduction of Formula G2 (Step 2);
Preparing the compound of Formula G4 by substitution or addition reaction of Formula G3 (Step 3);
Preparing the compound of Formula I by hydrolysis of compound of Formula G4(Step 4).
Each step in the above preparation method of scheme 5 is described in more detail as follows.
i) In the first step, the compound of Formula B6, prepared as described in step 4 in scheme 2, may be converted to Formula G2 by Sonogashira reaction with Formula G1 using catalytic amount of tetrakis(triphenylphosphine)palladium(0)(Pd(PPh3)4) or bis(triphenyl phosphine)palladium(II) dichloride(PdCl2(PPh3)2) and Copper(I) iodide under basic condition in one or more of tetrahydrofuran or N,N-dimethylformamide at 70-100℃ for 3-24 hour.
Example of preparing the compound of Formula G2 from the compound of Formula B6 with G1 by Sonogashira reaction in the above Step 1 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000174
ii) In the second step, the compound of Formula G2, prepared as described in step 1, may be converted to Formula G3 using Tin(II) chloride dehydrate in ethyl acetate or ethanol at room temperature for one day and it is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000175
iii) In the third step, the compound of Formula G3, prepared as described in step 2, may be converted to Formula G4 by substitution or addition.
The third step in the above preparation method of scheme 5 is described in more detail as follows.
In the third step of the preparation method, the desired compound of Formula G4 may be prepared by substitution or addition.
The compound of Formula G3 may be converted to Formula G4 by the above substitution in the presence of tert-butylnitrile with iodine in toluene at room temperature for 3 hours or by iodo substitution followed by substitution with amine compound using L-proline, cesium carbonate, copper(I) iodide in dimethylsulfoxide.
Example of preparing the compound of Formula G4 from the compound of Formula G3 by substitution or iodo substitution followed by amine substitution in the above Step 3 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000176
In the present invention, the compound of Formula G4 may be prepared by addition reaction which is carried out with the compound of Formula G3 and
Figure PCTKR2018004277-appb-I000177
,
Figure PCTKR2018004277-appb-I000178
or
Figure PCTKR2018004277-appb-I000179
(Rc3 in the Formula is same as that defined in the above Formula I) in dichloromethane or N,N-dimethylformamide at room temperature for 3-6 hours and it is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000180
The compound of Formula G3 may be converted to Formula G4 by another method of the addition reaction which is carried out with
Figure PCTKR2018004277-appb-I000181
(Rc3 in the Formula is same as that defined in the above Formula I) in the presence of triphosgene or 1,1'-carbonyldiimiazole in dichloromethane or tetrahydrofuran(THF) at room temperature for 2-6 hours and it is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000182
iv) In the fourth step, the compound of Formula G4, prepared as described in step 3, may be converted to Formula I by hydrolysis using lithium hydroxide in one or more of tetrahydrofuran, 1,4-dioxane or water at rt-80℃ for 4-48 hours.
Example of preparing the compound of Formula I from Formula G4 by hydrolysis in the above Step 4 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000183
Besides, another preparation method of the compound of Formula I according to the present invention is shown in the following reaction scheme 6.
[Scheme 6]
Figure PCTKR2018004277-appb-I000184
The compound of Formula I, which is a compound of the present invention, may be prepared by series of steps from the compound of Formula B6 as shown in Scheme 6.
R1, R2, R3, R6, R7, Rj1, Y and Z of Formula I, B6 and J3, illustrated in Scheme 6, are defined as below:
In the present Formula I,
Y is carbon or nitrogen,
R1 and R2 are each independently hydrogen, halo or trifluoromethyl,
Z is
Figure PCTKR2018004277-appb-I000185
or
Figure PCTKR2018004277-appb-I000186
,
n is 0, 1 or 2,
X1, X2 and X3 are each independently carbon or nitrogen,
R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000187
,
Figure PCTKR2018004277-appb-I000188
,
Figure PCTKR2018004277-appb-I000189
,
Figure PCTKR2018004277-appb-I000190
, CONRa1Ra2, NRa1Ra2, CH2NRa1Ra2, CH2Rc3, CORa3, ORa3, NRa4CORa3, NRa4CO2Ra3, NHCONHRa3, NHSO2Ra3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
wherein, m is 1 or 2,
Ra1 and Ra2 are each independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000191
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra3 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
Figure PCTKR2018004277-appb-I000192
,
Figure PCTKR2018004277-appb-I000193
,
Figure PCTKR2018004277-appb-I000194
or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
Ra4 is hydrogen or C1-6 alkyl,
R5 is hydrogen,
Figure PCTKR2018004277-appb-I000195
,
Figure PCTKR2018004277-appb-I000196
,
Figure PCTKR2018004277-appb-I000197
,
Figure PCTKR2018004277-appb-I000198
,
Figure PCTKR2018004277-appb-I000199
or
Figure PCTKR2018004277-appb-I000200
,
R6 and R7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
Rc3 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl,
W1, W2 and W3 are each independently oxygen, nitrogen, CHRw1, CRw1, NRw1 or CO,
wherein, Rw1 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl, C1-6 alkylamine, C1-6 alkyl alcohol,
Figure PCTKR2018004277-appb-I000201
,
Figure PCTKR2018004277-appb-I000202
(CH2)p heteroaryl or (CH2)p aryl, wherein, p is 1, 2 or 3.
The preparation method of the Formula I according to the present invention comprise:
Preparing the compound of Formula J2 by Sonogashira reaction of Formula B6 and J1 (Step 1);
Preparing the compound of Formula J3 by reduction of Formula J2 (Step 2);
Preparing the compound of Formula I by hydrolysis or addition of compound of Formula J3 (Step 3);
Each step in the above preparation method of scheme 6 is described in more detail as follows.
i) In the first step, the compound of Formula B6, prepared as described in step 4 in scheme 2, may be converted to Formula J2 by Sonogashira reaction with Formula J1 using catalytic amount of tetrakis(triphenylphosphine) palladium(0)(Pd(PPh3)4) or bis(triphenyl phosphine)palladium(II)dichloride (PdCl2(PPh3)2) and Copper(I)iodide under basic condition in one or more of tetrahydrofuran or N,N-dimethylformamide at 70-100℃ for 3-24 hour.
Example of preparing the compound of Formula J2 from the compound of Formula B6 with J1 by Sonogashira reaction in the above Step 1 of the preparing method of the present invention is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000203
ii) In the second step, the compound of Formula J2, prepared as described in step 1, may be converted to Formula J3 by reduction reaction with Tin(II) chloride dehydrate in ethyl acetate or ethanol at room temperature for one day and it is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000204
iii) In the third step, the compound of Formula J3, prepared as described in step 2, may be converted to Formula I by hydrolysis or addition reaction.
The third step in the above preparation method of scheme 6 is described in more detail as follows.
In the third step of the preparation method, the desired compound of Formula I may be prepared by hydrolysis or addition reaction.
The compound of Formula J3 may be converted to Formula I by above hydrolysis reaction under the condition of lithium hydroxide in one or more of tetrahydrofuran, 1,4-dioxane or water at rt-80℃ for 4-48 hours and it is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000205
Besides, the compound of Formula I may be prepared by addition reaction with Formula J3 under basic condition in N,N-dimethylformamide or tetrahydrofuran at room temperature or heating condition for 3 or 24 hours in the present invention and it is illustrated in the following reaction scheme.
Figure PCTKR2018004277-appb-I000206
In addition, the present invention provides a pharmaceutical compostion for the treatment, prevention, or amelioration of the metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis comprising the compound of Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
The metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis may be caused by FXR receptor activity. Exemplary diseases include hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, dyslipidemia, lipodystrophy, cholestasis/fibrosis, cholesterol gallstone disease, gastrointestinal disease or condition, hyperglycemia, diabetes, insulin resistance, metabolic inflexibility, nephropathy, liver diseases, atherosclerosis, cancer, inflammatory disorders, osteoporosis and skin aging.
The present invention provides a method of the treatment, prevention, or amelioration of metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis in a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition to the subject. The dosage of pharmaceutical composition of the present invention may vary depending on the patient's weight, age, gender, physical condition, diet, the time and mode of administration, excretion rates, and the severity of illness. Mammals(including human) are desirable for the individual without limit.
Compounds of the invention intended for pharmaceutical use may be administered as a solid or liquid, such as a tablet, capsule, solution or suspension. Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition(Mack Publishing Company, 1995).
Oral Administration
In one embodiment, the compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
Formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solid and liquid(including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids, emulsions or powders; lozenges(including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches. Liquid(including multiple phases and dispersed systems) formulations include emulsions, suspensions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules(made, for example, from gelatin or hydroxypropyl methyl cellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methyl cellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001)
The immediate release portion may comprise a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, powdered cellulose, loweralkyl-substituted hydroxypropyl cellulose, polacrilin potassium, starch, pregelatinizedstarch, sodium alginate, and mixtures thereof. Generally, the disintegrant will comprise from 1 wt% to 80 wt%, preferably from 5 wt% to 60 wt% of the layer.
Examples of matrix materials, fillers, or diluents include lactose, mannitol, xylitol, dextrose, sucrose, sorbitol, compressible sugar, microcrystalline cellulose, powdered cellulose, starch, pregelatinized starch, dextrates, dextran, dextrin, dextrose, maltodextrin, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, magnesium carbonate, magnesium oxide, poloxamers, polyethylene oxide, hydroxypropyl methyl cellulose and mixtures thereof.
When preparing dosage forms incorporating the compositions of the invention, the compounds may also be blended with conventional excipients such as binders, including gelatin, pregelatinized starch, and the like; lubricants, such as hydrogenated vegetable oil, stearic acid, and the like; diluents, such as lactose, mannose, and sucrose; disintegrants, such as carboxymethyl cellulose and sodium starch glycolate; suspending agents, such as povidone, polyvinyl alcohol, and the like; absorbants, such as silicon dioxide; preservatives, such as methylparaben, propylparaben, and sodium benzoate; surfactants; such as sodium lauryl sulfate, polysorbate 80, and the like; flavorants; and sweeteners. If present, the surfactants would comprise of 0.2 wt% to 5 wt% and the absorbants would comprise from 0.2 wt% to 1 wt%. Another excipients include one or more of: anti-oxidants, colorant, flavouring agents, preservatives and taste-masking agents.
Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting. The final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.
The formulation of tablets is discussed in °Pharmaceutical Dosage Forms: Tablets, Vol. 1¡±, by H. Lieberman and L.Lachman, Marcel Dekker, N.Y., N.Y., 1980 (ISBN 0-8247-6918-X).
Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release
Parenteral Administration
The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intra-arterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
Suitable devices for parenteral administration includes needle(including micro needle) injectors, needle-free injectors and infusion techniques. An example of a needle free injection is PowderjectTM.
Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents(preferably, to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non aqueous solution or as a powdered, dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
A proper dosage form such as combination with solubility enhancer can increase solubility of compound of formula I used in non-oral solution.
Formulations for parenteral administration may be formulated to be immediate and/or modified/controlled release. Controlled/modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and pro-grammed release. Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and PGLA microspheres.
Local Administration
The compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Li-posomes may also be used.
Does
In human patients, the precise daily dose administered depends on various factors such as the age, sex, weight and condition of the patient being treated. The amount of dose can be selected within the bounds of goal achieving treatment effect without harmful or serious adverse effect.
For instance, the dosage of the compound of invention may be administered in an effective amount raging from 0.05 to 1000mg daily on patients. The following dosage levels and other dosage levels herein are for the average human subject having a weight range of about 65 to 70kg. The skilled person will readily be able to determine the dosage levels required for a subject whose weight falls outside this range, such as children and the elderly.
The present invention explain, but are not limited, in detail through the following examples and experimental examples.
[Examples]
<Intermediate 1> 4-( bromomethyl )-5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole
Step 1 : Preparation of 2,6- dichlorobenzaldehyde oxime
Sodium hydroxide(6.3g, 160mmol) and 2,6-dichlorobenzaldehyde(25g, 140mmol) in ethanol(200ml) was added to hydroxylamine hydrochloride(11g, 160mmol) in water(100ml) and stirred for 24 hours at 90 ℃. The reaction mixture was evaporated in vacuum, filtered with water(200ml, 2 times) and dried in vacuum to afford the intermediate compound 2,6-dichlorobenzaldehyde oxime(25.9g, 96%).
1H-NMR (DMSO, 400MHz): δ 11.80 (s, 1H), 8.22 (s, 1H), 7.55 (d, 2H), 7.45-7.41 (dd, 1H).
Step 2 : Preparation of 2,6- dichloro -N- hydroxybenzimidoyl chloride
N-chlorosuccinimide(NCS, 18.4g, 140mmol) was added to a solution of the intermediate compound(Step 1)(25.9g, 140mmol) in chloroform(1000ml) and stirred for 4 hours at room temperature. The reaction mixture was evaporated in vacuum, diluted with dicholrometane and washed with water. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to afford the intermediate compound 2,6-dichloro-N-hydroxybenzimidoyl chloride(29g) without any further purification.
Step 3 : Preparation of ethyl 5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole -4- carboxylate
The intermediate compound(Step 2)(29g, 129mmol) was added to ethyl 3-cyclopropyl-3-oxopropanate(25ml, 194mmol) in triethylamine(150ml)and stirred for 24 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to afford the intermediate compound ethyl 5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate (22.37g, 56%).
1H-NMR (CDCl3, 400MHz): δ 7.41-7.38 (m, 2H), 7.35-7.31 (m, 4H), 3.69 (s, 3H), 2.91 (m, 1H), 1.43-1.39 (m, 2H), 1.30-1.26 (m, 2H).
Step 4 : (5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl )methanol
1M Diisobutylaluminium hydride(DIBAL-H, 144ml, 144mmol) was added to the intermediate compound(Step 3)(22.37g, 71.7mmol) in tetrahydrofuran(72ml) at 0oC and stirred for 7 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with 10 w/w% citric acid solution and water, The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatographyto afford the intermediate compound (5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methanol(12.2g, 60%).
1H-NMR (CDCl3, 400MHz): δ 7.44-7.40 (m, 2H), 7.37-7.33 (m, 1H), 4.41 (d, 2H), 2.19 (m, 1H), 1.40 (t, 1H), 1.30-1.25 (m, 2H), 1.17-1.10 (m, 2H).
Step 5 : Preparation of 4-( bromomethyl )-5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole
Triphenylphosphine(TPP, 16.9g, 64.53mmol) and tetrabromomethane(21.4g, 64.53mmol) was slowlly added to the intermediate compound(Step 4)(12.2g, 43.02mmol) in dichloromethane(158ml) at 0oC and stirred for 4 hours at room temperature. The reaction mixture was evaporated in vacuum and purified using silica chromatography to afford the title compound(13.44g, 90%).
1H-NMR (CDCl3, 400MHz): δ 7.46-7.45 (dd, 2H), 7.40-7.36 (dd, 1H), 4.23 (s, 2H), 2.12 (m, 1H), 1.32-1.23 (m, 2H), 1.22-1.17 (m, 2H).
<Example 1> 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl ) methoxy)phenyl)ethynyl)benzoic acid; ( I-1)
Step 1 : Preparation of tert - butyl(4-iodophenoxy)dimethylsilane
tert-Butyldimethylsilyl chloride (TBSCl, 2.1g, 13.6mmol) and imidazole (1.2g, 18.2mmol) were added to a solution of 4-Iodophenol(2g, 9.1mmol) in N,N-dimethylformamide (45ml) and stirred for 12 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with water. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to afford the intermediate compound tert-butyl(4-iodophenoxy)dimethylsilane(2.8g, 93%).
1H-NMR (CDCl3, 400MHz): δ 7.32 (m, 2H), 6.43 (m, 2H), 0.78 (t, 9H), 0.23 (t, 6H).
Step 2 : Preparation of tert -butyl(4-((trimethylsilyl)ethyl)phenoxy)silane
Trimethylsilylacetylene(2.4ml, 17mmol), bis(triphenylphosphine)palladium(ii) dichloride (PdCl2(PPh3)2, 0.6g, 0.85mmol), Copper(I) iodide(0.16g, 0.85mmol), and triethylamine(0.6ml, 4.25mmol) were added to a solution of the intermediate compound(Step 1)(2.8g, 8.5mmol) in N,N-dimethylformamide (50ml) and stirred for 12 hours at 80℃. The reaction mixture was diluted with Ethyl acetate and washed with water. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to afford the intermediate compound tert-butyl(4-((trimethylsilyl)ethyl)phenoxy)silane (1.99g, 77%).
1H-NMR (CDCl3, 400MHz): δ 7.32 (m, 2H), 6.43 (m, 2H), 0.78 (s, 9H), 0.25 (s, 9H), 0.23 (s, 6H).
Step 3 : Preparation of 4-(( trimethylsilly )ethyl)phenol
Potassium fluoride (KF, 3.8g, 65mmol) was added to a solution of the intermediate compound(Step 2)( 1.99g, 6.5mmol) in methanol (65ml) at 0℃ and stirred for 1 hour. The reaction mixture was diluted with dichloromethane and washed with water. The combined organic layers were dried over MgSO4, filtered, and evaporated in vacuum. The resulting 4-((trimethylsilly)ethyl)phenol was used for next step without any further purification.
Step 4 : Preparation of 5- cyclopropyl -3-(2,6- dichlorophenyl )-4-((4- ethynylphenoxy)methyl)isoxazole
4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxlazole(Intermediate 1)(2.25g, 6.5mmol) and potassium carbonate (1.34g, 9.75mmol) were added to a solution of the intermediate compound(Step 3)(1.25g, 6.5mmol) in N,N-dimethylformamide (65ml) stirred for 12 hours at room temperature. The reaction mixture was diluted with Ethyl acetate and washed with water. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to afford the intermediate compound 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-((4-ethynylphenoxy)methyl)isoxazole(2.05g, 82%)
1H-NMR (CDCl3, 400MHz): δ 7.41-7.30 (m, 5H), 6.83 (d, 1H), 6.66 (dd, 1H), 4.80 (s, 2H), 3.26 (s, 1H), 2.17-2.10 (m, 1H), 1.31-1.27 (m, 2H), 1.23-1.17 (m, 2H).
Step 5 : Preparation of methyl 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate
4-iodobenzoate (67mg, 0.52mmol), bis(triphenylphosphine)palladium(ii) dichloride (PdCl2(PPh3)2, 42mg, 0.06mmol), Copper(I) iodide(11.4mg, 0.06mmol), and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.4ml, 2.6mmol) were added to a solution of the intermediate compound(Step 4)(200mg, 0.52mmol) in N,N-dimethylformamide (5.2ml) and stirred for 4 hours at 80℃. The reaction mixture was diluted with Ethyl acetate and washed with water. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to afford the intermediate compound methyl 4-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate (175mg, 65%).
1H-NMR (MeOD, 400MHz): δ 8.03 (d, 2H), 8.01-7.40 (m, 7H), 6.83 (d, 2H), 4.94 (s, 2H), 3.93 (s, 3H), 2.37-2.34 (m, 1H), 1.24-1.22 (m, 4H).
Step 6 : Preparation of 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
lithium hydroxide(14.2mg, 0.34mmol) was added to a solution of the intermediate compound(Step 5)( 175mg, 0.34mmol) in 1,4-dioxane(3ml) and distilled water(0.4ml) and stirred for 18 hours at room temperature. The reaction mixture was acidified to pH=2~3 with 1N HCl and extracted with ethyl acetate. The combined organic layers were dried over MgSO4, filtered, and evaporated in vacuum to afford the title compound(133mg, 78%).
1H-NMR (CDCl3, 400MHz): δ 8.01 (dd, 2H), 7.55 (dd, 2H), 7.43-7.40 (m, 4H), 7.34-7.32 (m, 1H), 6.79 (d, 2H), 4.83 (s, 2H), 2.20-2.16 (m, 1H), 1.30-1.22 (m, 2H), 1.19-1.13 (m, 2H).
<Example 2> 3-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl ) methoxy)phenyl)ethynyl)benzoic acid; (I-2)
Step 1 : Preparation of methyl 3-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 2(Step 5). Thus, this intermediate compound(Step 4 of Example 1)(100mg, 0.26mmol) was reacted with 3-bromobenzoate (56mg, 0.26mmol), bis(triphenylphosphine) palladium(II) dichloride (PdCl2(PPh3)2, 21mg, 0.03mmol), Copper(I) iodide(5.7mg, 0.03mmol), and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.2ml, 1.3mmol) to afford the intermediate compound methyl 3-((4-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(40mg, 30%).
1H-NMR (CDCl3, 400MHz): δ 8.17 (s, 1H), 8.17-7.96 (m, 1H), 7.68-7.65 (m, 1H), 7.42-7.40 (m, 5H), 7.34-7.30 (m, 1H), 6.80-6.77 (m, 2H), 4.82 (s, 2H), 3.93 (s, 3H), 2.19-2.15 (m, 1H), 1.31-1.27 (m, 2H), 1.17-1.13 (m, 2H).
Step 2 : Preparation of 3-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol - 4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(40mg, 0.08mmol) was reacted with lithium hydroxide(LiOH, 3.3mg, 0.08mmol) to afford the title compound(30mg, 78%).
1H-NMR (CDCl3, 400MHz): δ 8.19-8.18 (m, 1H), 8.00-7.98 (m, 1H), 7.68-7.66 (m, 1H), 7.43-7.40 (m, 5H), 7.36-7.34 (m, 1H), 6.80-6.77 (m, 2H), 4.83 (s, 2H), 2.20-2.16 (m, 1H), 1.31-1.26 (m, 2H), 1.19-1.14 (m, 2H).
<Example 3> 3-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl ) methoxy )-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid; (I-3)
Step 1 : Preparation of tert -butyl(4- iodo -3-( trifluoromethyl ) phenoxy ) dimethylsilane
This compound was made using the procedure described for example 1(Step 1). Thus, 4-Iodo-3-(trifluoromethyl)phenol(40mg, 0.14mmol) was reacted with tert-Butyldimethylsilyl chloride (TBSCl, 32mg, 0.21mmol) and imidazole (19mg, 0.28mmol) to afford the intermediate compound tert-butyl(4-iodo-3-(trifluoro methyl)phenoxy)dimethylsilane(52mg, 93%).
1H-NMR (CDCl3, 400MHz): δ 7.64(d, 1H), 6.97 (d, 1H), 6.48 (dd, 1H), 0.96 (s, 9H), 0.16 (s, 6H).
Step 2 : Preparation of tert - butyldimethyl(3- ( trifluoromethyl )-4-(( trimethylsilyl ) ethynyl)phenoxy)silane
This compound was made using the procedure described for example 1(Step 2). Thus, this intermediate compound(Step 1)(52mg, 0.13mmol) was reacted with Trimethylsilylacetylene(0.036ml, 0.26mmol), bis(triphenylphosphine)palladium(ii) dichloride (PdCl2(PPh3)2, 9.1mg, 0.013mmol), Copper(I) iodide(2.4mg, 0.013mmol) and triethylamine(0.095ml, 0.65mmol) to afford the intermediate compound tert-butyldimethyl(3-(trifluoromethyl)-4-((trimethylsilyl)ethynyl) phenoxy)silane(41.1mg, 88%).
1H-NMR (CDCl3, 400MHz): δ 7.35 (d, 1H), 6.87 (d, 1H), 6.66 (dd, 1H), 0.96 (s, 9H), 0.25 (s, 9H), 0.19 (s, 6H).
Step 3 : Preparation of 3-( trifluoromethyl )-4-(( trimethylsilyl ) ethynyl )phenol
This compound was made using the procedure described for example 1(Step 3). Thus, this intermediate compound(Step 2)(41.1mg, 0.16mmol) was reacted with Potassium fluoride (KF, 93mg, 1.6mmol) to afford the intermediate compound 3-(trifluoromethyl)-4-((trimethylsilyl)ethynyl)phenol. The resulting residue was used for next step without any further purification.
Step 4 : Preparation of 5- cyclopropyl -3-(2,6- dichlorophenyl )-4-((4- ethynyl -3 -(trifluoromethyl)phenoxy)methyl)isoxazole
This compound was made using the procedure described for example 1(Step 4). Thus, this intermediate compound(Step 3)(0.16mmol) was reacted with 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxlazole(Intermediate 1)(50mg, 0.144mmol), and potassium carbonate (26.6mg, 0.192mmol) to afford the intermediate compound 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-((4- ethynyl-3-(trifluoromethyl)phenoxy)methyl)isoxazole(36mg, 50%).
1H-NMR (CDCl3, 400MHz): δ 7.50-7.48 (m, 1H), 7.40-7.30 (m, 3H), 7.08-7.04 (m, 1H), 6.90-6.86 (m, 1H), 4.86 (s, 2H), 3.25 (s, 1H), 2.17-2.11 (m, 1H), 1.35-1.22 (m, 2H), 1.18-1.14 (m, 2H).
Step 5 : Preparation of methyl 3-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)-2-(trifluoromethyl)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, this intermediate compound(Step 4)(36mg, 0.080mmol) was reacted with methyl 3-iodobenzoate(21mg, 0.080mmol), bis(triphenylphosphine)palladium(II) dichloride (PdCl2(PPh3)2, 5.6mg, 0.008mmol), Copper(I) iodide(1.5mg, 0.008mmol) and triethylamine(0.013ml, 0.096mmol)to afford the intermediate compound methyl 3-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)-2-(trifluoromethyl)phenyl)ethynyl)benzoate(3mg, 75%).
1H-NMR (CDCl3, 400MHz): δ 8.17-8.16 (m, 1H), 8.02-7.99 (m, 1H), 7.70-7.67 (m, 1H), 7.54-7.51 (m, 1H), 7.45-7.31 (m, 4H), 7.09-7.08 (m, 1H), 6.94-6.91 (m, 1H), 4.88 (s, 2H), 3.94 (s, 3H), 2.18-2.13 (m, 1H), 1.33-1.29 (m, 2H), 1.22-1.15 (m, 2H).
Step 6 : Preparation of 3-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol - 4- yl ) methoxy )-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 5)(35mg, 0.06mmol) was reacted with lithium hydroxide(2.5mg, 0.06mmol) to afford the title compound (23mg, 68%).
1H-NMR (CDCl3, 400MHz): δ 8.23-8.21 (m, 1H), 8.06-8.05 (m, 1H), 7.71-7.66 (m, 1H), 7.55-7.31 (m, 5H), 7.09-7.08 (m, 1H), 7.00-6.91 (m, 1H), 4.88 (s, 2H), 2.17-2.12 (m, 1H), 1.33-1.28 (m, 2H), 1.20-1.15 (m, 2H).
<Example 4> 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl ) methoxy )-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid; (I-4)
Step 1 : Preparation of methyl 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl ) methoxy )-2-(trifluoromethyl)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, the intermediate compound(Step 4 of Example 3) 5-cyclopropyl-3-(2,6- dichlorophenyl)-4-((4-ethynyl-3-(trifluoromethyl)phenoxy)methyl)isoxazole(45mg, 0.1mmol) was reacted with methyl 4-iodobenzoate (28mg, 0.1mmol), bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 13mg, 0.02mmol), copper(I) iodide(1.7mg, 0.01mmol) and triethylamine(0.06ml, 0.46mmol) to afford the intermediate compound methyl 4-((4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)phenyl)ethynyl)benzoate(42mg, 71%).
1H-NMR (CDCl3, 400MHz): δ 8.02 (dd, 2H), 7.57-7.52 (m, 3H), 7.41-7.39 (m, 2H), 7.35 (dd, 1H), 7.09 (d, 1H), 6.94 (dd, 1H), 4.88 (s, 2H), 3.93 (s, 3H), 2.17-2.13 (m, 1H), 1.32-1.27 (m, 2H), 1.20-1.16 (m, 2H).
Step 2 : Preparation of 4-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl ) methoxy )-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step1)(42mg, 0.07mmol) was reacted with lithium hydroxide(29mg, 0.7mmol) to afford the title compound(40mg, 100%).
1H-NMR (DMSO, 400MHz): δ 13.27 (s, 1H), 8.05 (d, 2H), 7.78 (d, 1H), 7.73-7.58 (m, 5H), 7.24-7.21 (m, 2H), 5.15 (s, 2H), 2.59 (m, 1H), 1.29-1.21 (m, 4H).
<Example 5> 4-((3- chloro -4- ethynylphenoxy )methyl)-5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole ; (I-5)
Step 1 : Preparation of tert-butyl(3-chloro-4-iodophenoxy)dimethylsilane
This compound was made using the procedure described for example 1(Step 1). Thus, 3-chloro-4-iodophenol(10g, 39.5mmol) was reacted with tert-butyldimethylsilyl chloride(TBSCl, 7.5g, 47.2mmol) and imidazole(3g, 59mmol) to afford theintermediate compound tert-butyl(3-chloro-4-iodo phenoxy)dimethylsilane(9g, 66%).
1H-NMR (CDCl3, 400MHz): δ 7.64(d, 1H), 6.97 (d, 1H), 6.48 (dd, 1H), 0.96 (s, 9H), 0.16 (s, 6H).
Step 2 : Preparation of tert-butyl(3-chloro-4-((trimethylsilyl)ethynyl)phenoxy) dimethylsilane
This compound was made using the procedure described for example 1(Step 2). Thus, the intermediate compound(Step 1)(9g, 24.4mmol) was reacted with trimethylsilylacetylene(6.76ml, 48.8mmol), bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 0.85g, 1.22mmol), copper(I) iodide(0.23g, 1.22mmol), triethylamine(15.3ml, 109.8mmol) to afford the intermediate compound tert-butyl(3-chloro-4-((trimethylsilyl)ethynyl)phenoxy)dimethylsilane(7.44g, 90%).
1H-NMR (CDCl3, 400MHz): δ 7.35 (d, 1H), 6.87 (d, 1H), 6.66 (dd, 1H), 0.96 (s, 9H), 0.25 (s, 9H), 0.19 (s, 6H).
Step 3 : Preparation of 3-chloro-4-((trimethylsilyl)ethynyl)phenol
This compound was made using the procedure described for example 1(Step 3). Thus, the intermediate compound(Step 2)(7.44g, 21.9mmol) was reacted with potassium fluoride(KF, 12.7g, 219mmol) to afford the intermediate compound 3-chloro-4-((trimethylsilyl)ethynyl)phenol and used without further purification.
Step 4 : Preparation of 4-((3- chloro -4- ethyntlphenoxy ) metehyl )-5- cyclopropyl -3-(2,6- dichlorophenyl)isoxazole
This compound was made using the procedure described for example 1(Step 4). Thus, the intermediate compound(Step 3)(4.92g, 21.9mmol) was reacted with 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole(example 1)(7.59g, 21.9mmol) and potassium carbonate(4.54g, 32.9mmol) to afford the title compound(7.15g, 78%).
1H-NMR (CDCl3, 400MHz): δ 7.41-7.30 (m, 4H), 6.83 (d, 1H), 6.66 (dd, 1H), 4.80 (s, 2H), 3.26 (s, 1H), 2.17-2.10 (m, 1H), 1.31-1.27 (m, 2H), 1.23-1.17 (m, 2H).
<Example 6> 4-((3- chloro -4-( phenylethynyl ) phenoxy )methyl)-5- cyclopropyl - 3-(2,6-dichlorophenyl)isoxazole; (I-6)
Step 1 : Preparation of 4-((3- chloro -4-( phenylethynyl ) phenoxy )methyl)-5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazole
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(example 6)(128mg, 0.306mmol) was reacted with bromobenzene(48mg, 0.306mmol), bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 21.5mg, 0.031mmol), copper(I) iodide(5.8mg, 0.031mmol) and triethylamine(0.052ml, 0.367mmol) to afford the title compound (7.15g, 78%).
1H-NMR (CDCl3, 400MHz): δ 7.54-7.52 (m, 2H), 7.42-7.31 (m, 7H), 6.87-6.86 (d, 1H), 6.69-6.66 (dd, 1H), 4.81 (s, 2H), 2.17-2.04 (m, 1H), 1.29-1.24 (m, 2H), 1.19-1.14 (m, 2H).
<Example 7> methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate; (I-7)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 6)(128mg, 0.31mmol) was reacted with methyl 3-iodobenzoate(80mg, 0.31mmol), bis(triphenylphosphine)palladium(II) dichloride (PdCl2(PPh3)2, 22mg, 0.03mmol), Copper(I) iodide(5.8mg, 0.03mmol) and triethylamine(0.052ml, 0.37mmol) to afford the title compound(107mg, 63%).
1H-NMR (CDCl3, 400MHz): δ 8.20-8.19 (m, 1H), 8.01-7.98 (m, 1H), 7.72-7.69 (m, 1H), 7.43-7.32 (m, 5H), 6.88-6.87 (m, 1H), 6.71-6.68 (m, 1H), 4.82 (s, 2H), 3.94 (s, 3H), 2.18-2.15 (m, 1H), 1.32-1.28 (m, 2H), 1.20-1.16 (m, 2H).
(Example 8) Methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoate (I-8)
Step 1 : Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-nitrobenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol(example 6)(3.6g, 8.59mmol) was reacted with methyl 3-bromo-5-nitrobenzoate(2.6g, 10.3mmol), bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 302mg, 0.429mmol), copper(I)iodide(81.8mg, 0.429mmol) and triethylamine(1.44ml, 10.3mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((cyclopropyl-3-(2,6-dichlorophenyl)isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-nitrobenzoate(3.9g, 80%).
1H-NMR (CDCl3, 400MHz): δ 8.78 (t, 1H), 8.51 (t, 1H), 8.46 *t, 1H), 7.44-7.40 (m, 3H), 7.36-7.32 (m, 1H), 6.89 (d, 1H), 6.73 (dd, 1H), 4.84 (s, 2H), 4.00 (s, 3H), 2.19-2.13 (m, 1H), 1.32-1.28 (m, 2H), 1.20-1.15 (m, 2H).
Step 2 : Preparation of methyl 3-amino-5-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
The intermediate compound(step 1) was dissolved in ethyl acetate(70ml) and ethanol(35ml) and tin(II) chloride dihydrate(15.5g, 68.7mmol) were added. The reaction was stirred at room temperature for 1 day. The reaction mixture was extracted with ethyl acetate and washed with water. The combined organic phase was dried over MgSO4, filtered, concentrated and purified by column chromatography on silica to give methyl 3-amino-5-((2-chloro-4-((cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate (3.0g, 77%).
1H-NMR (CDCl3, 400MHz): δ 7.59-7.58 (m, 1H), 7.41-7.27 (m, 5H), 7.00-6.99 (m, 1H), 6.87-6.86 (m, 1H), 6.69-6.67 (m, 1H), 4.82 (s, 2H), 3.90 (s,3H), 2.19-2.12 (m, 1H), 1.31-1.28 (m, 2H), 1.20-1.14 (m, 2H).
Step 3 : Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoate
The intermediate compound(step 2) was dissolved in N,N-dimethylform amide(8.8ml) and ethylchloroformate(250ul, 2.64mmol), triethylamine(369ul, 2.64mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene(DBU, 13 ul, 0.0881mmol) were added. The reaction was stirred at room temperature for 4 hours. The reaction mixture was extracted with ethyl acetate and washed with water. The combined organic phase was dried over MgSO4, filtered, concentrated and purified by column chromatography on silica to give the title compound(254mg, 65%).
1H-NMR (CDCl3, 400MHz): δ 13.42 (br, 1H), 8.03 (d, 1H), 7.82 (t, 1H), 7.65-7.61 (m, 2H), 7.58-7.54 (m, 1H), 7.13 (d, 1H), 6.87 (dd, 1H), 5.01 (s, 2H), 1.05-1.32 (m, 5H).
(Example 9) Methyl 3-( tert - butoxycarbonyl )amino)-5-((2- chloro -4- (( cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate (I-9)
Step 1 : Preparation of methyl 3-( tert - butoxycarbonyl )amino)-5-((2- chloro -4- (( cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 8(Step 3). Thus, methyl 3-amino-5-((2-chloro-4-((cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of example 9)(500mg, 0.880mmol) was reacted with di-tert-butyl dicarbonate(385mg, 1.76mmol), 4-dimethylaminopyridine(5.4mg, 0.044mmol) and triethylamine(0.2ml, 1.32mmol) to afford the title compound(300mg, 51%).
1H-NMR (CDCl3, 400MHz): δ 8.12 (t, 1H), 7.89 (t, 1H), 7.79 (t, 1H), 7.51 - 7.31 (m, 5H), 6.86 (d, 1H), 6.69 (dd, 1H), 6.61(s, 1H), 4.81 (s, 2H), 3.93 (s, 3H), 2.17 (m, 1H), 1.52 (s, 9H), 1.31 1.23 (m, 2H), 1.19 - 1.16 (m, 2H).
(Example 10) Methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)(methyl)amino)benzoate; (I-10)
Step 1 : Preparation of methyl 3-( tert - butoxycarbonyl )amino)-5-((2- chloro -4- (( cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)(methyl)amino)benzoate
The compound methyl 3-amino-5-((2-chloro-4-((cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoate(example 8)(220mg, 0.348mmol) was dissolved in N,N-dimethylformamide(5ml) and sodiumhydride(25mg, 1.04mmol) and iodomethane(87ul, 1.39mmol) were added. The reaction was stirred at room temperature for 20 hours. The reaction mixture was extracted with ethyl acetate and washed with water. The combined organic phase was dried over MgSO4, filtered, concentrated and purified by column chromatography on silica to afford the title compound(113mg, 48%).
1H-NMR (CDCl3, 400MHz): δ 8.02 (t, 1H), 7.88 (s, 1H), 7.62 (s, 1H), 7.42-7.38 (m, 1H), 7.35-7.31 (m, 1H), 6.87 (d, 1H), 6.70 (dd, 1H), 4.82 (s, 2H), 4.22 (q, 2H), 3.93 (s, 3H), 3.32(s, 3H), 2.17-2.13 (m, 1 H), 1.34(t, 3H), 1.32-1.24 (m, 2H), 1.23-1.14 (m, 2H).
<Example 11> ethyl (3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)phenyl)carbamate; (I-11)
Step 1 : Preparation of 4-((3- chloro -4-((3- nitrophenyl ) ethynyl ) phenoxy ) methyl)-5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazole
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(300mg, 0.72mmol) was reacted with 1-iodo-3-nitrobenzene(178.4mg, 0.72mmol), tetrakis(triphenylphosphine) palladium(0)(Pd(PPh3)4, 81mg, 0.07mmol), copper(I) iodide(13.3mg, 0.07mmol) and N,N -diisopropylethylamine(0.15ml, 0.86mmol) to afford the intermediate compound 4-((3-chloro-4-((3-nitrophenyl)ethynyl)phenoxy)methyl)-5-cyclo propyl-3-(2,6-dichlorophenyl)isoxazole(368.8mg, 95%).
1H-NMR (CDCl3, 400MHz): δ 8.36(s, 1H), 8.17(d, 1H), 7.82(d, 1H), 7.55-7.43(m, 2H), 7.42-7.40(m, 3H), 6.88(d, 1H), 6.71(dd, 1H), 4.83(s, 2H), 2.18-2.13(m, 1H), 1.31-1.30(m, 2H), 1.19-1.17(m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)aniline
This compound was made using the procedure described for example 8(Step 2). Thus, this intermediate compound(Step 1)(100mg, 0.19mmol) was reacted with tin(II) chloride dihydrate(208.9mg, 0.93mmol) to afford the intermediate compound 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4- yl)methoxy)phenyl)ethynyl)aniline(60mg, 62%).
1H-NMR (CDCl3, 400MHz): δ 7.70(s, 1H), 7.68(d, 1H), 7.55-7.33(m, 4H), 7.15-7.12(m, 1H), 6.99-6.93(m, 1H), 6.88(d, 1H), 6.66(dd, 1H), 4.80(s, 2H), 2.17-2.14(m, 1H), 1.30-1.24(m, 2H), 1.19-1.14(m, 2H).
Step 3 : Preparation of ethyl(3-((2-chloro-4-( (5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)phenyl)carbamate
Triethylamine(12.3ul, 0.08mmol) and ethylchloroformate(8.3ul, 0.08mmol) was added to a suspension of the intermediate compound(Step 2)(30mg, 0.06mmol) in dichloromethane and stirred for 7 hours at room temperature. Water was added to the reaction mixture and the product was extracted into dichloromethane. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to give the title compound(25mg, 72%).
1H-NMR (MeOD, 400MHz): δ 7.53(s, 1H), 7.43-7.41(m, 2H), 7.38-7.29(m, 3H), 7.17(t, 1H), 7.05(dd, 1H), 6.81(d, 1H), 6.65(dd, 1H), 5.90(s, 2H), 4.08(q, 2H), 2.28-2.21(m, 1H), 1.19(t, 3H), 1.14-1.08(m, 4H).
<Example 12> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzenesulfonamide; (I-12)
Step 1 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzenesulfonamide
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(75mg, 0.17mmol) was reacted with 3-bromobenzenesulfonamide(200mg, 0.85mmol), bis(triphenylphosphine) palladium(II) dichloride (PdCl2(PPh3)2, 13mg, 0.02mmol), Copper(I) iodide(3.5mg, 0.02mmol) and triethylamine(0.030ml, 0.21mmol) to afford the title compound(12mg, 12%).
1H-NMR (CDCl3, 400MHz): δ 8.08 (m, 1H), 7.86-.7.89 (m, 1H), 7.70-7.64 (m, 3H), 7.57-7.44 (m, 3H), 6.88 (m, 1H), 6.71-6.68 (m, 1H), 4.83 (s, 2H), 2.17-2.14 (m, 1H), 1.33-1.28 (m, 2H), 1.20-1.15 (m, 2H).
<Example 13> N - (3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)phenyl)methanesulfonamide; (I-13)
Step 1 : Preparation of N -(3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)phenyl)methanesulfonamide
Methanesulfonyl chloride(2drops) was added to a solution of 3-((2-chloro-4- ((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)aniline(Step 2 of example 11)(35mg, 0.0686mmol) in tetrahydrofuran(1ml) and triethylamine(0.05ml, 0.343mmol) was added to the reaction mixture and stirred for 8 hours. The reaction mixture was concentrated in vacuum, added 1N HCl(aq) and extracted into ethyl acetate. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to afford the title compound(27mg, 67%).
1H-NMR (CDCl3, 400MHz): δ 7.42-7.32 (m, 7H), 7.22-7.19 (m, 1H), 6.87 (d, 1H), 6.70-6.68 (dd, 1H), 6.38 (s, 1H), 4.82 (s, 2H), 6.04 (s, 3H), 2.15-2.14 (m, 1H), 1.31-1.24 (m, 2H), 1.19-1.15 (m, 2H).
<Example 14> N -(3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)phenyl)sulfamide; (I-14)
Step 1 : Preparation of N -(3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)phenyl)sulfamide
This compound was made using the procedure described for example 13(Step 1). Thus, 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4- yl)methoxy)phenyl)ethynyl)aniline(Step 2 of example 11)(34.8mg, 0.0683mmol) was reacted with chlorosulfonylisocyanate(2drops) and pyridine(15μl, 0.1366mmol) to afford the title compound(23.9mg, 89%).
1H-NMR (DMSO, 400MHz): δ 9.67 (s, 1H), 7.64-7.62 (m, 2H), 7.57-7.50 (m, 2H), 7.31-7.29 (d, 2H), 7.21-7.08 (m, 5H), 6.83-6.80 (dd, 1H), 4.98 (s, 2H), 1.21-1.17 (m, 2H), 1.15-1.13 (m, 2H).
<Example 15> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-15)
Step 1 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)phenyl)ethynyl)benzoate(Example 7)(105mg, 0.190mmol) was reacted with lithium hydroxide(8mg, 0.19mmol) to afford the title compound (66mg, 65%).
1H-NMR (CDCl3, 400MHz): δ 8.27-8.26 (m, 1H), 8.08-8.05 (m, 1H), 7.77-7.75 (m, 1H), 7.49-7.32 (m, 5H), 6.89-6.88 (m, 1H), 6.72-6.69 (m, 1H), 4.83 (s, 2H), 2.17-2.14 (m, 1H), 1.33-1.28 (m, 2H), 1.20-1.15 (m, 2H).
<Example 16> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-16)
Step 1 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(175mg, 0.42mmol)was reacted with methyl 4-bromobenzoate(100mg, 0.38mmol), bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 53mg, 0.08mmol), copper(I) iodide(7mg, 0.04mmol) and triethylamine(0.26ml, 1.89mmol) to afford the intermediate compound methyl 4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(150mg, 71%).
1H-NMR (CDCl3, 400MHz): δ 8.02 (dd, 2H), 7.59 (dd, 2H), 7.42-7.40 (m, 3H), 7.35 (dd, 1H), 6.88 (d, 1H), 6.71 (dd, 1H), 4.82 (s, 2H), 3.92 (s, 3H), 2.17-2.13 (m, 1H), 1.32-1.28 (m, 2H), 1.19-1.15 (m, 2H).
Step 2 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(150mg, 0.27mmol) was reacted with lithium hydroxide(114mg, 2.7mmol) to afford the title compound (106mg, 73%).
1H-NMR (DMSO, 400MHz): δ 13.16 (s, 1H), 7.98 (dd, 2H), 7.65-7.62 (m, 4H), 7.57-7.53 (m, 2H), 7.11 (d, 1H), 6.85 (dd, 1H), 4.99 (s, 2H), 2.46 (m, 1H), 1.22-1.12 (m, 4H).
<Example 17> 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)nicotinic acid; (I-17)
Step 1 : Preparation of methyl 6-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)nicotinate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Eample 5)(100mg, 0.239mmol) was reacted with methyl 6-bromonicotinate(61.9mg, 0.287mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate compound methyl 6-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl) ethynyl)nicotinate(77mg, 68%).
1H-NMR (CDCl3, 400MHz): δ 9.20 (dd, 1H), 8.28 (dd, 1H), 7.60 (dd, 1H), 7.50 (d, 1H), 7.43-7.39 (m, 2H), 7.36-7.31 (m, 1H), 6.89 (d, 1H), 6.71 (dd, 1H), 4.83 (s, 3 H), 3.97 (s, 3 H), 2.20-2.10(m, 1 H), 1.34-1.29 (m, 2H), 1.21-1.15 (m, 2H).
Step 2 : Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)nicotinic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(77mg, 0.14mmol) was reacted with lithium hydroxide(58mg, 1.40mmol) to afford the title compound(23.5mg, 27%).
1H-NMR (DMSO, 400MHz): δ 13.55 (br, 1H), 9.06 (dd, 1H), 8.29 (dd, 1H), 7.74 (dd, 1H), 7.65 7.60 (m, 3H), 7.53-7.58 (m, 1 H),7.13 (d, 1H), 6.87 (dd, 1H), 5.01 (s, 2H), 1.25-1.12 (m, 5H).
<Example 18> 2-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)isonicotinic acid; (I-18)
Step 1 : Preparation of methyl 2-((4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)isonicotinate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Eample 5)(100mg, 0.239mmol) was reacted with methyl 2-bromoisonicotinate(61.9mg, 0.287mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate compound methyl 2-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl) ethynyl)isonicotinate(47.6mg, 36%).
1H-NMR (CDCl3, 400MHz): δ 8.77 (dd, 1H), 8.07 (dd, 1H), 7.78 (dd, 1H), 7.49 (d, 1H),7.31-7.44 (m, 2H), 7.26 (s, 1H), 6.89 (d, 1H), 6.71 (dd, 1H), 4.83 (s, 2H), 3.98 (s, 3H), 2.18-2.13 (m, 1H), 1.35-1.21 (m, 2 H), 1.21-1.11 (m, 2H).
Step 2 : Preparation of 2-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)isonicotinic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(47.6mg, 0.086mmol) was reacted with lithium hydroxide(36mg, 0.86mmol) to afford the title compound(27mg, 58%).
1H-NMR (DMSO, 400MHz): δ 13.73(br, 1H), 8.03 (d, 1H), 7.82 (t, 1H), 7.60 -7.65 (m, 1 H), 7.58-7.53 (m, 3 H), 7.13 (d, 1H),6.87 (dd, 1H), 5.01 (s, 2H), 1.32-1.03(m, 5H).
<Example 19> 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)picolinic acid; (I-19)
Step 1 : Preparation of methyl 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)picolinate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Eample 5)(100mg, 0.239mmol) was reacted with methyl 6-bromopicolinate(65.9mg, 0.287mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate compound methyl 6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)picolinate(60.4mg, 45%).
1H-NMR (CDCl3, 400MHz): δ 8.06 (dd, 1H), 7.83 (t, 1H), 7.70 (dd 1H), 7.50 (d, 1H), 7.43-7.39 (m, 2H),7.36-7.31 (m, 1H), 6.88 (d, 1H),6.70 (dd, 1H), 4.83 (s, 2H), 4.49 (q, 2H), 2.18-2.12(m, 1H), 1.45 (t, 3H), 1.30 (dd, 2H), 1.17 (dd, 2H).
Step 2 : Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)picolinic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(60.4g, 0.106mmol) was reacted with lithium hydroxide(44.5mg, 1.06mmol) to afford the title compound(9.7mg, 17%).
1H-NMR (DMSO, 400MHz): δ 13.42 (br, 1H), 8.03 (d, 1H), 7.82 (t, 1H), 7.65-7.61 (m, 2H), 7.58-7.54 (m, 1H), 7.13 (d, 1H), 6.87 (dd, 1H), 5.01 (s, 2H), 1.05-1.32 (m, 5H).
<Example 20> 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)nicotinic acid; (I-20)
Step 1 : Preparation of methyl5 -((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)nicotinate
This compound was made using the procedure described for example 1(Step 5). Thus 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol(Example 5)(100mg, 0.239mmol) was reacted with methyl 5-bromonicotinate(65.9mg, 0.287mmol), bis(triphenylphosphine) palladium(II)Dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I)iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate compound methyl 5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)nicotinate(68.8mg, 52%).
1H-NMR (CDCl3, 400MHz): δ 9.13 (s, 1H), 8.90 (s, 1H), 8.41 (d, 1H), 7.46-7.40 (m, 3H), 7.36-7.32 (m, 1H), 6.90 (d, 1H), 6.72 (dd, 1H), 4.84 (s, 2H), 3.97 (s, 3H), 2.16 (m, 1H), 1.32-1.28 (m, 2H), 1.21-1.15 (m, 2H).
Step 2 : Preparation of 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)nicotinic acid
This compound was made using the procedure described for example 1(Step 6). Thus the intermediate compound(Step 1)(68.8mg, 0.124mmol) was reacted with lithium hydroxide(52mg, 1.24mmol) to afford the title compound(44.8mg, 67%).
1H-NMR (CDCl3, 400MHz): δ 9.26 (s, 1H), 8.98 (s, 1H), 8.54 (d, 1H), 7.45-7.40 (m, 3H), 7.36-7.32 (m, 1H), 6.89 (d, 1H), 6.72 (dd, 1H), 4.84 (s, 2H), 2.16 (m, 1H), 1.32-1.28 (m, 2H), 1.19-1.17 (m, 2H).
<Example 21> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(dimethylamino)benzoic acid; (I-21)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(dimethylamino)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.26mmol) was reacted with methyl 4-bromo-3-(dimethylamino)benzoate(67mg, 0.26mmol), bis (triphenylphosphine) palladium(II) dichloride (PdCl2(PPh3)2, 21mg, 0.03mmol), Copper(I) iodide(5.7mg, 0.03mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.2ml, 1.3mmol)to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(dimethylamino)benzoate(70mg, 42%).
1H-NMR (CDCl3, 400MHz): δ 7.55-7.54 (m, 1H), 7.42-7.31 (m, 5H), 7.02-7.01 (m, 1H), 6.87-6.86 (m, 1H), 6.70-6.67 (m, 1H), 4.82 (s, 2H), 3.91 (s, 3H), 3.01 (s, 6H), 2.18-2.14 (m, 1H), 1.32-1.28 (m, 2H), 1.19-1.16 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(dimethylamino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(70mg, 0.118mmol) was reacted with lithium hydroxide(4.9mg, 0.118mmol) to afford the title compound (54mg, 78%).
1H-NMR (CDCl3, 400MHz): δ 7.60 (s, 1H), 7.43-7.32 (m, 5H), 7.05-7.04 (m, 1H), 6.88-6.87 (m, 1H), 6.70-6.68 (m, 1H), 4.82 (s, 2H), 3.02 (s, 6H), 2.18-2.14 (m, 1H), 1.32-1.29 (m, 2H), 1.19-1.16 (m, 2H).
<Example 22> 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)picolinic acid; (I-22)
Step 1 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-3-(dimethylamino)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.26mmol) was reacted with methyl 4-bromo-3-(dimethylamino)benzoate(67mg, 0.26mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.2ml, 1.3mmol) to afford the intermediate compound methyl 4-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-3-(dimethylamino)benzoate(80mg, 55%).
1H-NMR (CDCl3, 400MHz): δ 7.58 (br, 1H), 7.53 (br, 1H), 7.43-7.41 (m, 3H), 7.35-7.31 (m, 1H), 6.87 (d, 1H), 6.716.68 (dd, 1H), 4.82 (s, 2H), 3.91 (s, 3H), 3.02 (s, 6H), 2.15 (m, 1H), 1.32-1.29 (m, 2H), 1.19-1.14 (m, 2H).
Step 2 : Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)picolinic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(80mg, 0.14mmol) was reacted with lithium hydroxide(58.7 mg, 1.4 mmol) to afford the title compound (42mg, 55%).
1H-NMR (DMSO, 400MHz): δ 7.92 (d, 1H), 7.79-7.76 (dd, 1H), 7.65-7.62 (m, 2H), 7.57-7.52 (m, 2H), 7.07 (d, 1H), 6.93 (d, 1H), 6.83-6.80 (dd, 1H), 4.98 (s, 2H), 3.08 (s, 6H), 2.49 (m, 1H), 1.21-1.13 (m, 4H).
<Example 23> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-(dimethylamino)benzoic acid; (I-23)
Step 1 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-(dimethylamino)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(200mg, 0.52mmol) was reacted with methyl 4-bromo-2-(dimethylamino)benzoate(134mg, 0.52mmol), bis(triphenyl phosphine)palladium(II) dichloride (PdCl2(PPh3)2, 42mg, 0.06mmol), Copper(I) iodide(11.4mg, 0.06mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.4ml, 2.6mmol) to afford the intermediate compound methyl 4-((2-chloro -4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-(dimethylamino)benzoate(132mg, 43%).
1H-NMR (CDCl3, 400MHz): δ 7.66-7.64 (m, 1H), 7.43-7.32 (m, 4H), 7.09-7.08 (m, 1H), 7.02-6.99 (m, 1H), 6.88-6.87 (m, 1H), 6.70-6.68 (m, 1H), 4.82 (s, 2H), 3.91 (s, 3H), 2.87 (s, 6H), 2.18-2.14 (m, 1H), 1.32-1.28 (m, 2H), 1.20-1.16 (m, 2H).
Step 2 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-(dimethylamino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(132mg, 0.221mmol) was reacted with lithium hydroxide(9.3mg, 0.221mmol) to afford the title compound (36mg, 28%).
1H-NMR (CDCl3, 400MHz): δ 8.26-8.24 (m, 1H), 7.57-7.52 (m, 2H), 7.43-7.33 (m, 4H), 6.89-6.88 (m, 1H), 6.72-6.69 (m, 1H), 4.83 (s, 2H), 2.84 (s, 6H), 2.16-2.12 (m, 1H), 1.31-1.28 (m, 2H), 1.19-1.15 (m, 2H).
<Example 24> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(diethylamino)benzoic acid; (I-24)
Step 1 : Preparation of Methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(diethylamino)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(20mg, 0.052mmol) was reacted with methyl 4-bromo-2-(diethylamino)benzoate(14.9mg, 0.052mmol), bis(tripheny lphosphine)palladium(II) dichloride (PdCl2(PPh3)2, 4.2mg, 0.006mmol), Copper(I) iodide(1.14mg, 0.006mmol) and 1,8-Diazabicyclo[5.4.0] undec-7-ene(DBU, 0.04ml, 0.26mmol)to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)-5-(diethylamino)benzoate(9mg, 28%).
1H-NMR (CDCl3, 400MHz): δ 7.55-7.54 (m, 1H), 7.42-7.31 (m, 5H), 7.02-7.01 (m, 1H), 6.87-6.86 (m, 1H), 6.70-6.67 (m, 1H), 4.82 (s, 2H), 3.91 (s, 3H), 3.49 (s, 3H), 3.42-3.37 (m, 3H), 2.18-2.14 (m, 1H), 1.32-1.28 (m, 2H), 1.20-1.16 (m, 6H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(diethylamino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(9mg, 0.0144mmol) was reacted with lithium hydroxide(0.6mg, 0.0144mmol) to afford the title compound (5mg, 57%).
1H-NMR (CDCl3, 400MHz): δ 7.52-7.50 (m, 1H), 7.42-7.40 (m, 3H), 7.35-7.31 (m, 2H), 6.99-6.98 (m, 1H), 6.87-6.86 (m, 1H), 6.70-6.67 (m, 1H), 4.82 (s, 2H), 33.49 (s, 3H), 3.42-3.37 (m, 3H), 2.17-2.15 (m, 1H), 1.31-1.30 (m, 2H), 1.20-1.16 (m, 6H).
<Example 25> 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-25)
Step 1 : Preparation of 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, methyl 3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of Example 8)(71mg, 0.13mmol) was reacted with lithium hydroxide(54.6mg, 1.30mmol) to afford the title compound (54mg, 78%).
1H-NMR (CDCl3, 400MHz): δ 7.62 (s, 1H), 7.41-7.31 (m, 5H), 7.01-6.99 (m, 1H), 6.86-6.85 (m, 1H), 6.69-6.68 (m, 1H), 4.81 (s, 2H), 2.16-2.14 (m, 1H), 1.31-1.29 (m, 2H), 1.18-1.15 (m, 2H).
<Example 26> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-(dimethylamino)benzoic acid; (I-26)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-(dimethylamino)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.26mmol) was reacted with methyl 3-bromo-4-(dimethylamino)benzoate(67mg, 0.26mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.2ml, 1.3mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-(dimethylamino)benzoate(70mg, 48%).
1H-NMR (CDCl3, 400MHz): δ 8.14 (d, 1H), 7.87-7.84 (dd, 1H), 7.42-7.38 (m, 3H), 7.35-7.31 (m, 1H), 6.86 (d, 1H), 6.82 (d, 1H), 6.70-6.68 (dd, 1H), 4.82 (s, 2H), 3.88 (s, 3H), 3.14 (s, 6H), 2.16 (m, 1H), 1.30-1.26 (m, 2H), 1.24-1.16 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-(dimethylamino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(70mg, 0.12mmol) was reacted with lithium hydroxide(50.4 mg, 1.2mmol) to afford the title compound(35mg, 53%).
1H-NMR (DMSO, 400MHz): δ 7.95 (d, 1H), 7.79-7.76 (dd, 1H), 7.64-7.62 (m, 2H), 7.57-7.51 (m, 2H), 7.07 (d, 1H), 6.93 (d, 1H), 6.83-6.80 (dd, 1H), 4.97 (d, 1H), 3.08 (s, 6H), 2.47 (m, 1H), 1.23-1.13 (m, 4H).
<Example 27> 33- chloro -5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-27)
Step 1 : Preparation of methyl 3- chloro -5-((2- chloro -4-((5- cyclopropyl - 3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.26mmol) was reacted with methyl 3-bromo-5-chlorobenzoate(65mg, 0.26mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene(DBU, 0.2ml, 1.3mmol) to afford the intermediate compound methyl 3-chloro-5-((2-chloro-4-((5- cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(87mg, 61%).
1H-NMR (CDCl3, 400MHz): δ 8.06 (m, 1H), 7.96 (m, 1H), 7.67 (m, 1H), 7.42-7.35 (m, 3H), 7.34-7.31 (m, 1H), 6.88 (d, 1H), 6.71-6.68 (dd, 1H), 4.83 (s, 2H), 3.94 (s, 3H), 2.15 (m, 1H), 1.31-1.24 (m, 2H), 1.18-1.16 (m, 2H).
Step 2 : Preparation of 3- chloro -5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(87mg, 0.16mmol) was reacted with lithium hydroxide(67.2mg, 1.6mmol) to afford the title compound(43mg, 50%).
1H-NMR (DMSO, 400MHz): δ 7.93 (br, 1H), 7.88 (br, 1H), 7.64-7.62 (m, 3H), 7.56 (m, 2H), 7.10 (d, 1H), 6.85-6.83 (dd, 1H), 4.99 (s, 2H), 2.47 (m, 1H), 1.22-1.14 (m, 4H).
<Example 28> 4- chloro -3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-28)
Step 1 : Preparation of methyl 4- chloro -3-((2- chloro -4-((5- cyclopropyl - 3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.26mmol) was reacted with methyl 3-bromo-4-chlorobenzoate(65mg, 0.26mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene(DBU, 0.2ml, 1.3mmol) to afford the intermediate compound methyl 4-chloro-3-((2-chloro-4-((5- cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(87mg, 61%).
1H-NMR (CDCl3, 400MHz): δ 8.22 (d, 1H), 7.92-7.89 (dd, 1H), 7.51-7.40 (m, 4H), 7.35-7.33 (m, 1H), 6.88 (d, 1H), 6.71-6.69 (dd, 1H), 4.83 (s, 2H), 3.93 (s, 3H), 2.15 (m, 1H), 1.31-1.24 (m, 2H), 1.18-1.16 (m, 2H).
Step 2 : Preparation of 4- chloro -3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(87mg, 0.16mmol) was reacted with lithium hydroxide(67.2mg, 1.6mmol) to afford the title compound(43mg, 50%).
1H-NMR (DMSO, 400MHz): δ 8.10 (d, 1H), 7.94-7.91 (dd, 1H), 7.72 (d, 1H), 7.65-7.53 (m, 4H), 7.11 (d, 1H), 6.87-6.84(d, 1H), 5.00 (s, 2H), 2.47 (m, 1H), 1.21-1.13 (m, 4H).
<Example 29> 2- chloro -5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-29)
Step 1 : Preparation of methyl 2- chloro -5-((2- chloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(example 5)(155mg, 0.37mmol) was reacted with methyl 5-bromo-2-chlorobenzoate(100mg, 0.34mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 48mg, 0.06mmol), copper(I) iodide(6.5mg, 0.03mmol) and triethylamine(0.23ml, 1.7mmol) to afford the intermediate compound methyl 2-chloro-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(155mg, 78%).
1H-NMR (CDCl3, 400MHz): δ 7.98 (s, 1H), 7.55 (dd, 1H), 7.44-7.31 (m, 5H), 6.87 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 3.94 (s, 3H), 2.17-2.13 (m, 1H), 1.32-1.27 (m, 2H), 1.19-1.15 (m, 2H).
Step 2 : Preparation of 2- chloro -5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(155mg, 0.264mmol) was reacted with lithium hydroxide(58.7mg, 2.64mmol) to afford the title compound(75mg, 50%).
1H-NMR (DMSO, 400MHz): δ13.65 (s, 1H), 7.88 (d, 1H), 7.67-7.53 (m, 6H), 7.10 (d, 1H), 6.85 (dd, 1H), 4.99 (s, 2H), 2.46 (m, 1H), 1.22-1.12 (m, 4H).
<Example 30> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-fluorobenzoic acid; (I-30)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-fluorobenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(50mg, 0.119mmol) was reacted with methyl 3-fluoro-5-iodobenzoate(40mg, 0.143mmol), bis(triphenylphosphine) palladium(II) dichloride (PdCl2(PPh3)2, 8.4mg, 0.012mmol), Copper(I) iodide(2.3mg, 0.012mmol) and triethylamine(0.020ml, 0.143mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-fluorobenzoate(23mg, 34%).
1H-NMR (CDCl3, 400MHz): δ 7.99-7.98 (m, 1H), 7.71-7.67 (m, 1H), 7.43-7.32 (m, 5H), 6.88-6.87 (m, 1H), 6.71-6.69 (m, 1H), 4.83 (s, 2H), 3.94 (s, 3H), 2.17-2.15 (m, 1H), 1.33-1.28 (m, 2H), 1.19-1.16 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-fluorobenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(23mg, 0.040mmol) was reacted with lithium hydroxide(1.7mg, 0.040mmol) to afford the title compound(17mg, 76%).
1H-NMR (CDCl3, 400MHz): δ 8.05-8.04 (m, 1H), 7.76-7.73 (m, 1H), 7.47-7.43 (m, 4H), 7.36-7.32 (m, 1H), 6.89-6.88 (m, 1H), 6.72-6.69 (m, 1H), 4.83 (s, 2H), 2.18-2.14 (m, 1H), 1.33-1.30 (m, 2H), 1.17-1.15 (m, 2H).
<Example 31> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethyl)benzoic acid; (I-31)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(50mg, 0.119mmol) was reacted with methyl 3-bromo-5-(trifluoromethyl)benzoate(41mg, 0.143mmol), bis (triphenyl phosphine)palladium(II) dichloride (PdCl2(PPh3)2, 8.4mg, 0.012mmol), Copper(I) iodide(2.3mg, 0.012mmol) and triethylamine(0.020ml, 0.143mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethyl)benzoate(56mg, 76%).
1H-NMR (CDCl3, 400MHz): δ 8.35 (s, 1H), 8.23 (s, 1H), 7.94 (s, 1H), 7.43-7.31 (m, 4H), 6.89-6.88 (m, 1H), 6.73-6.70 (m, 1H), 4.83 (s, 2H), 3.98 (s, 3H), 2.18-2.14 (m, 1H), 1.33-1.28 (m, 2H), 1.20-1.17 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(55mg, 0.089mmol) was reacted with lithium hydroxide(3.7mg, 0.0.089mmol) to afford the title compound(50mg, 93%).
1H-NMR (CDCl3, 400MHz): δ 8.40 (s, 1H), 8.29 (s, 1H), 7.99 (s, 1H), 7.52-7.32 (m, 4H), 6.90-6.89 (m, 1H), 6.73-6.70 (m, 1H), 4.84 (s, 2H), 2.18-2.14 (m, 1H), 1.32-1.28 (m, 2H), 1.20-1.15 (m, 2H).
<Example 32> 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-ethynylbenzoic acid; (I-32)
Step 1 : Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-ethynylbenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol(example 5)(11.2mg, 0.027mmol) was reacted with methyl 3-bromo-5-((trimethylsilyl)ethynyl)benzoate(7.6mg, 0.032mmol), bis (triphenyl phosphine)palladium(II)dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate methyl 3-((2-chloro-4-((cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-ethynylbenzoate(14.7mg, 85%).
1H-NMR (CDCl3, 400MHz): δ 8.10 (t, 1H), 8.08 (t, 1H), 7.78 (t, 1H), 7.51-7.32 (m, 4 H), 6.87 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 3.93 (s, 3H), 2.24-2.10 (m, 1H), 1.30-1.26 (m, 2H), 1.23-1.12 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-ethynylbenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step1)(14.7mg, 0.023mmol) was reacted with lithium hydroxide(9.5mg, 0.23mmol) to afford the title compound(4.0mg, 31%).
1H-NMR (CDCl3, 400MHz): δ 8.98 (br, 1H), 8.24-8.20 (m, 1H), 8.17- 8.12(m, 1H), 7.87-7.85 (m, 1H), 7.44-7.39 (m, 3H), 7.37-7.34 (m, 1H), 6.88 (d, 1H), 6.70 (dd, 1H), 4.83 (s, 2H), 3.16 (s, 1H), 2.12 - 2.19 (m, 1H), 1.35-1.28 (m, 2H), 1.22-1.14 (m, 2H).
<Example 33> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-cyanobenzoic acid; (I-33)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-cyanobenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(200mg, 0.52mmol) was reacted with methyl 3-bromo-5-cyanobenzoate(129mg, 0.52mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 42mg, 0.0.6mmol), copper(I) iodide(11.4mg, 0.06mmol) and1,8-Diazabicyclo[5.4.0]undec-7-ene(DBU, 0.4ml, 2.6mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-cyanobenzoate(165mg, 55%).
1H-NMR (CDCl3, 400MHz): δ 8.39 (s, 1H), 8.26(s, 1H), 7.97(s, 1H), 7.45-7.34(m, 4H), 6.91(d, 1H), 6.75-6.72(dd, 1H), 4.86(s, 2H), 4.00(s, 3H), 2.19-2.15(m, 1H), 1.35-1.31(m, 2H), 1.22-1.17(m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-cyanobenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(165mg, 0.28mmol)was reacted with lithium hydroxide(117mg, 2.8mmol) to afford the title compound(97mg, 62%).
1H-NMR (DMSO, 400MHz): δ 8.20 (s, 1H), 8.17 (s, 1H), 8.01 (s, 1H), 7.64-7.53 (m, 4H), 7.11 (dd, 1H), 6.86-6.83 (dd, 1H), 4.99 (s, 2H), 2.48 (m, 1H), 1.24-1.12 (m, 4H).
<Example 34> 3-((2,6- dichloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-34)
Step 1 : Preparation of tert-butyl(3,5-dichloro-4-iodophenoxy)dimethylsillane
This compound was made using the procedure described for example 1(Step 1). Thus, 3,5-dichloro-4-iodophenol(2g, 6.92mmol) was reacted with tert-Butyldimethylsilyl chloride(TBSCl, 1.56g, 10.38mmol) and imidazole (0.94g, 13.84mmol) to afford the intermediate compound tert-butyl(3,5-dichloro-4- iodophenoxy)dimethylsillane(2.45g, 88%).
1H-NMR (CDCl3, 400MHz): δ 7.82 (s, 2H), 0.96 (s, 9H), 0.16 (s, 6H).
Step 2 : Preparation of tert-butyl(3,5-dichloro-4-((trimethylsilyl)ethynyl) phenoxy)dimethylsillane
This compound was made using the procedure described for example 1(Step 2). Thus, this intermediate compound(Step 1)(2.45g, 6.09mmol) was reacted with Trimethylsilylacetylene( 1.73ml, 12.18mmol), bis(triphenylphosphine) palladium(II) dichloride (PdCl2(PPh3)2, 0.43g, 0.61mmol), Copper(I) iodide(0.12g, 0.61mmol) and triethylamine(1.7ml, 12.18mmol) to afford the intermediate compound tert-butyl(3,5-dichloro-4-((trimethylsilyl)ethynyl)phenoxy) dimethyl sillane(1.12g, 52%).
1H-NMR (CDCl3, 400MHz): δ 7.82 (s, 2H), 0.96 (s, 9H), 0.25 (s, 9H), 0.16 (s, 6H).
Step 3 : Preparation of 3,5- dichloro -4-(( trimethylsilyl ) ethynyl )phenol
This compound was made using the procedure described for example 1(Step 3). Thus, this intermediate compound(Step 2)( 1.12g, 3.17mmol) was reacted with Potassium fluoride (KF, 1.84g, 31.7mmol) to afford the intermediate compound 3,5-dichloro-4-((trimethylsilyl)ethynyl)phenol. The resulting residue was used for next step without any further purification.
Step 4 : Preparation of 5- cyclopropyl -4-((3,5- dichloro -4- ethynylphenoxy ) methyl)-3-(2,6-dichlorophenyl)isoxazole
This compound was made using the procedure described for example 1(Step 4). Thus, this intermediate compound(Step 3)(3.17mmol) was reacted with 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxlazole(Intermediate 1)(1.1g, 3.17mmol) and potassium carbonate (0.66g, 4.76mmol) to afford the intermediate compound 5-cyclopropyl-4-((3,5-dichloro-4-ethynylphenoxy) methyl)-3-(2,6-dichlorophenyl)isoxazole(1.16g, 81%).
1H-NMR (CDCl3, 400MHz): δ 7.41-7.30 (m, 3H), 6.83 (d, 1H), 6.66 (dd, 1H), 4.80 (s, 2H), 3.26 (s, 1H), 2.17-2.10 (m, 1H), 1.31-1.27 (m, 2H), 1.23-1.17 (m, 2H).
Step 5 : Preparation of methyl 3-((2,6- dichloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, this intermediate compound(Step 4)(200mg, 0.48mmol) was reacted with methyl 3-bromobenzoate(103mg, 0.48mmol), bis(triphenylphosphine) palladium(II) dichloride (PdCl2(PPh3)2, 35mg, 0.05mmol), Copper(I) iodide(10mg, 0.05mmol) and triethylamine(0.14ml, 0.96mmol) to afford the intermediate compound methyl 3-((2,6-dichloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(158mg, 56%).
1H-NMR (CDCl3, 400MHz): δ 8.22-8.21 (m, 1H), 8.02-8.00 (m, 1H), 7.75-7.72 (m, 1H), 7.46-7.32 (m, 4H), 6.81 (d, 2H), 4.83 (s, 2H), 3.94 (s, 3H), 2.17-2.12 (m, 1H), 1.34-1.30 (m, 2H), 1.20-1.16 (m, 2H).
Step 6 : Preparation of 3-((2,6- dichloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 5)(158mg, 0.269mmol) was reacted with lithium hydroxide(112mg, 2.70mmol) to afford the title compound(150mg, 97%).
1H-NMR (CDCl3, 400MHz): δ 8.08-8.07 (m, 1H), 7.89-7.88 (m, 1H), 7.45-7.28 (m, 5H), 6.68-6.67 (m, 2H), 4.75 (s, 2H), 2.11-2.08 (m, 1H), 1.27-1.26 (m, 2H), 1.15-1.13 (m, 2H).
<Example 35> 2- chloro -3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-35)
Step 1 : Preparation of methyl 2- chloro -3-((2- chloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Exaple 5)(268mg, 0.64mmol) was reacted with methyl 3-boromo-2-chlorobenzoate(173mg, 0.58mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 81mg, 0.12mmol), copper(I) iodide(11mg, 0.06mmol) and triethylamine(0.4ml, 2.9mmol) to afford the intermediate compound methyl 2-chloro-3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(152mg, 44%).
1H-NMR (CDCl3, 400MHz): δ 7.72-7.67 (m, 2H), 7.46-7.40 (m, 3H), 7.35-7.24 (m, 2H), 6.88 (d, 1H), 6.71 (dd, 1H), 4.82 (s, 2H), 3.94 (s, 3H), 2.17-2.13 (m, 1H), 1.32-1.28 (m, 2H), 1.19-1.14 (m, 2H).
Step 2 : Preparation of 2- chloro -3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(152mg, 0.26mmol) was reacted with lithium hydroxide(109mg, 2.6mmol) to afford the title compound(86mg, 58%).
1H-NMR (DMSO, 400MHz): δ 13.61 (s, 1H), 7.78 (t, 2H), 7.64-7.53 (m, 4H), 7.48 (t, 1H), 7.11 (d, 1H), 6.86 (dd, 1H), 4.99 (s, 2H), 2.47 (m, 1H), 1.24-1.12 (m, 4H).
<Example 36> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoic acid; (I-36)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(60mg, 0.143mmol) was reacted with methyl 2-fluoro-3-iodobenzoate(48mg, 0.171mmol), bis(triphenylphosphine) palladium(II) dichloride (PdCl2(PPh3)2, 10.1mg, 0.014mmol), Copper(I) iodide(2.8mg, 0.014mmol) and triethylamine(0.024ml, 0.172mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoate(76mg, 93%).
1H-NMR (CDCl3, 400MHz): δ 7.99-7.98 (m, 1H), 7.71-7.30 (m, 4H), 6.98-6.97 (m, 1H), 6.78-6.77 (m, 1H), 6.61-6.59 (m, 1H), 4.80 (s, 2H), 3.93 (s, 3H), 2.17-2.15 (m, 1H), 1.23-1.19 (m, 2H), 1.15-1.10 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(76mg, 0.133mmol) was reacted with lithium hydroxide(11.2mg, 0.266mmol) to afford the title compound(62mg, 83%).
1H-NMR (CDCl3, 400MHz): δ 7.82-7.80 (m, 1H), 7.43-7.28 (m, 4H), 6.94-6.93 (m, 1H), 6.77-6.76 (m, 1H), 6.59-6.57 (m, 1H), 4.76 (s, 2H), 2.14-2.07 (m, 1H), 1.23-1.19 (m, 2H), 1.15-1.10 (m, 2H).
<Example 37> 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoic acid; (I-37)
Step 1 : Preparation of methyl 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(60mg, 0.143mmol) was reacted with methyl 2-fluoro-5-iodobenzoate(48mg, 0.171mmol), bis(triphenylphosphine) palladium(II) dichloride (PdCl2(PPh3)2, 10.1mg, 0.014mmol), Copper(I) iodide(2.8mg, 0.014mmol) and triethylamine(0.024ml, 0.172mmol) to afford the intermediate compound methyl 5((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoate(42mg, 51%).
1H-NMR (CDCl3, 400MHz): δ 8.21-8.20 (m, 1H), 7.78-7.75 (m, 1H), 7.50-7.40 (m, 4H), 7.20-7.15 (m, 1H), 7.00-6.98 (m, 1H), 6.84-6.81 (m, 1H), 5.14 (s, 2H), 4.15 (s, 3H), 2.23-2.21 (m, 1H), 1.45-1.41 (m, 2H), 1.21-1.18 (m, 2H).
Step 2 : Preparation of 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(42mg, 0.0735mmol) was reacted with lithium hydroxide(9.3mg, 0.221mmol) to afford the title compound(32mg, 79%).
1H-NMR (CDCl3, 400MHz): δ 8.14-8.13 (m, 1H), 7.64-7.61 (m, 1H), 7.41-7.31 (m, 4H), 7.12-7.07 (m, 1H), 6.85-6.84 (m, 1H), 6.68-6.66 (m, 1H), 4.81 (s, 2H), 2.17-2.10 (m, 1H), 1.31-1.27 (m, 2H), 1.19-1.14 (m, 2H).
<Example 38> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-fluorobenzoic acid; (I-38)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-fluorobenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(50mg, 0.119mmol) was reacted with methyl 4-fluoro-3-iodobenzoate(40mg, 0.143mmol), bis(triphenylphosphine) palladium(II) dichloride (PdCl2(PPh3)2, 8.4mg, 0.012mmol), Copper(I) iodide(2.3mg, 0.012mmol) and triethylamine(0.020ml, 0.143mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-fluorobenzoate(54mg, 66%).
1H-NMR (CDCl3, 400MHz): δ 8.20-8.19 (m, 1H), 7.79-7.76 (m, 1H), 7.52-7.41 (m, 4H), 7.22-7.17 (m, 1H), 7.01-6.99 (m, 1H), 6.84-6.81 (m, 1H), 5.14 (s, 2H), 4.16 (s, 3H), 2.23-2.21 (m, 1H), 1.46-1.42 (m, 2H), 1.22-1.19 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-fluorobenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(54mg, 0.0946mmol) was reacted with lithium hydroxide(7.9mg, 0.189mmol) to afford the title compound(40mg, 76%).
1H-NMR (CDCl3, 400MHz): δ 8.20-8.19 (m, 1H), 7.97-7.96 (m, 1H), 7.46-7.29 (m, 4H), 7.04-7.02 (m, 1H), 6.84-6.83 (m, 1H), 6.66-6.64 (m, 1H), 4.80 (s, 2H), 2.17-2.10 (m, 1H), 1.30-1.28 (m, 2H), 1.18-1.13 (m, 2H).
<Example 39> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethoxy)benzoic acid (I-39)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethyl)-5-(trifluoromethoxy)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.23mmol) was reacted with methyl 3-bromo-5-(trifluoromethoxy)benzoate(68.8mg, 0.23mmol), bis(triphenyl phosphine)palladium(II)dichloride(PdCl2(PPh3)2, 16mg, 0.023mmol), Copper(I) iodide(4.4.mg, 0.023mmol) and triethylamine(0.1ml, 0.71mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethyl)-5-(trifluoromethoxy)benzoate(67.0mg, 50%).
1H-NMR (CDCl3, 400MHz): δ 8.12 (s, 1H), 8.11 (s, 1H), 7.73 (s, 1H), 7.54-7.31 (m, 4H), 6.88 (d, 1H), 6.71 (dd, 1H), 4.83 (s, 2H), 3.95 (s, 3H), 2.19-2.12 (m, 1H), 1.37-1.29 (m, 2H), 1.26-1.18 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethoxy)benzoic acid
This compound was made using the procedure described for example 1(step 6). Thus, this intermediate compound(Step 1)(67.0mg, 0.10mmol) was reacted with LiOH(44.0mg, 1.05mmol) to afford the title compound(58mg, 93%).
1H-NMR (CDCl3, 400MHz): δ 8.17 (s, 1H), 7.89 (s, 1H), 7.59 (s, 1H), 7.43-7.32 (m, 4H), 6.88 (d, 1H), 6.72 (dd, 1H), 4.83 (s, 2H),2.19-2.12 (m, 1H), 1.32-1.27 (m, 2H), 1.24-1.14 (m, 2H).
<Example 40> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-methoxybenzoic acid; (I-40)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-methoxybenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 6)(150mg, 0.35mmol) was reacted with methyl 3-bromo-5-methoxybenzoate(88mg, 0.35mmol), bis(triphenylphosphine) palladium(II)dichloride(PdCl2(PPh3)2, 12.5mg, 0.018mmol), Copper(I) iodide(3.4.mg, 0.018mmol) and triethylamine(0.1ml, 1.07mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethyl)-5-methoxybenzoate(24.0mg, 12%).
1H-NMR (CDCl3, 400MHz): δ 7.80 (s, 1H), 7.79 (s, 1H), 7.54-7.52 (m, 2H), 7.42-7.33 (m, 2H), 7.23 (t, 1H), 6.87 (d, 1H), 6.70 (dd, 1H), 4.82 (s, 2H), 4.0 (s, 3H), 3.86 (s, 3H), 2.17-2.13 (m, 1H), 1.32-1.28 (m, 2H), 1.19-1.14 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-methoxybenzoic acid
This compound was made using the procedure described for example 1(step 6). Thus, this intermediate compound(Step 1)(24.0mg, 0.04mmol) was reacted with LiOH(16.7mg, 0.40mmol) to afford the title compound(9mg, 40%).
1H-NMR (CDCl3, 400MHz): δ 7.76 (s, 1H), 7.50 (s, 1H), 7.49-7.30 (m, 4H), 7.27 (s, 1H), 7.17 (s, 1H), 6.81 (dd, 1H), 4.77 (s, 2H), 3.81 (s, 3H), 2.13-2.10 (m, 1H), 1.26-1.20 (m, 2H), 1.14-1.10 (m, 2H).
<Example 41> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoic acid; (I-41)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoate
This compound was made using the procedure described for example 1(Step 5). Thus 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol(Example 5)(3.2g, 13mmol) was reacted with methyl 3-bromo-5-formylbenzoate(3.71g, 16mmol), bis(triphenylphosphine) palladium(II) Dichloride(PdCl2(PPh3)2(420mg, 0.65mol), copper(I)iodide(114mg, 0.65mol) and triethylamine(2.2ml, 16mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)-5-formylbenzoate(4.1g, 58%).
1H-NMR (CDCl3, 400MHz): δ 10.06 (s, 1H), 8.46-8.40 (m, 2H), 8.20-8.19 (m, 1H), 7.43-7.31 (m, 4H), 6.89(d, 1H), 6.71 (dd, 1H), 4.83 (s, 2H), 3.98 (s, 3H), 2.17-2.13 (m, 1H), 1.32-1.25 (m, 2H), 1.19-1.16 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus the intermediate compound(Step 1)(100mg, 0.172mmol) was reacted with lithium hydroxide(72.2mg, 1.72mmol) to afford the title compound(35mg, 33%).
1H-NMR (DMSO, 400MHz): δ13.70 (s, 1H), 10.10 (s, 1H), 8.41(s, 1H), 8.26-8.23 (m, 2H), 7.64-7.53 (m, 4H), 7.11 (d, 1H), 6.86 (dd, 1H), 4.99 (s, 2H), 2.66-2.32 (m, 1H), 1.20-1.14 (m, 4H).
<Example 42> 3-((2- Chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole -4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropylamino)methyl)benzoic acid; (I-42)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole -4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropylamino)methyl)benzoate
Cyclopropylamine(0.042ml, 0.60mmol) and acetic acid(16mg, 0.258mmol) was added to a solution of intermediate compound(Step 1 of Example 41)(150mg, 0.258mmol) in 1,2-dichloroethane(2ml)and stirred for 12 hours at room temperature. Sodium cyanoborohydride(49mg, 0.775mmol) was added to a solution of reaction mixture and stirred for 2 hours at room temperature. The reaction mixture was concentrated in vacuum, added dichloromethane and washed brine. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to give the intermediate compound 3-((2-Chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole-4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropylamino)methyl)benzoate(100mg, 64%).
1H-NMR (CDCl3, 400MHz): δ 8.10 (s, 1H), 7.93 (s, 1H), 7.68 (s, 1H), 7.42-7.35 (m, 4H), 6.87 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 3.92 (s, 3H), 3.45-3.41 (m, 4H), 2.25-2.12 (m, 4H), 1.32-1.14 (m, 4H).
Step 2 : Preparation of 3-((2- Chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole -4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropylamino)methyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(58mg, 0.12mmol) was reacted with lithium hyroxide(40mg, 0.96mmol) to afford the title compound(62mg, 82%).
1H-NMR (DMSO, 400MHz): δ 12.50 (brs, 1H), 7.93 (s, 1H), 7.88 (s, 1H), 7.70 (s, 1H), 7.63-7.53 (m, 4H), 7.09 (d, 1H), 6.83 (dd, 1H), 4.98 (s, 2H), 3.82 (s, 2H), 2.10-2.04 (m, 1H), 1.20-1.13 (m, 5H), 0.38-0.30 (m, 4H).
<Example 43> 3-( Azetidine -1- ylmethyl )-5-((2- chloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazole-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-43)
Step 1 : Preparation of Methyl 3-( azetidine -1- ylmethyl )-5-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazole-4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 42(Step 1). Thus, methyl-3-((chloro-4((cyclopropyl-3-(2,6-dichlorophenyl)isoxazole- 4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoate(Step 1 of Example 41)(150mg, 0.258mmol) was reacted with azetidinecyclopropylamine(40ul, 0.60mmol) and acetic acid(16mg, 0.258mmol), Sodium cyanoborohydride(49mg, 0.775mmol) to afford the intermediate compound methyl 3-(azetidine-1-ylmethyl)-5- ((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-yl)methoxy) phenyl)ethynyl)benzoate(100mg, 64%).
1H-NMR (CDCl3, 400MHz): δ 8.07 (s, 1H), 7.94 (s, 1H), 7.66 (s, 1H), 7.41-7.30 (m, 4H), 6.87 (d, 1H), 6.69 (dd, 1H), 4.81 (s, 2H), 3.92 (s, 3H), 3.88 (s, 2H), 2.17-2.11 (m, 2H), 1.31-1.13 (m, 5H), 0.47-0.39 (m, 4H).
Step 2 : Preparation of 3-( Azetidine -1- ylmethyl )-5-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazole-4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(23mg, 0.04mmol) was reacted with lithium hyroxide(15mg, 0.36mmol) to afford the title compound(11mg, 49%).
1H-NMR (CDCl3, 400MHz): δ 8.64 (s, 1H), 8.25 (s, 1H), 7.47 (s, 1H), 7.41-7.31 (m, 4H), 6.86 (d, 1H), 6.68 (dd, 1H), 4.81 (s, 2H), 4.05 (s, 2H), 3.95-3.90 (m, 2H), 2.18-2.11 (m, 1H), 1.31-1.14 (m, 6H).
<Example 44> 3-((2- Chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole -4-yl)methoxy)phenyl)ethynyl)-5-((methylamino)methyl)benzoic acid; (I-44)
Step 1 : Preparation of Methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazole -4-yl)methoxy)phenyl)ethynyl)-5-((methylamino)methyl)benzoate
This compound was made using the procedure described for example 42(Step 1). Thus, methyl-3-((chloro-4((cyclopropyl-3-(2,6-dichlorophenyl)isoxazole -4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoate(Step 1 of example 41) (150mg, 0.258mmol) was reacted with methylamine(0.1ml, 0.60mmol) and acetic acid(16mg, 0.258mmol), Sodium cyanoborohydride(49mg, 0.775mmol) to afford the intermediate compound methy 3-((2-chloro-4-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazole-4-yl)methoxy)phenyl)ethynyl)-5-((methylamino)methyl)benzoate(100mg, 64%).
1H-NMR (CDCl3, 400MHz): δ 8.19 (s, 1H), 7.99 (s, 1H), 7.69 (s, 1H), 7.41-7.31 (m, 4H), 6.87 (d, 1H), 6.70 (dd, 1H), 4.82 (s, 2H), 3.93 (s, 3H), 3.66 (s, NH, 1H), 2.50 (s, 2H), 2.17-2.13 (m, 1H), 2.04 (s, 3H), 1.31-1.27 (m, 2H), 1.23-1.13 (m, 2H).
Step 2 : Preparation of 3-((2- Chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole -4-yl)methoxy)phenyl)ethynyl)-5-((methylamino)methyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(26mg, 0.04mmol) was reacted with lithium hyroxide(18mg, 0.43mmol) to afford the title compound(8.5mg, 32%).
1H-NMR (DMSO, 400MHz): δ 8.18 (s, 1H), 7.93 (s, 1H), 7.67-7.52 (m, 5H), 7.09 (d, 1H), 6.83 (dd, 1H), 4.98 (s, 2H), 4.01 (s, 2H), 1.25-1.11 (m, 5H).
<Example 45> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((ethylamino)methyl)benzoic acid; (I-45)
Step 1 : Preparation of methyl3 -((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((ethylamino)methyl)benzoate
This compound was made using the procedure described for example 42(Step 1). Thus methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoate(Step 1 of Example 41)(150mg, 0.258mmol) was reacted withacetic acid(16mg, 0.258mmol), 6.0M ethylamine(0.1ml, 0.60mmol) and sodium cyanoborohydride(49mg, 0.775mmol) to afford the intermediate compound 3-((2-chloro-4-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((ethylamino)methyl)benzoate(100mg, 64%).
1H-NMR (CDCl3, 400MHz): δ 8.08 (s, 1H), 7.95 (s, 1H), 7.69 (s, 1H), 7.42-7.38 (m, 3H), 7.35-7.31 (m, 1H), 6.87 (d, 1H), 6.69 (dd, 1H), 4.81 (s, 2H), 3.92 (s, 3H), 3.84 (s, 2H), 2.70 (q, 2H), 2.18-2.13 (m, 1H), 1.31-1.27 (m, 2H), 1.20-1.12 (m, 5H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((ethylamino)methyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus the intermediate compound(Step 1)(100mg, 0.164mmol) was reacted with lithium hydroxide(69mg, 1.64mmol) to afford the title compound(88mg, 91%).
1H-NMR (DMSO, 400MHz): δ 8.14 (s, 1H), 8.01 (s, 1H), 7.88 (s, 1H), 7.64-7.61 (m, 2H), 7.57-7.53 (m, 2H), 7.10 (d, 1H), 6.85 (dd, 1H), 4.98 (s, 2H), 4.18 (s, 2H), 2.97 (q, 2H), 2.52-2.47 (m, 1H), 1.23-1.17 (m, 5H), 1.59-1.32 (m, 2H).
<Example 46> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((2,2,2-trifluoroethyl)amino)methyl)benzoic acid; (I-46)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((2,2,2-trifluoroethyl)amino)methyl)benzoate
This compound was made using the procedure described for example 42(Step 1). Thus methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoate (Step 1 of Example 41)(200mg, 0.344mmol) was reacted withacetic acid(21mg, 0.344mmol), trifluoroethylamine(51mg, 0.516mmol) and sodium cyanoborohydride(65mg, 1.03mmol) to afford the intermediate compound 3-((2-chloro-4-((5-cyclopropy l-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(((2,2,2-trifluoroethyl)amino)methyl)benzoate(176mg, 77%).
1H-NMR (CDCl3, 400MHz): δ 8.08 (s, 1H), 7.94 (s, 1H), 7.68 (s, 1H), 7.43-7.38 (m, 3H), 7.33-7.29 (m, 1H), 6.86 (d, 1H), 6.69 (dd, 1H), 4.81 (s, 3H), 3.96-3.93 (m, 5H), 3.22 (q, 2H), 2.18-2.12 (m, 1H), 1.29-1.22 (m, 2H), 1.19-1.16 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((2,2,2-trifluoroethyl)amino)methyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus the intermediate compound(Step 1)(176mg, 0.254mmol) was reacted with lithium hydroxide(54mg, 1.28mmol) to afford the title compound(130mg, 78%).
1H-NMR (CDCl3, 400MHz): δ 7.83-7.74 (m, 2H), 7.37-7.33 (m, 3H), 7.27-7.23 (m, 2H), 7.15-7.13 (m, 1H), 6.74 (d, 1H), 6.55 (dd, 1H), 4.72 (s, 2H), 4.14 (q, 2H), 3.59 (s, 2H), 2.11-2.02 (m, 1H), 1.20-1.11 (m, 2H), 0.90-0.85 (m, 2H).
<Example 47> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((isopropylamino)methyl)benzoic acid; (I-47)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((isopropylamino)methyl)benzoate
This compound was made using the procedure described for example 42(Step 1). Thus methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoate(Step 1 of Example 41)(200mg, 0.344mmol) was reacted with acetic acid(21mg, 0.344mmol), isopropylamine(31mg, 0.516mmol) and sodium cyanoborohydride(65mg, 1.03mmol) to afford the intermediate compound 3-((2-chloro-4-((5-cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((isopropylamino)methyl)benzoate(95mg, 44%).
1H-NMR (CDCl3, 400MHz): δ 8.07 (s, 1H), 7.95 (s, 1H), 7.69 (s, 1H), 7.42-7.39 (m, 3H), 7.35-7.31 (m, 1H), 6.87 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 3.92 (s, 3H), 3.82 (s, 2H), 2.88-2.82 (m, 1H), 2.17-2.12 (m, 1H), 1.32-1.27 (m, 2H), 1.25-1.24 (m, 2H), 1.16(d, 6H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((isopropylamino)methyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus the intermediate compound(Step 1)(95mg, 0.144mmol) was reacted with lithium hydroxide(61mg, 1.44mmol) to afford the title compound(71mg, 81%).
1H-NMR (DMSO, 400MHz): δ 9.04 (s, 1H), 8.17 (s, 1H), 8.03 (s, 1H), 7.99 (s, 1H), 7.64-7.62 (m, 2H), 7.57-7.53 (m, 2H), 7.11 (d, 1H), 6.86 (dd, 1H), 4.99 (s, 2H), 4.24 (s, 2H), 3.30-3.25 (m, 1H), 2.50-2.47 (m, 1H), 1.31 (d, 6H), 1.20-1.12 (m, 4H).
<Example 48> 3-(( tert - butylamino )methyl)-5-((2- chloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-48)
Step 1 : Preparation of methyl 3-(( tert - butylamino )methyl)-5-((2- chloro -4- ((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 42(Step 1). Thus methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoate (Step 1 of Example 41)(200mg, 0.344mmol) was reacted withacetic acid(21mg, 0.344mmol), tert-butylamine(38mg, 0.516mmol) and sodium cyanoborohydride(65mg, 1.03mmol) to afford the intermediate compound methyl 3-((tert-butyl amino)methyl)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(45mg, 21%).
1H-NMR (CDCl3, 400MHz): δ 8.05(s, 1H), 7.96(s, 1H), 7.71 (s, 1H), 7.41-7.38(m, 3H), 7.35-7.31(m, 1H), 6.87(d, 1H), 6.69(dd, 1H), 4.81(s, 2H), 4.32(s, 1H), 3.94(s, 3H), 3.76(s, 2H), 2.18-2.12(m, 1H), 1.38-1.31(m, 2H), 1.27-1.14(m, 2H).
Step 2 : Preparation of 3-(( tert - butylamino )methyl)-5-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus the intermediate compound(Step 1)(45mg, 0.070mmol) was reacted with lithium hydroxide(30mg, 0.70mmol) to afford the title compound(45mg, 83%).
1H-NMR (DMSO, 400MHz): δ 13.45 (s, 1H), 9.03 (s, 1H), 8.19 (s, 1H), 8.04 (s, 1H), 8.01 (s, 1H), 7.64-7.62 (m, 2H), 7.58-7.53 (m, 2H), 7.11 (d, 1H), 6.86 (dd, 1H), 4.99 (s, 2H), 4.22 (s, 2H), 3.30-3.25 (m, 1H), 2.50-2.46 (m, 1H), 1.38 (s, 9H), 1.20-1.12 (m, 4H).
<Example 49> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((dimethylamino)methyl)benzoic acid; (I-49)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((dimethylamino)methyl)benzoate
This compound was made using the procedure described for example 42(Step 1). Thus methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoate (Step 1 of Example 41)(200mg, 0.344mmol) was reacted with acetic acid(21mg, 0.344mmol), dimethylamine(34ul, 0.516mmol) and sodium cyanoborohydride(65mg, 1.03mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((dimethylamino)methyl)benzoate(65mg, 34%).
1H-NMR (CDCl3, 400MHz): δ 8.13 (s, 1H), 7.95 (s, 1H), 7.72 (s, 1H), 7.41-7.31 (m, 4H), 6.86 (d, 1H), 6.68 (dd, 1H), 4.81 (s, 2H), 3.92 (s, 3H), 3.63 (s, 2H), 2.38 (s, 6H), 2.18-2.12 (m, 1H), 1.31-1.25 (m, 2H), 1.17-1.12 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((dimethylamino)methyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus the intermediate compound(Step 1)(65mg, 0.04mmol) was reacted with lithium hydroxide(40mg, 0.40mmol) to afford the title compound(9.7mg, 40%).
1H-NMR (CDCl3, 400MHz): δ 8.71 (s, 1H), 8.23 (s, 1H), 7.48 (s, 1H), 7.41-7.31 (m, 4H), 6.86 (d, 1H), 6.68 (dd, 1H), 4.81 (s, 2H), 3.69 (s, 2H), 2.69 (s, 6H), 2.18-2.11 (m, 1H), 1.31-1.27 (m, 2H), 1.19-1.14 (m, 2H).
<Example 50> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(morpholinomethyl)benzoic acid; (I-50)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(morpholinomethyl)benzoate
This compound was made using the procedure described for example 42(Step 1). Thus methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoate(Step 1 of example 41)(200mg, 0.344mmol) was reacted with acetic acid(21mg, 0.344mmol), morpholine(45mg, 0.516mmol) and sodium cyanoborohydride(65mg, 1.03mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(morpholinomethyl)benzoate(99mg, 44%).
1H-NMR (CDCl3, 400MHz): δ 8.09 (s, 1H), 7.95 (s, 1H), 7.69 (s, 1H), 7.42-7.39 (m, 3H), 7.35-7.31 (m, 1H), 6.88 (d, 1H), 6.70 (dd, 1H), 4.82 (s, 2H), 3.93 (s, 3H), 3.72-3.70 (m, 4H), 3.52 (s, 2H), 2.45-2.44 (m, 4H), 2.17-2.13 (m, 1H), 1.32-1.24 (m, 2H), 1.19-1.14 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(morpholinomethyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus the intermediate compound(Step 1)(99mg, 0.151mmol) was reacted with lithium hydroxide(63mg, 1.51mmol) to afford the title compound(85mg, 96%).
1H-NMR (DMSO, 400MHz): δ 7.96-7.76 (m, 3H), 7.64-7.62 (m, 2H), 7.57-7.53 (m, 2H), 7.10 (d, 1H), 6.85 (dd, 1H), 4.99 (s, 2H), 3.78 (s, 2H), 3.30-3.25 (m, 4H), 2.50-2.46 (m, 5H), 1.27-1.11 (m, 4H).
<Example 51> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((oxetan-3-ylamino)methyl)benzoic acid; (I-51)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((oxetan-3-ylamino)methyl)benzoate
This compound was made using the procedure described for example 42(Step 1). Thus methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoate(Step 1 of Example 41)(200mg, 0.344mmol) was reacted with acetic acid(21mg, 0.344mmol), oxetan-3-yl amine(38mg, 0.516mmol) and sodium cyanoborohydride(65mg, 1.03mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((oxetan-3-ylamino)methyl)benzoate(98mg, 45%).
1H-NMR (CDCl3, 400MHz): δ 8.08 (s, 1H), 7.92 (s, 1H), 7.66 (s, 1H), 7.41-7.29 (m, 4H), 6.88 (d, 1H), 6.70 (dd, 1H), 4.82 (s, 2H), 4.78 (t, 2H), 4.42 (t, 2H), 4.03-3.99 (m, 1H), 3.92 (s, 3H), 3.77 (s, 2H), 2.19-2.11 (m, 1H), 1.29-1.23 (m, 2H), 1.17-1.13 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((oxetan-3-ylamino)methyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus the intermediate compound(Step 1)(98mg, 0.154mmol) was reacted with lithium hydroxide(64mg, 1.54mmol) to afford the title compound(40mg, 46%).
1H-NMR (DMSO, 400MHz): δ 7.91-7.89 (m, 2H), 7.66 (s, 1H), 7.59-7.56 (m, 2H), 7.53-7.49 (m, 2H), 6.98 (d, 1H), 6.80 (dd, 1H), 4.94 (s, 2H), 4.60 (t, 2H), 4.37 (t, 2H), 4.01-3.97 (m, 1H), 3.77 (s, 2H), 2.42-2.38 (m, 1H), 1.21-1.17 (m, 2H), 1.10-1.07 (m, 2H).
<Example 52> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(methylamino)benzoic acid; (I-52)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(methylamino)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.26mmol) was reacted with methyl 3-bromo-5-(methylamino)benzoate(63mg, 0.26mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.2ml, 1.3mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methylamino)benzoate(70mg, 48%).
1H-NMR (DMSO, 400MHz): δ 7.52-7.39 (m, 4H), 7.34 (t, 1H), 7.21-7.20 (dd, 1H), 6.91-6.88 (m, 2H), 6.76-6.73 (dd, 1H), 4.39 (s, 2H), 3.88 (s, 3H), 2.79 (s, 3H), 2.34 (m, 1H), 1.28-1.20 (m, 4H).
Step 2 : Preparation of3 -((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(methylamino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(70mg, 0.13mmol) was reacted with lithium hydroxide(54.5mg, 1.3mmol) to afford the title compound(36.8mg, 53%).
1H-NMR (DMSO, 400MHz): δ 7.64 (d, 1H), 7.62 (d, 1H), 7.57-7.52 (m, 2H), 7.21 (m, 1H),7.14 (t, 1H), 7.08 (d, 1H), 6.83 (d, 1H), 6.80 (m, 1H), 6.13 (br, 1H), 4.98 (s, 2H), 2.71 (d, 3H), 2.47 (m, 1H), 1.23-1.12 (m, 4H).
<Example 53> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(ethylamino)benzoic acid; (I-53)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(ethylamino)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.26mmol) was reacted with methyl 3-bromo-5-(ethylamino)benzoate(67mg, 0.26mmol), bis(triphenyl phosphine)palladium(II) dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.2ml, 1.3mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5- cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(ethylamino)benzoate(70mg, 48%).
1H-NMR (DMSO, 400MHz): δ 7.52-7.39 (m, 4H), 7.34 (t, 1H), 7.21-7.20 (dd, 1H), 6.91-6.88 (m, 2H), 6.76-6.73 (dd, 1H), 4.39 (s, 2H), 3.88 (s, 3H), 3.03 (m, 2H), 2.79 (s, 3H), 2.34 (m, 1H), 1.28-1.20 (m, 4H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(ethylamino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 2)(70mg, 0.13mmol) was reacted with lithium hydroxide(54.5mg, 1.3mmol) to afford the title compound(37.7mg, 53%).
1H-NMR (DMSO, 400MHz): δ 7.64 (d, 1H), 7.62 (d, 1H), 7.57-7.52 (m, 2H), 7.21 (, 1H), 7.14 (t, 1H), 7.08 (d, 1H), 6.83 (d, 1H), 6.80 (m, 1H), 6.13 (br, 1H), 4.98 (s, 2H), 2.71 (d, 3H), 2.52 (m, 2H), 2.47 (m, 1H), 1.23-1.12 (m, 4H).
<Example 54> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(isopropylamino)benzoic acid; (I-54)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(isopropylamino)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(50mg, 0.119mmol) was reacted with methyl 3-iodo-5-(isopropylamino)benzoate(46mg, 0.143mmol), bis(triphenylphosphine) palladium(II) dichloride (PdCl2(PPh3)2, 8.4mg, 0.012mmol), Copper(I) iodide(2.3mg, 0.012mmol) and triethylamine(0.020ml, 0.143mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5- cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(isopropylamino)benzoate(23mg, 34%).
1H-NMR (CDCl3, 400MHz): δ 7.99-7.98 (m, 1H), 7.71-7.67 (m, 1H), 7.43-7.32 (m, 5H), 6.88-6.87 (m, 1H), 6.71-6.69 (m, 1H), 4.83 (s, 2H), 3.94 (s, 3H), 2.17-2.15 (m, 1H), 1.33-1.28 (m, 2H), 1.19-1.16 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(isopropylamino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(23mg, 0.040mmol) was reacted with lithium hydroxide(17mg, 0.40mmol) to afford the title compound (13mg, 56%).
1H-NMR (CDCl3, 400MHz): δ 8.05-8.04 (m, 1H), 7.76-7.73 (m, 1H), 7.47-7.43 (m, 4H), 7.36-7.32 (m, 1H), 6.89-6.88 (m, 1H), 6.72-6.69 (m, 1H), 4.83 (s, 2H), 2.18-2.14 (m, 1H), 1.33-1.30 (m, 2H), 1.17-1.15 (m, 2H).
<Example 55> 3-( azetidin -1- yl )-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-55)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-iodobenzoate
tert-butyl nitrite (0.126ml, 1.05mmol) and iodine (536mg, 2.11mmol)were added to a solution of methyl 3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of example 8)(300mg, 0.528mmol) in toluene (5ml) and stirred for 1 hour at 55?. The reaction mixture was diluted with ethyl acetate and washed with water. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to give the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)-5-iodobenzoate(108mg, 44%).
1H-NMR (CDCl3, 400MHz): δ 8.20 (t, 1H), 7.99 (dt, 1H), 7.70 (dt, 1H), 7.46-7.22 (m, 4H), 6.88 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 3.94 (s, 3H), 2.19-2.12 (m, 1H), 1.33-1.24 (m, 2H), 1.23-1.14 (m, 2H).
Step 2 : Preparation of methyl 3-( azetidin -1- yl )-5-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
Azetidine(12mg, 0.13mmol), L-proline(2.2mg,0.019mmol), cesium carbonate (36mg, 0.11mmol) and copper(I) iodide(1.6mg, 0.01mmol) were added to a solution of the intermediate compound(Step 1)(44mg, 0.065mmol) in dimethyl sulfoxide(1ml) and stirred for 1 day at 80℃. The reaction mixture was diluted with ethyl acetate and washed with water. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to give the intermediate compound methyl 3-(azetidin-1-yl)-5- ((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(14mg, 36%).
1H-NMR (CDCl3, 400MHz): δ 7.55 (d, 1H), 7.42-7.31 (m, 4H), 7.05-7.04 (m, 1H), 6.87-6.86 (m, 1H), 6.72-6.67 (m, 2H), 4.82 (s, 2H), 3.97-3.90 (m, 7H), 2.43-2.38 (m, 2H), 2.18-2.13 (m, 1H), 1.32-1.29 (m, 2H), 1.19-1.16 (m, 2H).
Step 3 : Preparation of 3-( azetidin -1- yl )-5-((2- chloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 2)(14mg, 0.023mmol) was reacted with lithium hydroxide(10mg, 0.23mmol) to afford the title compound(14mg, 99%).
1H-NMR (CDCl3, 400MHz): δ 7.60 (m, 1H), 7.41-7.31 (m, 4H), 7.07 (m, 1H), 6.87-6.86 (m, 1H), 6.68-6.66 (m, 2H), 4.81 (s, 2H), 3.94-3.90 (m, 4H), 2.40-2.37 (m, 2H), 2.16-2.14 (m, 1H), 1.30-1.27 (m, 2H), 1.18-1.14(m, 2H).
<Example 56> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(pyrrolidin-1-yl)benzoic acid; (I-56)
Step 1 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-(pyrrolidin-1-yl)benzoate
This compound was made using the procedure described for example 55(Step 2). Thus, methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-iodobenzoate(Step 1 of example 55)(44mg, 0.065mmol) was reacted with pyrrolidine(15mg, 0.13mmol), L-proline(2.2mg,0.019mmol), cesium carbonate(36mg, 0.11mmol) and copper(I) iodide(1.6mg, 0.01mmol)to afford the intermediate compound methyl 4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-(pyrrolidin-1-yl)benzoate(14mg, 36%).
1H-NMR (CDCl3, 400MHz): δ 7.48 (d, 1H), 7.43-7.40 (m, 3H), 7.36-7.32 (m, 1H), 7.19-7.18 (m, 1H), 6.88-6.84 (m, 2H), 6.70-6.67 (m, 1H), 4.82 (s, 2H), 3.91 (s, 3H), 3.33 (t, 4H), 2.17-2.15 (m, 1H), 2.03-2.01 (m, 4H), 1.32-1.28 (m, 2H), 1.20-1.16 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(pyrrolidin-1-yl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(14mg, 0.031mmol) was reacted with lithium hydroxide(13mg, 0.31mmol) to afford the title compound (11mg, 62%).
1H-NMR (CDCl3, 400MHz): δ 7.55-7.32 (m, 5H), 7.24-7.23 (m, 1H), 6.90-6.87 (m, 2H), 6.70-6.67 (m, 1H), 4.82 (s, 2H), 3.35 (t, 4H), 2.18-2.13 (m, 1H), 2.14-2.02 (m, 4H), 1.31-1.28 (m, 2H), 1.19-1.15 (m, 2H).
<Example 57> 3-( azetidin -3- ylamino )-5-((2- chloro -4-((5- cyclopropyl -3- (2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid hydrochloride; (I-57)
Step 1 : Preparation of tert -butyl 3-((3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methoxycarbonyl)phenyl)amino)azetidine-1-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(example 5)(300mg, 0.72mmol) was reacted with tert-butyl 3-((3-bromo-5-(methoxycarbonyl)phenyl)amino)azetidine-1-carboxylate (277.38mg, 0.72mmol), bis(triphenylphosphine) palladium(II) dichloride (PdCl2(PPh3)2, 49mg, 0.07mmol), copper(I) iodide(13mg, 0.07mmol) and triethylamine(0.12ml, 0.86mmol) to afford the intermediate compound tert-butyl 3-((3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)-5-(methoxycarbonyl)phenyl)amino)azetidine-1- carboxylate(370mg, 71%).
1H-NMR (CDCl3, 400MHz): δ 7.60(s, 1H), 7.41-7.32(m, 4H), 7.21(s, 1H), 6.90(s, 1H), 6.81(d, 1H), 6.69(dd, 1H), 4.82(s, 2H), 4.36-4.32(m, 2H), 4.19-4.11(m, 2H), 3.90(s, 3H), 3.73(dd, 1H), 2.16-2.05(m, 1H), 1.48(s, 9H), 1.42-1.24(m, 2H), 1.19-1.15(m, 2H).
Step 2 : Preparation of 3-((1-( tert - butoxycarbonyl ) azetidine -3- yl )amino)-5- ((2- chloro -4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(step 6). Thus, this intermediate compound(Step 1)(35mg, 0.048mmol) was reacted with lithium hydroxide(17mg, 0.48mmol) to afford the intermediate compound 3-((1-(tert-butoxycarbonyl)azetidine-3-yl)amino)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid(29mg, 85%).
1H-NMR (CDCl3, 400MHz): δ 7.66 (s, 1H), 7.43-7.39 (m, 3H), 7.35-7.33 (m, 1H), 7.19 (s, 1H), 6.87 (d, 2H), 6.70 (dd, 1H), 4.82 (s, 2H), 4.37-4.33 (m, 2H), 4.28-4.26 (m, 1H), 3.78-3.74 (m, 2H), 2.19-2.17 (m, 1H), 1.49 (s, 9H), 1.30-1.28 (m, 2H), 1.26-1.20 (m, 2H).
Step 3 : Preparation of 3-( azetidine -3- ylamino )-5-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid
This intermediate compound(Step 2)(29mg, 0.041mmol) was dissolved in dichloromethane. 5~6N HCl solution(41ul, 0.20mmol) was added at 0℃, after stirring at room temperature for 3h. The reaction mixture added ethyl acetate and washed with water. The combined organic layers were dried over MgSO4, filtered, and recrystalized to afford the title compound(10mg, 38%).
1H-NMR (DMSO, 400MHz): δ 8.93(br s, 2H), 7.64 (d, 2H), 7.62-7.52 (m, 2H), 7.31 (s, 1H), 7.15 (d, 1H), 7.09 (d, 1H), 6.85-6.81 (m, 2H), 4.98 (s, 2H), 4.48-4.44 (m, 1H), 4.29-4.27 (m, 2H), 3.87-3.78 (m, 2H), 1.23-1.19 (m, 2H), 1.17-1.14 (m, 2H).
<Example 58> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(piperidin-4-ylamino)benzoic acid hydrochloride; (I-58)
Step 1 : Preparation of tert -butyl 4-((3-((2- chloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methoxycarbonyl)phenyl)amino)piperidine-1-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(300mg, 0.72mmol) was reacted with tert-butyl 4-((3-bromo-5-(methoxycarbonyl)phenyl)amino)piperidine-1- carboxylate (298mg, 0.72mmol), bis(triphenylphosphine)palladium(II) dichloride (PdCl2(PPh3)2, 49mg, 0.07mmol), copper(I) iodide(13mg, 0.07mmol) and triethylamine(0.12ml, 0.86mmol) to afford the intermediate compound tert-butyl 4-((3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methoxycarbonyl)phenyl)amino)piperidine-1-carboxylate(340mg, 63%).
1H-NMR (CDCl3, 400MHz): δ 7.52 (s, 1H), 7.41-7.31 (m, 3H), 7.26 (s, 1H), 7.21 (s, 1H), 6.89-6.86 (m, 2H), 6.67 (dd, 1H), 4.81 (s, 2H), 4.14-4.09 (m, 2H), 3.90 (s, 3H), 3.79-3.68 (m, 2H), 2.98-2.88 (m, 2H), 2.46-2.44 (m, 1H), 2.21-2.10 (m, 1H), 2.18-2.00 (m, 2H), 1.48 (s, 9H), 1.38-1.33 (m, 2H), 1.29-1.18 (m, 2H).
Step 2 : Preparation of 3-((1-( tert - butoxycarbonyl ) piperidine -4- yl )amino)-5- ((2- chloro -4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(step 6). Thus, this intermediate compound(Step 1)(49.4mg, 0.07mmol) was reacted with lithium hydroxide(27.6mg, 0.7mmol) to afford 3-((1-(tert-butoxycarbonyl) piperidine-4-yl)amino)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid(18mg, 35%).
1H-NMR (CDCl3, 400MHz): δ 7.72 (s, 2H), 7.58-7.29 (m, 4H), 6.93 (s, 1H), 6.87 (s, 1H), 6.68 (dd, 1H), 4.82 (s, 2H), 4.20-4.00 (m, 2H), 3.58-3.46 (m, 1H), 3.09-2.98 (m, 2H), 2.28-2.17 (m, 2H), 1.47 (s, 9H), 1.35-1.30 (m, 2H), 1.29-1.26 (m, 2H).
Step 3 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(piperdine-4-ylamino)benzoic acid
This intermediate compound(Step 2)( 18mg, 0.024mmol) was dissolved in dichloromethane. 5~6N HCl solution(12ul, 0.048mmol) was added at 0℃, after stirring at room temperature for 3h. The reaction mixture added ethyl acetate and washed with water. The combined organic layers were dried over MgSO4, filtered, and recrystalized to afford the title compound(7mg, 44%).
1H-NMR (MeOD, 400MHz): δ 7.66-7.50 (m, 3H), 7.48-7.43 (m, 3H), 7.14 (s, 1H), 6.94 (s, 1H), 6.78 (dd, 1H), 4.98 (s, 2H), 3.82-3.70 (m, 2H), 3.53-3.41 (m, 2H), 3.33-3.12 (m, 2H), 2.38-2.22 (m, 2H), 1.90-1.80 (m, 2H), 1.25-1.22 (m, 2H).
<Example 59> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(piperazin-1-yl)benzoic acid hydrochloride; (I-59)
Step 1 : Preparation of tert -butyl 4-(3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methoxycarbonyl) phenyl) piperazin -1-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.239mmol) was reacted with tert-butyl 4-(3-bromo-5-(methoxycarbonyl)phenyl)piperazin-1-carboxylate (70mg, 0.287 mmol), bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and triethylamine (0.2ml, 1.44mmol) to afford the intermediate compound tert-butyl 4-(3-((2-chloro-4- ((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methoxycarbonyl)phenyl)piperazin-1-carboxylate(114mg, 65%).
1H-NMR (CDCl3, 400MHz): δ 7.71 (s, 1H), 7.57 (s, 1H), 7.44-7.41 (m, 3H), 7.38-7.34 (m, 1H), 7.24 (d, 1H), 6.90-6.89 (d, 1H), 6.72-6.70 (dd, 1H), 4.84 (s, 2H), 6.94 (s, 3H), 3.62-3.60 (t, 4H), 3.23 (s, 4H), 2.20-2.15 (m, 1H), 1.51 (s, 9H), 1.34-1.26 (m, 2H), 1.21-1.18 (m, 2H).
Step 2 : Preparation of 3-(4-( tert - buthoxycarbonyl ) piperazin -1- yl )-5-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(114mg, 0.15mmol)와 lithium hydroxide(63mg, 1.5mmol) to afford the intermediate compound 3-(4-(tert- buthoxycarbonyl)piperazin-1-yl)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid(108mg, 98%).
1H-NMR (CDCl3, 400MHz): δ 7.68 (s, 1H),7.53-7.52 (m, 1H), 7.35-7.32 (m, 3H), 7.28-7.24 (m, 1H), 6.81-6.80 (d, 1H), 6.64-6.61 (dd, 1H), 4.75 (s, 2H), 3.54-3.52 (t, 4H), 3.15 (s, 4H), 2.10-2.05 (m, 1H), 1.42 (s, 9H), 1.25-1.21 (m, 2H), 1.11-1.09 (m, 2H).
Step 3 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(piperazin-1-yl)benzoic acid hydrochloride
This compound was made using the procedure described for example 57(Step 3). Thus, the intermediate compound(Step 2)(108mg, 0.14mmol) was reacted with 6M solution of hydrochloric acid to afford the title compound (59mg, 64%).
1H-NMR (MeOD, 400MHz): 7.70-7.67 (m, 2H), 7.55-7.44 (m, 4H), 7.39-7.38 (m, 1H), 6.95-6.94 (d, 1H), 6.80-6.77 (dd, 1H), 4.91 (s, 3H), 3.53-3.50 (m, 4H), 3.42-3.40 (m, 4H), 2.40-2.35 (m, 1H), 1.25-1.21 (m, 4H).
<Example 60> 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-methylbenzoic acid; (I-60)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-methy-5-nitrobenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Exaple 5)(100mg, 0.239mmol) was reacted with methyl 3-bromo-4-methyl-5-nitrobenzoate(78.6mg, 0.287mmol), bis(triphenyl phosphine) palladium(II) dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-methy-5-nitrobenzoate(88mg, 60%).
1H-NMR (CDCl3, 400MHz): δ 7.65 (d, 1H), 7.42-7.40 (m, 3H), 7.35-7.31 (m, 2H), 6.88 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 3.89 (s, 3H), 2.42 (s, 3H), 2.18-2.13 (m, 1H), 1.32-1.28 (m, 2H), 1.19-1.15 (m, 2H).
Step 2 : Preparation of methyl 3-amino-5-((2- chloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-methybenzoate
This compound was made using the procedure described for example 8(Step 2). Thus, the intermediate compound(Step 1)(88mg, 0.14mmol) was reacted with tin(II) chloride dihydrate(315mg, 1.4mmol) to afford the intermediate compound methyl 3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-methybenzoate(50mg, 61%).
1H-NMR (CDCl3, 400MHz): δ 7.65 (d, 1H), 7.42-7.40 (m, 3H), 7.35-7.31 (m, 2H), 6.88 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 3.89 (s, 3H), 3.78 (s, 2H), 2.42 (s, 3H), 2.18-2.13 (m, 1H), 1.32-1.28 (m, 2H), 1.19-1.15 (m, 2H).
Step 3 : Preparation of 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-methylbenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 2)(50mg, 0.08mmol) was reacted with lithium hydroxide(36mg, 0.8mmol) to afford the title compound(53mg, 108%).
1H-NMR (DMSO, 400MHz): δ 12.65 (s, 1H), 7.64 (d, 1H), 7.62 (s, 1H), 7.57-7.53 (m, 2H), 7.27 (s, 2H), 7.08 (d, 1H), 6.82 (dd, 1H), 5.34 (s, 2H), 4.98(s, 2H), 2.47 (m, 1H), 2.29 (s, 3H), 1.23-1.19 (m, 2H), 1.17-1.13 (m, 2H).
<Example 61> 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-methoxybenzoic acid; (I-61)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-4-methoxy-5-nitrobenzoate
This compound was made using the procedure described for example 1(step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.26mmol)was reacted with methyl 3-bromo-4-methoxy-5-nitrobenzoate(72mg, 0.26mmol), tetrakis(triphenyl phosphine) palladium(0) (Pd(PPh3)4, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and N,N -diisopropylethylamine(0.52ml, 2.98mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-methoxy-5-nitrobenzoate(102.8mg, 63%).
1H-NMR (DMSO, 400MHz): δ 12.60 (s, 1H), 8.26 (d, 1H), 7.97 (d, 1H), 7.89 (t, 1H), 7.83 (t, 1H), 7.50-7.44(m, 1H), 7.40 (d, 1H), 7.21 (t, 1H), 4.37 (s, 2H), 3.79-3.67 (m, 1H), 3.59-3.33 (m, 3H), 3.29-3.06 (m, 3H).
Step 2 : Preparation of methyl 3-amino-5-((2- chloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-methoxybenzoate
This compound was made using the procedure described for example 8(Step 2). Thus, this intermediate compound(Step 1)(102.8mg, 0.164mmol) was reacted with tin(II) chloride dihydrate(369mg, 1.64mmol) to afford the intermediate compound methyl 3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-methoxybenzoate(80mg, 51%).
1H-NMR (DMSO, 400MHz): δ 12.60 (s, 1H), 8.26 (d, 1H), 7.97 (d, 1H), 7.89 (t, 1H), 7.83 (t, 1H), 7.50-7.44 (m, 1H), 7.40 (d, 1H), 7.21 (t, 1H), 4.37 (s, 2H), 3.79-3.67 (m, 1H), 3.59-3.33 (m, 3H), 3.29-3.06 (m, 3H).
Step 3 : Preparation of 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-methoxybenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 2)(80mg, 0.14mmol) was reacted with lithium hydroxide(58.7 mg, 1.4 mmol) to afford the title compound(42mg, 55%).
1H-NMR (MeOD, 400MHz): δ 7.54 (s, 1H), 7.43-7.51 (m, 4H), 6.94 (d, 1H), 6.79 (dd, 1H), 4.97 (s, 2H), 4.05 (s, 3H), 2.32-2.42 (m, 1H), 1.27-1.37 (m, 2H), 0.88-0.96 (m, 2H).
<Example 62> 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methoxybenzoic acid; (I-62)
Step 1 : Preparation of methyl 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methoxy-3-nitrobenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(140mg, 0.33mmol) was reacted with methyl 5-bromo-2-methoxy-3-nitrobenzoate(96.9mg, 0.33mmol), tetrakis(triphenyl phosphine)palladium(0)(Pd(PPh3)4, 34.7mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and N,N -diisopropylethylamine(69ul, 0.4mmol) to afford the intermediate compound methyl 5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methoxy-3-nitrobenzoate(126.5mg, 61.1%).
1H-NMR (CDCl3, 400MHz): δ 8.13 (s, 1H), 8.02 (s, 1H), 7.43-7.33 (m, 4H), 6.88 (d, 1H), 6.67-6.65 (m, 1H), 4.83 (s, 2H), 4.01 (s, 3H), 3.97 (s, 3H), 2.18-2.13 (m, 1H), 1.33-1.26 (m, 2H), 1.20-1.15 (m, 2H).
Step 2 : Preparation of methyl 3-amino-5-((2- chloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methoxy benzoate
This compound was made using the procedure described for example 8(Step 2). Thus, this intermediate compound(Step 1)(126.5mg, 0.2mmol) was reacted with tin(II) chloride dihydrate(225.63mg, 1.0mmol) to afford the intermediate compound methyl 3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methoxybenzoate(51mg, 43%).
1H-NMR (CDCl3 , 400MHz): δ 7.39-7.33 (m, 5H), 7.05 (s, 1H), 6.86 (s, 1H), 6.68 (dd, 1H), 4.80 (s, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 2.15-2.05 (m, 1H), 1.29-1.24 (m, 2H), 1.16-1.11 (m, 2H).
Step 3 : Preparation of 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methoxybenzoic acid
This compound was made using the procedure described for example 1(step 6). Thus, this intermediate compound(Step 2)(51mg, 0.09mmol) was reacted with lithium hydroxide(36mg, 0.9mmol) to afford the title compound(37.3mg, 71%).
1H-NMR (MeOD, 400MHz): δ 7.55-7.50 (m, 2H), 7.48-7.46 (m, 1H), 7.41 (d, 1H), 7.21 (d, 1H), 7.08 (d, 1H), 6.92 (d, 1H), 6.76 (dd, 1H), 4.95 (s, 2H), 4.13 (s, 3H), 2.38-2.34 (m, 1H), 1.30-1.22 (m, 4H).
<Example 63> 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-methylbenzoic acid; (I-63)
Step 1 : Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-methylbenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.239mmol) was reacted with methyl 3-bromo-5-methylbenzoate(65.5mg, 0.287mmol), bis (triphenylphosphine) palladium(II)dichloride(PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I)iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-methylbenzoate(87mg, 31%).
1H-NMR (CDCl3, 400MHz): δ 8.00 (s, 1H), 7.82 (s, 1H), 7.53 (s, 1H), 7.42-7.35 (m, 3H), 7.33-7.26 (m, 1H), 6.87 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 3.92 (s, 3H), 2.40 (s, 3H), 2.22-2.11 (m, 1H), 1.32-1.29 (m, 2H), 1.21-1.15 (m, 2H).
Step 2 : Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-methylbenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(step1)(87mg, 0.153mmol) was reacted with lithium hydroxide(64.3mg, 1.53mmol) to afford the title compound(28.8mg, 34%).
1H-NMR (DMSO, 400MHz): δ 13.43 (br, 1H), 7.81 (d, 1H), 7.65-7.63 (m, 1H), 7.59 (br, 1H), 7.58-7.54 (m, 1H), 7.10 (d, 1H), 6.84 (dd, 1H), 4.99 (s, 2H), 2.39 (s, 3H), 1.21-1.11 (m, 5H).
<Example 64> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-cyclopropylbenzoic acid; (I-64)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-cyclopropylbenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(77.3mg, 0.18mmol)was reacted with methyl 3-cyclopropyl-5-iodobenzoate(55.8mg, 0.18mmol), tetrakis(triphenyl phosphine)palladium(0)(Pd(PPh3)4, 23㎎, 0.02mmol), copper(I) iodide(4mg, 0.02mmol) and N,N -diisopropylethylamine(38ul, 0.22mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-cyclopropylbenzoate(45.9mg, 43%).
1H-NMR (CDCl3, 400MHz): δ 7.97 (t, 1H), 7.69 (t, 1H), 7.43-7.38 (m, 4H), 7.36-7.31 (m, 1H), 6.87 (d, 1H), 6.69 (dd, 1H), 4.80 (s, 2H), 3.92 (s, 3H), 2.24-2.12 (m, 1H), 1.98-1.90 (m, 1H), 1.33-1.28 (m, 2H), 1.20-1.14 (m, 2H), 1.05-0.99 (m, 2H), 0.79-0.73 (m, 2H).
Step 2 : Preparation of 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methoxybenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(45.9mg, 0.077mmol) was reacted with lithium hydroxide(32.5mg, 0.77mmol) to afford the title compound(22.8mg, 51%).
1H-NMR (DMSO, 400MHz): δ 7.77 (d, 1H), 7.66-7.60 (m, 3H), 7.59-7.52 (m, 2H), 7.44 (s, 1H), 7.08 (d, 1H), 6.83 (dd, 1H), 4.98 (s, 2H), 2.57-2.53 (m, 1H), 2.10-2.01 (m, 1H), 1.24-1.18 (m, 2H), 1.16-1.09 (m, 2H).
<Example 65> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-ethylbenzoic acid; (I-65)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-ethylbenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(84.7mg, 0.2mmol) was reacted with methyl 3-ethyl-5-iodobenzoate(58.7mg, 0.2mmol), tetrakis(triphenylphosphine) palladium(0)(Pd(PPh3)4, 23.1mg, 0.02mmol), copper(I) iodide(3.8mg, 0.02mmol) and N,N -diisopropylethylamine(41.8ul, 0.24mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-ethylbenzoate(78.2mg, 67%).
1H-NMR (CDCl3, 400MHz): δ 8.01 (t, 1H), 7.84 (t, 1H), 7.54 (t, 1H), 7.43-7.41 (m, 1H), 7.39 (d, 2H), 7.36-7.32 (m, 1H), 6.87 (d, 1H), 6.69 (dd, 1H), 4.81 (s, 2H), 3.92 (s, 3H), 2.69 (q, 2H), 2.19-2.11 (m, 1H), 1.32-1.22 (m, 5H), 1.20-1.14 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-ethylbenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(78.2mg, 0.13mmol) was reacted with lithium hydroxide(56.5mg, 1.3mmol) to afford the title compound(27mg, 37%).
1H-NMR (MeOD, 400MHz): δ 7.93 (d, 2H), 7.62-7.53 (m, 3H), 7.52-7.46 (m, 2H), 6.96 (d, 1H), 6.80 (dd, 1H), 4.99 (s, 2H), 2.75 (q, 2H), 2.44-2.34 (m, 1H), 1.30 (t, 3H), 1.27-1.21 (m, 4H).
<Example 66> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-isopropylbenzoic acid; (I-66)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-isopropylbenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(64.2mg, 0.15mmol) was reacted with methyl 3-iodo-5-isopropylbenzoate(46.6mg, 0.15mmol), tetrakis(triphenylphosphine) palladium(0)(Pd(PPh3)4, 17.3mg, 0.02mmol), copper(I) iodide(2.9mg, 0.02mmol) and N,N -diisopropylethylamine(31.3ul, 0.18mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-isopropylbenzoate(76.3mg, 86%).
1H-NMR (CDCl3, 400MHz): δ 8.02 (t, 1H), 7.87 (t, 1H), 7.56 (t, 1H), 7.44-7.39 (m, 3H), 7.36-7.31 (m, 1H), 6.87 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 3.92 (s, 3H), 3.00-2.91 (m, 1H), 2.20-2.12 (m, 1H), 1.32-1.29 (m, 2H), 1.28 (d, 6H), 1.21-1.14 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-isopropylbenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(76.3mg, 0.13mmol) was reacted with lithium hydroxide(53.8 mg, 1.3mmol) to afford the title compound(37mg, 50%).
1H-NMR (DMSO, 400MHz): δ 7.84 (d, 2H), 7.65-7.61 (m, 2H), 7.53-7.59 (m, 2H), 7.09 (d, 1H), 6.84 (dd, 1H), 4.89 (s, 2H), 3.06-2.96 (m, 1H), 1.23 (d, 6H), 1.21-1.17 (m, 2H), 1.17-1.15 (m, 2H).
<Example 67> 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol - 4-yl)methoxy)phenyl)ethynyl)-5-iodobenzoic acid; (I-67)
Step 1 : Preparation of 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-iodobenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-iodobenzoate (Step 1 of example 56)(87mg, 0.153mmol) was reacted with lithium hydroxide (66.7mg, 1.59mmol)to afford the title compound(41mg, 39%).
1H-NMR (DMSO, 400MHz): δ 13.50 (br, 1H), 8.22(t, 1H), 8.11(t, 1H), 7.98 (t, 1H), 7.65-7.61 (m, 3H), 7.59-7.53 (m, 1H), 7.10 (d, 1H), 6.85 (dd, 1H), 4.99 (s, 2H), 2.39 (s, 3H), 1.27-1.12 (m, 5H).
<Example 68> 3-((2,5- dichloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-68)
Step 1 : Preparation of tert-butyl(2,5-dichloro-4-iodophenoxy)dimethylsilane
This compound was made using the procedure described for example 1(Step 1). Thus, 2,5-dichloro-4-iodophenol(0.5g, 1.73mmol) was reacted with tert-buty ldimethylsilylchloride(TBSCl, 0.39g, 2.60mmol), imidazole(0.23g, 3.46mmol) to afford the intermediate compound tert-butyl(2,5-dichloro- 4-iodophenoxy) dimethylsilane(0.61g, 88%).
1H-NMR (CDCl3, 400MHz): δ 7.24 (s, 1H), 6.97 (s, 1H), 0.96 (s, 9H), 0.16 (s, 6H).
Step 2 : Preparation of tert-butyl(2,5-dichloro-4-((trimethylsilyl)ethynyl) phanoxy)dimethylsilane
This compound was made using the procedure described for example 1(Step 2). Thus, this intermediate compound(Step 1)(0.61g, 1.52mmol) was reacted with bis(triphenylphosphine)palladium(II) dichloride((PdCl2(PPh3)2, 106.68mg, 0.15mmol), Copper(I) iodide(29mg, 1.22mmol), triethylamine(0.42ml, 3.04mmol) to afford the intermediate compoundtert-butyl(2,5-dichloro-4-((trimethylsilyl) ethynyl)phanoxy)dimethylsilane(368.97mg, 65%).
1H-NMR (CDCl3, 400MHz): δ 7.24 (s, 1H), 6.97 (s, 1H), 0.96 (s, 9H), 0.25 (s, 9H), 0.16 (s, 6H).
Step 3 : Preparation of 2,5-dichloro-4-((trimethylsilyl)ethynylphenol
This compound was made using the procedure described for example 1(Step 3). Thus, this intermediate compound(Step 2)(368.97mg, 0.99mmol)was reacted with Potassium fluoride(KF, 574mg, 9.9mmol) to afford the intermediate compound 2,5-dichloro-4-((trimethylsilyl)ethynylphenol(185mg, 45%) and used directly for the next step without further purification.
Step 4 : Preparation of 5- cyclopropyl -4-((2,5- dichloro -4- ethynylphenoxy ) methyl)-3-(2,6-duchlorophenyl)isoxazole
This compound was made using the procedure described for example 1(Step 4). Thus, this intermediate compound(Step 3)(256.6mg, 0.99mmol) was reacted with 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole(Intermediate 1)(343.6mg, 0.99mmol), potassium carbonate(205.2mg, 1.49mmol) to afford the intermediate compound 5-cyclopropyl-4-((2,5-dichloro-4-ethynylphenoxy) methyl)-3-(2,6-duchlorophenyl)isoxazole(345.4mg, 77%).
1H-NMR (CDCl3, 400MHz): δ 7.41-7.30 (m, 3H), 6.83 (d, 1H), 6.66 (dd, 1H), 4.80 (s, 2H), 3.26 (s, 1H), 2.17-2.10 (m, 1H), 1.31-1.27 (m, 2H), 1.23-1.17 (m, 2H).
Step 5 : Preparation of methyl 3-((2,5- dichloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, this intermediate compound(Step 4)(345.4mg, 0.762mmol) was reacted with bis(triphenylphosphine)palladium(II) dichloride((PdCl2(PPh3)2, 49mg, 0.07mmol), Copper(I) iodide(7mg, 0.035mmol) and 1,8-Diazabicyclo[5.4.0]undec -7-ene(DBU, 0.16ml, 1.05mmol) to afford the intermediate compound methyl 3-((2,5-dichloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole -4-yl)methoxy)phenyl)ethynyl)benzoate(232.7mg, 52%).
1H-NMR (DMSO, 400MHz): δ 11.33 (s, 1H), 8.06 (t, 1H), 8.02-7.98 (m, 1H), 7.83-7.79 (m, 1H), 7.77 (s, 1H), 7.61 (t, 1H), 7.12 (s, 1H), 3.89 (s, 3H).
Step 6 : Preparation of 3-((2,5- dichloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 2(Step 6). Thus, this intermediate compound(Step 5)(232.7mg, 0.40mmol) was reacted with lithium hydroxide(167.8mg, 4mmol) to afford the title compound(133mg, 58%).
1H-NMR (CDCl3, 400MHz): δ 8.04 (t, 1H), 7.97(d, 1H), 7.79-7.71 (m, 2H), 7.65-7.52 (m, 4H), 7.45 (s, 1H), 5.14 (s, 2H), 1.28-1.12 (m, 5H).
<Example 69> 3-((2,3- dichloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-69)
Step 1 : Preparation of tert-butyl(2,3-dichloro-4-iodophenoxy)dimethylsilane
This compound was made using the procedure described for example 1(Step 1). Thus, 2,3-dichloro-4-iodophenol(0.5g, 1.73mmol) was reacted with tert-butyldimethylsilylchloride(TBSCl, 0.39g, 2.60mmol), imidazole(0.23g, 3.46mmol) to afford the intermediate compound tert-butyl(2,3-dichloro-4- iodophenoxy)dimethylsilane(0.61g, 88%).
1H-NMR (CDCl3, 400MHz): δ 7.42 (m, 1H), 6.42 (m, 1H), 0.96 (s, 9H), 0.16 (s, 6H).
Step 2 : Preparation of tert-butyl(2,3-dichloro-4-((trimethylsilyl)ethynyl) phanoxy)dimethylsilane
This compound was made using the procedure described for example 1(Step 2). Thus, this intermediate compound(Step 1)(0.61g, 1.52mmol) was reacted with bis(triphenylphosphine)palladium(II) dichloride((PdCl2(PPh3)2, 106.68mg, 0.15mmol), Copper(I) iodide(29mg, 1.22mmol), triethylamine(0.42ml, 3.04mmol) to afford the intermediate compound tert-butyl(2,3-dichloro-4-((trimethylsilyl) ethynyl)phanoxy)dimethylsilane(368.97mg, 65%).
1H-NMR (CDCl3, 400MHz): δ 7.42 (m, 1H), 6.42 (m, 1H), 0.96 (s, 9H), 0.25 (s, 9H), 0.16 (s, 6H).
Step 3 : Preparation of 2,3-dichloro-4-((trimethylsilyl)ethynylphenol
This compound was made using the procedure described for example 1(Step 3). Thus, this intermediate compound(Step 2)(368.97mg, 0.99mmol)was reacted with Potassium fluoride(KF, 574mg, 9.9mmol) to afford the intermediate compound 2,3-dichloro-4-((trimethylsilyl)ethynylphenol(185mg, 45%) and used directly for the next step without further purification.
Step 4 : Preparation of 5- cyclopropyl -4-((2,3- dichloro -4- ethynylphenoxy ) methyl)-3-(2,6-duchlorophenyl)isoxazole
This compound was made using the procedure described for example 1(Step 4). Thus, this intermediate compound(Step 3)(256.6mg, 0.99mmol) was reacted with 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole(Intermediate 1)(343.6mg, 0.99mmol) and potassium carbonate(205.2mg, 1.49mmol) to afford the intermediate compound 5-cyclopropyl-4-((2,3-dichloro-4-ethynylphenoxy) methyl)-3-(2,6-duchlorophenyl)isoxazole(345.4mg, 77%).
1H-NMR (CDCl3, 400MHz): δ 7.41-7.30 (m, 3H), 6.83 (d, 1H), 6.66 (dd, 1H), 4.80 (s, 2H), 3.26 (s, 1H), 2.17-2.10 (m, 1H), 1.31-1.27 (m, 2H), 1.23-1.17 (m, 2H).
Step 5 : Preparation of methyl 3-((2,3- dichloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, this intermediate compound(Step 4)(345.4mg, 0.762mmol) was reacted with bis(triphenylphosphine)palladium(II) dichloride((PdCl2(PPh3)2, 49mg, 0.07mmol), Copper(I) iodide(7mg, 0.035mmol) and 1,8-Diazabicyclo[5.4.0]undec -7-ene(DBU, 0.16ml, 1.05mmol) to afford the intermediate compound methyl 3-((2,3-dichloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)benzoate (232.7mg, 52%).
1H-NMR (DMSO, 400MHz): δ 8.06 (t, 1H), 8.03-7.78 (m, 2H), 7.96-7.53 (m, 5H), 7.27 (d, 1H), 5.15 (s, 2H), 3.89 (s, 3H), 1.28-1.13 (m, 5H).
Step 6 : Preparation of 3-((2,3- dichloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 5)(232.7mg, 0.40mmol) was reacted with lithium hydroxide(167.8mg, 4mmol) to afford the title compound(133mg, 58%).
1H-NMR (DMSO, 400MHz): δ 8.05 (t, 1H), 7.99 (d, 1H), 7.79 (d, 1H), 7.67-7.53 (m, 5H), 7.26 (d, 1H), 5.14 (s, 2H), 1.12-1.26 (m, 5H).
<Example 70> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole -4- yl ) methoxy )-6-fluorophenyl)ethynyl)benzoic acid (I-70)
Step 1 : Preparation of tert-butyl(3-chloro-5-fluoro-4-iodophenoxy)dimethyl silane
This compound was made using the procedure described for example 1(Step 1). Thus, 3-chloro-5-fluoro-4-iodophenol(0.5g, 1.84mmol) was reacted with tert-butyldimethylsilyl chloride(TBSCl, 0.39g, 2.60mmol), imidazole(0.23g, 3.46mmol) to afford the intermediate compound tert-butyl(3-chloro-5- fluoro-4-iodophenoxy)dimethylsilane(0.54g, 76%).
1H-NMR (CDCl3, 400MHz): δ 7.69 (d, 1H), 6.97 (d, 1H), 0.96 (s, 9H), 0.16 (s, 6H).
Step 2 : Preparation of tert -butyl(3- chloro -5- fluoro -4- iodophenoxy - ((trimethylsilyl)ethynyl)phenoxy))dimethylsilane
This compound was made using the procedure described for example 1(Step 2). Thus, this intermediate compound(Step 1)(0.54g, 1.40mmol)was reacted with bis(triphenylphosphine)palladium(II)dichloride((PdCl2(PPh3)2, 106.68mg, 0.14 mmol), copper(I) iodide (29mg, 0.14mmol) and triethylamine(0.42ml, 3.04mmol) to afford the intermediate compound tert-butyl(3-chloro-5-fluoro-4- ((trimethylsilyl)ethylnyl)phenoxy)dimethylsilane(239.91mg, 48%).
1H-NMR (CDCl3, 400MHz): δ 7.69 (d, 1H), 6.97 (d, 1H), 0.96 (s, 9H), 0.25 (s, 9H), 0.16 (s, 6H).
Step 3 : Preparation of 3-chloro-5-fluoro-4-((trimethylsilyl)ethylnyl)phenol
This compound was made using the procedure described for example 1(Step 3). Thus, this intermediate compound(Step 2)(239.91mg, 0.67mmol) was reacted with Potassium fluoride(390mg, 6.7mmol) to afford the intermediate compound 3-chloro-5-fluoro-4-((trimethylsilyl)ethylnyl)phenol without further purification.
Step 4 : Preparation of 4-((3- chloro -4- ethynyl -5- fluorophenoxy )methyl)-5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazole
This compound was made using the procedure described for example 1(Step 4). Thus, this intermediate compound(Step 3)(162.6mg, 0.67mmol) was reacted with 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole(Intermediate 1)(232.5mg, 0.67mmol), potassium carbonate(138.90mg, 1.01mmol) to afford the intermediate compound 4-((3-chloro-4-ethynyl-5-fluorophenoxy)methyl)-5- cyclopropyl-3-(2,6-dichlorophenyl)isoxazole(210.7mg, 72%).
1H-NMR (CDCl3, 400MHz): δ 7.41-7.30 (m, 3H), 6.83 (d, 1H), 6.66 (dd, 1H), 4.80 (s, 2H), 3.26 (s, 1H), 2.17-2.10 (m, 1H), 1.31-1.27 (m, 2H), 1.23-1.17 (m, 2H).
Step 5 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole -4-yl)methoxy)-6-fluorophenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, this intermediate compound(Step 4)(210.7mg, 0.48mmol) was reacted with bis(triphenylphosphine)palladium(II) dichloride((PdCl2(PPh3)2, 35mg, 0.05mmol), copper(I) iodide(9.5mg, 0.05mmol), 1,8-Diazabicyclo(5.4.0)undec-7-ene(DBU, 0.36ml, 2.4mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-yl)methoxy)-6-fluorophenyl)ethynyl)benzoate(131.5mg, 48%).
1H-NMR (CDCl3, 400MHz): δ 8.21 (t, 1H), 8.02-7.99 (m, 1H), 7.73-7.71 (m, 1H), 7.45-7.32 (m, 4H), 6.71 (d, 1H), 6.50 (dd, 1H), 4.81 (s, 2H), 3.93 (s, 3H), 2.16-2.12 (m, 1H), 1.32-1.27 (m, 2H), 1.21-1.16 (m, 2H).
Step 6 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazole -4-yl)methoxy)-6-fluorophenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 5)(131.5mg, 0.23mmol) was reacted with lithium hyroxide(96.5mg, 2.3mmol) to afford the title compound(79.4mg, 62%).
1H-NMR (CDCl3, 400MHz): δ 8.29 (s, 1H), 8.09 (d, 1H), 7.79 (d, 1H), 7.50-7.33 (m, 4H), 6.71 (d, 1H), 6.51 (dd, 1H), 4.82 (s, 2H), 2.17-2.11 (m, 1H), 1.33-1.28 (m, 2H), 1.21-1.16 (m, 2H).
<Example 71> 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methylbenzoic acid; (I-71)
Step 1 : Preparation of methyl 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methyl-3-nitrobenzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Exaple 5)(100mg, 0.239mmol) was reacted with methyl 5-bromo-2-methyl-3-nitrobenzoate(70.1mg, 0.287mmol), bis(triphenyl phosphine)palladium(II) dichloride((PdCl2(PPh3)2, 21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate compound methyl 5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methyl-3-nitrobenzoate(105.2mg, 72%).
1H-NMR (CDCl3, 400MHz): δ 8.11-8.10 (d, 1H), 7.96 (d, 1H), 7.42-7.39 (m, 3H), 7.35-7.31 (m, 1H), 6.88-6.87 (d, 1H), 6.71-6.69 (dd, 1H), 4.83 (s, 2H), 3.95 (s, 3H), 2.63 (s, 3H), 2.17-2.13 (m, 1H), 1.32-1.28 (m, 2H), 1.26-1.15 (m, 2H).
Step 2 : Preparation of methyl 3-amino-5-((2- chloro -4-((5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methylbenzoate
This compound was made using the procedure described for example 8(Step 2). Thus, the intermediate compound(Step 1)(105.2mg, 0.172mmol) was reacted with tin(II) chloride dihydrate(388mg, 1.72mmol) to afford the intermediate compound methyl 3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methylbenzoate (62mg, 62%).
1H-NMR (CDCl3, 400MHz): δ 7.42-7.31 (m, 5H), 6.97 (d, 1H), 6.86 (d, 1H), 6.68 (dd, 1H), 4.81 (s, 2H), 3.89 (s, 3H), 3.76 (s, 2H), 2.35 (s, 3H), 2.17-2.13 (m, 1H), 1.32-1.28 (m, 2H), 1.19-1.15 (m, 2H).
Step 3 : Preparation of 3-amino-5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methylbenzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 2)(62mg, 0.106mmol) was reacted with lithium hydroxide(44mg, 1.06mmol) to afford the title compound (53mg, 88%).
1H-NMR (DMSO, 400MHz): δ 7.64-7.62 (m, 2H), 7.57-7.48 (m, 2H), 7.06 (dd, 2H), 6.92 (d, 1H), 6.82 (dd, 1H), 5.28 (s, 2H), 4.97 (s, 2H), 2.47 (m, 1H), 2.21 (s, 3H), 1.21-1.19 (m, 2H), 1.14-1.13 (m, 2H).
<Example 72> 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol - 4-yl)methoxy)phenyl)ethynyl)-5-(3-ethylureido) benzoic acid; (I-72)
Step 1 : Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(3-ethylureido) benzoate
The intermediate compound methyl 3-amino-5-((2-chloro-4-((cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of example 8)(150mg, 0.264mmol) was dissolved in dichlromethane(3ml) and ethylisocyanite(31ul, 0.396mmol) was added. The reaction was stirred at room temperature for 1day. The reaction mixture was extracted with ethyl acetate and washed with water. The combined organic phase was dried over MgSO4, filtered, concentrated and purified by column chromatography on silica to afford the intermediate compound methyl 3-((2-chloro-4-((cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(3-ethylureido) benzoate(117mg, 69%).
1H-NMR (CDCl3, 400MHz): δ 7.95 (t, 1H), 7.86 (t, 1H), 7.79 (t, 1H), 7.44-7.38 (m, 2H), 7.36-7.30 (m, 2H), 6.85 (d, 1H), 6.67 (dd, 1H), 5.41 (s, 2H), 4.82 (s, 2H), 3.89 (s, 3H), 3.74 (q, 1H), 2.19-2.10 (m, 1 H), 1.24-1.20 (m, 3H), 1.15-1.11 (m, 4H).
Step 2 : Preparation of 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(3-ethylureido) benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(105mg, 0.165mmol) was reacted with lithium hydroxide(58mg, 1.65mmol) to afford the title compound(20.6mg, 20%).
1H-NMR (DMSO, 400MHz): δ 13.12 (br, 1H), 8.82 (s, 1H), 7.93 (s, 1H), 7.88 (s, 1H), 7.64-7.62 (m, 2H), 7.57-7.55 (m, 2H), 7.09 (d, 1H), 6.84 (dd, 1H), 4.99 (s, 2H), 3.11 (s, 2H), 1.24-1.15 (m, 5H), 1.07-1.04 (q, 3H).
<Example 73> 3- acetamido -5-((2- chloro -4-(( cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-73)
Step 1 : Preparation of methyl 3- acetamido -5-((2- chloro -4-(( cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
The intermediate compound methyl 3-amino-5-((2-chloro-4-((cyclopropyl- 3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of example 8)(100mg, 0.176mmol) was dissolved in N,N-dimethylform amide(1.7ml) and acetylchloride(26ul, 0.264mmol) and triethylamine(55ul, 0.264mmol) were added. The reaction was stirred at room temperature for 1day. The reaction mixture was extracted with ethyl acetate and washed with water. The combined organic phase was dried over MgSO4, filtered, concentrated and purified by column chromatography on silica to afford the intermediate compound methyl 3-acetamido-5-((2-chloro-4-((cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(44mg, 41%).
1H-NMR (CDCl3, 400MHz): δ 8.23 (t, 1H), 7.91 (dd, 1H), 7.50-7.40 (m, 2H), 7.38-7.32(m, 2H), 6.88 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 4.27 (q, 1H), 4.26 (q, 2H), 3.94 (s, 3H), 2.31 (s, 3H), 2.19-2.12 (m, 1 H), 1.33-1.24 (m, 2H), 1.23-1.14 (m, 2H).
Step 2 : Preparation of 3- acetamido -5-((2- chloro -4-(( cyclopropyl -3- (2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
The intermediate compound(Step 1) was dissolved in 1,4-dioxane(1.0ml)/ water and lithium hydroxide(58mg, 0.716mmol) was added. The reaction was stirred at room temperature for 18 hours. The pH of reaction mixture was adjusted 4 to 5 with 1N solution of hydrochloric acid and the reaction mixture was extracted with ethyl acetate and washed with water. The combined organic phase was dried over MgSO4, filtered, concentrated to afford the title compound(18.0mg, 42%).
1H-NMR (DMSO, 400MHz): δ 13.45 (br, 1H), 10.25 (br, 1H), 8.15 (s, 1H), 8.04 (s, 1H), 7.68 (s, 1H), 7.64-7.20 (m, 2H), 7.58-7.54 (m, 2H), 7.09 (d, 1H), 6.84 (dd, 1H), 4.99 (s, 2H), 2.07(s, 3H), 1.21-1.14 (m, 5H).
<Example 74> 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol - 4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoic acid; (I-74)
Step 1 : Preparation of 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, methyl 3-((2-chloro-4-((cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4- yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoate(Example 8)(55.1mg, 0.086mmol) was reacted with lithium hydroxide(36.1mg, 0.86mmol) to afford the title compound(45.2mg, 84%).
1H-NMR (DMSO, 400MHz): δ 13.55 (br, 1H), 9.98 (s, 1H), 8.09 (s, 1H), 7.87 (s, 1H), 7.64-7.62 (m, 3H), 7.58-7.54 (m, 1H), 7.09 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 4.16 (q, 2H), 1.25(t, 3H), 1.21-1.14 (m, 5H).
<Example 75> 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)(methyl)amino)benzoic acid; (I-75)
Step 1 : Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoate
This compound was made using the procedure described for example 10(Step 1). Thus, methyl 3-((2-chloro-4-((cyclopropyl-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoate(Example 8) (50mg, 0.078mmol) was reacted with sodium hydride(5.6mg, 0.234mmol) and iodomethane(6ul, 0.093mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)(methyl)amino)benzoate(35mg, 69%).
1H-NMR (CDCl3, 400MHz): δ 8.02 (t, 1H), 7.88 (s, 1H), 7.62 (s, 1H), 7.42-7.38 (m, 1H), 7.35-7.31 (m, 1H), 6.87 (d, 1H), 6.70 (dd, 1H), 4.82 (s, 2H), 4.22 (q, 2H), 3.93 (s, 3H), 3.32(s, 3H), 2.17-2.13 (m, 1 H), 1.34(t, 3H), 1.32-1.24 (m, 2H), 1.23-1.14 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate(Step 1)(20mg, 0.031mmol) was reacted with lithium hydroxide(12.8mg, 0.31mmol) to afford the title compound(18mg, 94%).
1H-NMR (DMSO, 400MHz): δ 13.38 (br, 1H), 7.88 (t, 1H), 7.83 (t, 1H), 7.72 (t, 1H), 7.64-7.62(m, 2H), 7.57-7.53 (m, 2H), 7.10 (d, 1H), 6.85 (dd, 1H), 4.98 (s, 2H), 4.13 (q, 2H), 3.27 (s, 3H), 1.23-1.11 (m, 8H).
<Example 76> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropoxycarbonyl)amino)benzoic acid; (I-76)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropoxycarbonyl)amino)benzoate
Diisopropylamine(0.3ml, 1.8mmol)was added to a solution of cyclopropanol (0.1ml, 1.8mmol) and triphosgene(267mg, 0.9mmol) in dichloromethane which was cooled to 0℃ and stirred for 1 hour at room temperature. 3-Amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of example 8)(100mg, 0.18mmol) and diisopropylethylamine(0.12ml, 0.54mmol) was added to the reaction mixture and stirred for 3 hours at room temperature. Water was added to the reaction mixture and the product was extracted into dichloromethane. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to afford the intermediate compound methyl3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropoxycarbonyl)amino)benzoate(35mg, 30%).
1H-NMR (CDCl3, 400MHz): δ 7.96 (m, 1H), 7.84 (m, 2H), 6.86 (d, 1H), 6.69 (dd, 1H), 7.42-7.31 (m, 4H), 6.86 (d, 1H), 6.72 (dd, 1H), 5.64 (s, 2H), 4.82 (s, 2H), 3.92 (s, 3H), 2.16 (m, 1H), 1.31-1.14 (m, 4H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropoxycarbonyl)amino)benzoic acid
This compound was made using the procedure described for example1(Step 6). Thus, this intermediate compound(Step 1)(30mg, 0.046mmol) was reacted with lithium hydroxide(19mg, 0.46mmol)to afford the title compound(9mg, 31%).
1H-NMR (DMSO, 400MHz): δ 9.92 (s, 1H), 8.02 (s, 1H), 7.79 (s, 1H), 7.65-7.63 (m, 3H), 7.59-7.54 (m, 2H), 7.10 (m, 1H), 6.85-6.82 (m, 1H), 5.02 (s, 2H), 4.09(m, 1H), 1.23-1.14 (m, 6H), 0.72-0.70 (m, 4H).
<Example 77> 3-(( tert - butoxycarbonyl )amino)-5-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-77)
Step 1 : Preparation of 3-(( tert - butoxycarbonyl )amino)-5-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 5). Thus, methyl 3-((tert-butoxycarbonyl)amino)-5-((2-chloro-4-((5-cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Example 9)(300mg, 0.449mmol) was reacted with lithium hydroxide(188mg, 4.49mmol) to afford the title compound(227mg, 77%).
1H-NMR (DMSO, 400MHz): δ 13.27 (br, 1H), 8.10(t, 1H), 7.84 (t, 1H), 7.64-7.60 (m, 3H), 7.57-7.56 (m, 2H), 7.09 (d, 1H), 6.84 (dd, 1H), 4.99 (s, 2H), 1.49 (s, 9H), 1.19-1.14 (m, 5H).
<Example 78> 3-(( tert - butoxycarbonyl )(methyl)amino)-5-((2- chloro -4-(( cyclo propyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-78)
Step 1 : Preparation of methyl 3-(( tert - butoxycarbonyl )(methyl)amino)-5- ((2- chloro -4-((cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 10(Step 1). Thus, methyl 3-((2-chloro-4-((cyclopropyl-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)(methyl)amino)benzoate(example 9)(220mg, 0.329mmol) was reacted with sodium hydride(24mg, 0.988mmol) and iodomethane(87ul, 1.31mmol) to afford the intermediate compound methyl 3-((tert-butoxycarbonyl)(methyl)amino)-5-((2-chloro-4-((cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(102mg, 45%).
1H-NMR (CDCl3, 400MHz): δ 7.98 (t, 1H), 7.88 (t, 1H), 7.60 (s, 1H), 7.42-7.39 (m, 3H), 7.35-7.31 (m, 1H), 6.87 (d, 1H), 6.70 (dd, 1H), 4.82 (s, 2H), 3.93 (s, 3H), 3.29 (s, 3H), 2.17 (m, 1H), 1.46(s, 9H), 1.32 1.24 (m, 2H), 1.19-1.15 (m, 2H).
Step 2 : Preparation of 3-(( tert - butoxycarbonyl )(methyl)amino)-5-((2- chloro - 4-(( cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(100mg, 0.146mmol) was reacted with lithium hydroxide(61.5mg, 1.46mmol) to afford the title compound(28.3mg, 29%).
1H-NMR (DMSO, 400MHz): δ 13.37 (br, 1H), 7.88(t, 1H), 7.79 (t, 1H), 7.67(s, 1H), 7.64-7.62 (m, 2H), 7.57-7.53 (m, 2H), 7.10 (d, 1H), 6.85 (dd, 1H), 4.98 (s, 2H), 3.27 (s, 3H), 1.40 (s, 9H), 1.21-1.11 (m, 5H).
<Example 79> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((cyclopropylmethoxy)carbonyl)amino)benzoic acid; (I-79)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((cyclopropylmethoxy)carbonyl)amino)benzoate
This compound was made using the procedure described for example 76(Step 1). Thus, 3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of example8)(100mg, 0.18mmol), diisopropylamine(0.3ml, 1.6mmol), triphosgene(53mg, 0.18mmol), cyclopropanemethanol(0.03ml, 0.35mmol) and N, N-diisopropylethyl amine(0.12ml, 0.54mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropylmethoxy)amino)benzoate(38mg, 32%).
1H-NMR (CDCl3, 400MHz): δ 7.93 (m, 1H), 7.89 (m, 2H), 7.43-7.32 (m, 4H), 6.87 (d, 1H), 6.72 (dd, 1H), 4.82 (s, 2H), 4.03 (s, 1H), 4.01 (m, 1H), 3.93 (s, 3H), 2.16 (m, 1H), 1.56-1.16 (m, 4H), 0.62 (m, 2H), 0.34 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((cyclopropylmethoxy)carbonyl)amino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(30mg, 0.045mmol) was reacted with lithium hydroxide(19mg, 0.46mmol) to afford the title compound(15mg, 52%).
1H-NMR (DMSO, 400MHz): δ 9.92 (s, 1H), 7.97 (s, 1H), 7.74 (s, 1H), 7.54 (m, 3H), 7.46 (m, 2H), 6.99 (m, 1H), 6.72 (dd, 1H), 4.88 (s, 2H), 3.84 (d, 2H), 1.84 (d, 2H), 1.13-1.04 (m, 4H), 0.46 (m, 2H), 0.22 (m, 2H).
<Example 80> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((2-cyclopropylethoxy)carbonyl)amino)benzoic acid; (I-80)
Step 1 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((2-cyclopropylethoxy)carbonyl)amino)benzoate
This compound was made using the procedure described for example 76(Step 1). Thus, 3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of example 8)(150mg, 0.264mmol), 1,1'-carbonyldiimidazole(47mg, 0.29mmol) and cyclopropylethyl alcohol(43mg, 0.5mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy) phenyl)ethynyl)-5-(((2-cyclopropylethoxy)carbonyl)amino)benzoate(30mg, 17%)).
1H-NMR (CDCl3, 400MHz): δ 7.92 (s, 1H), 7.89 (s, 2H), 7.44-7.32 (m, 4H), 6.87 (m, 1H), 6.70 (m, 1H), 4.82 (s, 2H), 4.27 (m, 2H), 3.92 (s, 3H), 2.17 (m, 1H), 1.60 (m, 2H), 1.33-1.16 (m, 4H), 0.76 (m, 1H), 0.49 (m, 2H), 0.11 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((2-cyclopropylethoxy)carbonyl)amino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(30mg, 0.044mmol) was reacted with lithium hydroxide(50mg, 1.2mmol) to afford the title compound(153g, 44%).
1H-NMR (DMSO, 400MHz): δ 9.84 (s, 1H), 7.96 (s, 1H), 7.75 (s, 1H), 7.52 (m, 3H), 7.45 (d, 2H), 6.98 (d, 1H), 6.72 (dd, 1H), 5.64 (s, 2H), 4.87 (s, 2H), 4.06(m, 2H), 1.43 (m, 2H), 0.74-0.65 (m, 4H), 0.30 (m, 2H), 0.01 (m, 2H).
<Example 81> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((2-hydroxyethoxy)carbonyl)amino)benzoic acid; (I-81)
Step 1 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((2-hydroxyethoxy)carbonyl)amino)benzoate
This compound was made using the procedure described for example 78(Step 1). Thus, 3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of example 8)(70mg, 0.123mmol), 1,1'-carbonyldiimidazole(22mg, 0.136mmol) and ethylene glycol (13.6ul, 0.24mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(((2-hydroxyethoxy)carbonyl)amino)benzoate(20mg, 25%)).
1H-NMR (CDCl3, 400MHz): δ 7.94 (m, 1H), 7.90 (m, 1H), 7.42-7.32 (m, 4H), 7.00 (s, 1H), 6.87 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 4.53 (m, 3H), 4.35 (m, 1H), 3.92 (s, 3H), 2.17 (m, 1H), 1.32-1.16 (m, 4H).
Step 2 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(((2-hydroxyethoxy)carbonyl)amino)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(20mg, 0.03mmol) was reacted with lithium hydroxide(50mg, 1.2mmol) to afford the title compound(11mg, 57%).
1H-NMR (DMSO, 400MHz): δ 9.93 (s, 1H), 8.03 (s, 1H), 7.78 (s, 1H), 7.64 (m, 3H), 7.54 (m, 2H), 7.09 (d, 1H), 6.83 (dd, 1H), 4.98 (s, 2H), 4.12 (t, 2H), 3.63 (m, 2H), 1.23-1.14 (m, 5H).
<Example 82> 3-((( azetidin -3- yloxy )carbonyl)amino)-5-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-82)
Step 1 : Preparation of tert -butyl-3-(((3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl-ethynyl)-5-(methoxycarbonyl)phenyl)carbamoyl)oxy)azetidine-1-carboxylate
This compound was made using the procedure described for example 78(Step 1). Thus, 3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of example 8)(170mg, 0.30mmol), tert-butyl 3-hydroxyazetidine -1-carboxylate(120mg, 0.69mmol), N,N-diisopropylethylamine(0.19ml, 1.04mmol) and triphosgene(72mg, 0.24mmol) to afford the intermediate compound tert-butyl-3-(((3-((2-chloro-4-((5- cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl-ethynyl)-5-(methoxycarbonyl)phenyl)carbamoyl)oxy)azetidine-1-carboxylate(80mg, 35%).
1H-NMR (CDCl3, 400MHz): δ 7.94 (m, 2H), 7.86 (s, 1H), 7.43-7.32 (m, 3H), 6.94 (s, 1H), 6.87 (m, 1H), 6.69 (dd, 1H), 5.23 (m, 1H), 4.82 (s, 2H), 4.29 (m, 2H), 3.98 (m, 2H), 3.93 (s, 3H), 2.16 (m, 1H), 1.56 (m, 9H), 1.45-1.15 (m, 4H).
Step 2 : Preparation of 3-((( azetidin -3- yloxy )carbonyl)amino)-5-((2- chloro -4- ((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(30mg, 0.04mmol) was reacted with lithium hydroxide(19mg, 0.46mmol) to afford the title compound(12mg, 61%).
1H-NMR (DMSO, 400MHz): δ 13.28 (s, 1H), 10.08 (s, 1H), 8.10 (s, 1H), 7.87 (s, 1H), 7.64 (m, 3H), 7.55 (m, 2H), 7.10 (m, 1H), 6.84 (dd, 1H), 4.99 (s, 2H), 3.95 (d, 2H), 1.24-1.19 (m, 7H), 0.57 (m, 2H), 0.35 (m, 2H).
<Example 83> 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(2-oxooxazolidin-3-yl)benzoic acid; (I-83)
Step 1 : Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(2-oxooxazolidin-3- yl)benzoate
The intermediate compound methyl 3-amino-5-((2-chloro-4-((cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of example 8)(100mg, 0.176mmol) was dissolved in acetonitrile(2ml) and 2-chlroroethylchloroformate(27.3ul, 0.264mmol) and potassium carbonate (36.5mg, 0.264mmol) was added. The reaction was heated at 80℃for 4 hours. The reaction mixture was extracted with ethyl acetate and washed with water. The combined organic phase was dried over MgSO4, filtered, concentrated and purified by column chromatography on silica to afford the intermediate compound methyl 3-((2-chloro-4-((cyclopropyl-3-(2,6-dichlorophenyl)isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(2-oxooxazolidin-3-yl)benzoate(73mg, 65%).
H-NMR (CDCl3, 400MHz): δ 8.01 (t, 1H), 7.97 (t, 1H), 7.95 (t, 1H), 7.42-7.40 (m, 3H), 7.35-7.31 (m, 1H), 6.87 (d, 1H), 6.70 (dd, 1H), 4.82 (s, 2H), 4.54 (q, 2H), 4.14 (q, 2H), 3.91 (s, 3H), 2.19 (m, 1H) 1.31-1.27 (m, 2H), 1.201.16 (m, 2H).
Step 2 : Preparation of 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(2-oxooxazolidin-3-yl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(65mg, 0.101mmol) was reacted with lithium hydroxide(43mg, 1.019mmol) to afford the title compound(21mg, 33%).
1H-NMR (DMSO, 400MHz): δ 13.45 (br, 1H), 8.16 (s, 1H), 7.89 (s, 1H), 7.76 (s, 1H), 7.64-7.62 (m, 2H), 7.59-7.53 (m, 2H), 7.10 (d, 1H), 6.85 (dd, 1H), 4.99 (s, 2H), 4.48 (q, 2H), 4.16 (q, 2H), 1.24-1.13 (m, 5H).
<Example 84> 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)isophthalic acid; (I-84)
Step 1 : Preparation of dimethyl 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)isophthalate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(example 6)(196.2mg, 0.47mmol) was reacted with dimethyl 5-iodoisophthalate(150mg, 0.47mmol), tetrakis(triphenylphosphine) palladium(0) (Pd(PPh3)4, 54.3mg, 0.05mmol), copper(I) iodide(10mg, 0.05mmol) and N,N - diisopropylethylamine(0.1ml, 0.56mmol) to afford the intermediate compound dimethyl 5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)isophthalate(278mg, 97%).
1H-NMR (CDCl3, 400MHz): δ 8.64 (t, 1H), 8.37 (d, 1H), 7.41-7.50 (m, 2H), 7.32-7.40 (m, 3H), 6.90 (d, 1H), 6.73 (d, 1H), 4.85 (s, 2H), 3.98 (s, 6H), 2.13-2.23 (m, 1H), 1.30-1.37 (m, 2H), 1.16-1.24 (m, 2H).
Step 2 : Preparation of 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)metoxy)phenyl)ethynyl)isophthalic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(278mg, 0.46mmol) was reacted with lithium hydroxide(193mg, 4.6mmol) to afford the title compound(66.6mg, 71.5%).
1H-NMR (MeOD, 400MHz): δ 8.61 (t, 1H), 8.30 (d, 2H), 7.55 (d, 1H), 7.53 (d, 1H), 7.50 (d, 1H), 7.48 (d, 1H), 6.96 (d, 1H), 6.80 (d, 1H), 4.97 (s, 2H), 2.33-2.42 (m, 1H), 1.21-1.27 (m, 4H).
<Example 85> 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(piperazine-1-carbonyl)benzoic acid hydrochloride; (I-85)
Step 1 : Preparation of tert -butyl 4-(3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methoxycarbonyl)benzoyl)piperazine-1-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(example 6)(115mg, 0.27mmol)was reacted with tert-butyl 4-(3-(methoxycarbonyl)benzoyl)piperazine-1-carboxylate(130mg, 0.27mmol), tetrakis(triphenylphosphine)palladium(0)(Pd(PPh3)4, 34.7mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol), N,N -diisopropylethyl amine(56.4ul, 0.32mmol) to afford the intermediate compound tert-butyl 4-(3-((2- chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methoxycarbonyl)benzoyl)piperazine-1-carboxylate(88mg, 43%).
1H-NMR (CDCl3, 400MHz): δ 8.24 (s, 1H), 8.00 (s, 1H), 7.74 (s, 1H), 7.50-7.38(m, 3H), 7.35-7.31 (m, 1H), 6.88 (d, 1H), 6.70 (dd, 1H), 4.83 (s, 3H), 3.99 (s, 3H), 3.85-3.80 (m, 2H), 3.66-3.40(m, 6H), 2.21-2.12 (m, 1H), 1.48 (s, 9H), 1.38-1.32 (m, 2H), 1.20-1.12(m, 2H).
Step 2 : Preparation of 3-(4-( tert - butoxycarbonyl ) piperazine -1-carbonyl) -5-((2- chloro -4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(88mg, 0.12mmol) was reacted with lithium hydroxide(48.3mg, 1.2mmol) to afford the 3-(4-(tert-butoxycarbonyl) piperazine-1-carbonyl)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid(61mg, 67.7%).
1H-NMR (CDCl3 , 400MHz): δ 8.28 (s, 1H), 8.05 (s, 1H), 7.79 (s, 1H), 7.45-7.33 (m, 3H), 7.31-7.28(m, 1H), 6.88 (s, 1H), 6.70 (dd, 1H), 4.83 (s, 2H), 3.90-3.82(m, 1H), 3.62-3.30 (m, 6H), 2.30-2.12 (m, 2H), 1.48 (s, 9H), 1.38-1.33 (m, 2H), 1.29-1.16 (m, 2H).
Step 3 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(piperazine-1-carbonyl)benzoic acid hydrochloride
This compound was made using the procedure described for example 57(step 3). Thus, this intermediate compound(Step 2)(61mg, 0.08mmol) was reacted with 5~6N HCl solution(48ul, 0.24mmol) to afford the title compound(35mg, 64%).
1H-NMR (DMSO, 400MHz): δ 13.56 (br, 1H), 8.07 (s, 1H), 7.99 (s, 1H), 7.84 (s, 1H), 7.66-7.60 (m, 2H), 7.58-7.52 (m, 2H), 7.19 (s, 1H), 6.85 (dd, 1H), 4.99 (s, 2H), 3.82-3.74 (m, 3H), 3.42-3.34 (m, 2H), 3.21-3.10 (m, 4H), 1.31-1.19 (m, 4H).
<Example 86> 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4 -yl)methoxy)phenyl)ethynyl)-5-(methylsulfonamido)benzoic acid; (I-86)
Step 1 : Preparation of methyl 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(methylsulfonamido)benzoate
The intermediate compound methyl 3-amino-5-((2-chloro-4-((cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(Step 2 of example 8)(150mg, 0.264mmol) was dissolved in dichloromethane(2ml) /N,N-dimethylformamide(1ml) and methylsulfonyl chloride(22.5ul, 0.290mmol) and 1,8-Diazobicyclo[5.4.0]undec-7-ene(DBU, 40ul, 0.264mmol) were added. The reaction was stirred at room temperature for 1day. The reaction mixture was extracted with ethyl acetate and washed with water. The combined organic phase was dried over MgSO4, filtered, concentrated and purified by column chromatography on silica to afford the intermediate compound methyl 3-((2-chloro-4-((cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methylsulfonamido)benzoate(74mg, 44%).
1H-NMR (CDCl3, 400MHz): δ 8.01 (t, 1H), 7.79 (t, 1H), 7.61 (t, 1H), 7.42-7.40 (m, 2H), 7.35-7.31 (m, 1H), 6.88 (d, 1H), 6.71 (dd, 1H), 6.56 (s, 1H), 4.82 (s, 2H), 3.94 (s, 3H), 2.19 (m, 1H) 1.05-1.32 (m, 4H).
Step 2 : Preparation of 3-((2- chloro -4-(( cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-5-(methylsulfonamido)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(step 1)(20mg, 0.031mmol) was reacted with lithium hydroxide(13mg, 0.31mmol) to afford the title compound(16mg, 85%).
1H-NMR (DMSO, 400MHz): δ 13.33 (br, 1H), 10.14 (s, 1H), 7.81(s, 1H), 7.73 (s, 1H), 7.64-7.61 (m, 2H), 7.59-7.57 (m, 1H), 7.53 (s, 1H), 7.10 (d, 1H), 6.85 (dd, 1H), 4.98 (s, 2H), 3.06 (s, 3H), 1.05-1.32 (m, 5H).
<Example 87> 3-((2- chloro -4-((5- cyclopropyl -3-(2-( trifluoromethyl )phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-87)
Step 1 : Preparation of 2-(trifluoromethyl)benzoaldehyde oxime
This compound was made using the procedure described for Intermediate 1(Step 1). Thus, 2-(trifluoromethyl)benzoaldehyde(11g, 160mmol) was reacted with sodium hydroxide(6.3g, 160mmol), 2,6-dichlorobenzoaldehyde(25g, 140mmol) to afford the intermediate compound 2-(trifluoromethyl)benzo aldehyde oxime(25.9g, 96%).
1H-NMR (CDCl3, 400MHz): δ8.53-8.52 (t, 1H), 8.04-8.02 (d, 1H), 7.85 (s, 1H), 7.72-7.70 (d, 1H), 7.60-7.56 (t, 1H), 7.53-7.51 (d, 1H).
Step 2 : Preparation of N -hydroxy-2-(trifluoromethyl)bezamidoyl chloride
This compound was made using the procedure described for Intermediate1(Step 2). Thus, the intermediate compound(Step 1)(25.9g, 140mmol) was reacted with N-chloro succinimide(NCS, 18.4g, 140mmol) to afford N-hydroxy-2-(trifluoro methyl)bezamidoyl chloride(29g) and used without further purification.
1H-NMR (CDCl3, 400MHz): δ8.57 (s, 1H), 7.77-7.75 (d, 1H), 7.67-7.58 (m, 3H).
Step 3 : Preparation of ethyl 5-cyclopropyl-3-(2-(trifluoromethyl)phenyl) ioxazol-4-carboxylate
This compound was made using the procedure described for Intermediate1(Step 1). Thus, the intermediate compound(Step 2)(29g, 129mmol) was reacted with ethyl 3-cyclopropyl-3-oxopropanoate(25ml, 194mmol) andtriethylamine(150ml) to afford the intermediate compound ethyl 5-cyclopropyl-3-(2-(trifluoromethyl) phenyl)ioxazol-4-carboxylate(22.37g, 56%).
1H-NMR (CDCl3, 400MHz): δ 7.80-7.78 (m, 1H), 7.66-7.62 (m, 2H), 7.42-7.40 (m, 1H), 3.64 (s, 3H), 2.07-2.03 (m, 1H), 1.16-1.12 (m, 2H), 1.01-0.97 (m, 2H).
Step 4 : Preparation of (5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol -4-yl)methanol
This compound was made using the procedure described for Intermediate 1(Step 4). Thus, the intermediate compound(Step 3)(22.37g, 71.7mmol) was reacted with 1M diisobutylaluminium hydride in THF (DIBAL-H, 144ml, 144mmol) to afford the intermediate compound (5-cyclopropyl-3-(2-(trifluoromethyl)phenyl )isoxazol-4-yl)methanol(12.2g, 60%).
1H-NMR (CDCl3, 400MHz): δ 7.81-7.79 (m, 1H), 7.65-7.57 (m, 2H), 7.47-7.45 (m, 1H), 4.40 (s, 2H), 2.19-2.12 (m, 1H), 1.27-1.23 (m, 2H), 1.15-1.10 (m, 2H).
Step 5 : Preparation of 4-(bromomethyl)-5-cyclopropyl-3-(2-(trifluoromethyl) phenyl)ioxazole
This compound was made using the procedure described for Intermediate 1(Step 5). Thus, the intermediate compound(Step 4)(12.2g, 43.02mmol) was reacted with triphenyl phosphite(TPP, 16.9g, 64.53mmol), tetrabromomethane(21.4g, 64.53mmol) to afford the intermediate compound 4-(bromomethyl)-5- cyclopropyl-3-(2-(trifluoromethyl)phenyl)ioxazole(13.44g, 90%).
1H-NMR (CDCl3, 400MHz): δ7.83-7.81 (m, 1H), 7.68-7.62 (m, 2H), 7.55-7.53 (m, 1H), 4.20 (s, 2H), 2.12-2.08 (m, 1H), 1.30-1.25 (m, 2H), 1.24-1.18 (m, 2H).
Step 6 : Preparation of 4-((3- chloro -4- ethynylphenoxy )methyl)- 5- cyclopropyl -3-(2-(trifluoromethyl)phenyl)ioxazole
This compound was made using the procedure described for example 1(Step 4). Thus, the intermediate compound(Step 5)(7.59g, 21.9mmol) was reacted with 3-chloro-4-((trimethylsilyl)ethynyl)phenol(Step 3 of example 5)(4.92g, 21.9mmol), potassium carbonate(4.54g, 32.9mmol) to afford the intermediate compound 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2- (trifluoro methyl)phenyl)ioxazole(7.15g, 78%).
1H-NMR (CDCl3, 400MHz): δ 7.41-7.30 (m, 4H), 6.83 (d, 1H), 6.66 (dd, 1H), 4.80 (s, 2H), 3.26 (s, 1H), 2.17-2.10 (m, 1H), 1.31-1.27 (m, 2H), 1.23-1.17 (m, 2H).
Step 7 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2-( trifluoro methyl)phenyl)ioxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 6)(128mg, 0.31mmol) was reacted with methyl 3-iodobenzoate(80mg, 0.31mmol), bis(triphenylphosphine)palladium(II) dichloride (PdCl2(PPh3)2, 22mg, 0.03mmol), copper(I) iodide(5.8mg, 0.03mmol), triethylamine(0.052ml, 0.37mmol) to afford the intermediate compoundmethyl 3-((2-chloro-4-((5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)ioxazol-4-yl)methoxy)phenyl)ethynyl)benzoate(107mg, 63%).
1H-NMR (CDCl3, 400MHz): δ 8.20 (s, 1H), 8.00-7.98 (m, 1H), 7.81-7.79 (m, 1H), 7.72-7.69 (m, 1H), 7.62-7.59 (m, 2H), 7.45-7.41 (m, 3H), 6.88-6.87 (d, 1H), 6.71-6.68 (dd, 1H), 4.75 (s,2H), 3.93 (s, 3H), 2.14-2.10 (m, 1H), 1.28-1.26 (m, 2H), 1.18-1.14 (m, 2H).
Step 8 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2-( trifluoromethyl ) phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 7)(107mg, 0.20mmol) was reacted with lithium hydroxide(84mg, 2.0mmol) to afford the title compound(92.5mg, 86%).
1H-NMR (DMSO, 400MHz): δ 13.27 (s, 1H), 8.02 (s, 1H), 7.97-7.65 (d, 1H), 7.92-7.90 (d, 1H), 7.80-7.71 (m, 3H), 7.59-7.55 (m, 3H), 7.14-7.13 (d, 1H), 6.89-6.86 (dd, 1H), 4.95 (s, 2H), 2.51-2.42 (m, 1H), 1.21-1.10 (m, 4H).
<Example 88> 3-((2- chloro -4-((5- cyclopropyl -3-(2-( trifluoromethoxy )phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid; (I-88)
Step 1 : Preparation of 2-(trifluoromethoxy)benzoaldehyde oxime
This compound was made using the procedure described for Intermediate 1(Step 1). Thus, 2-(trifluoromethyl)benzoaldehyde(11g, 160mmol) was reacted with sodium hydroxide(6.3g, 160mmol), 2,6-dichlorobenzoaldehyde(25g, 140mmol) to afford the intermediate compound 2-(trifluoromethoxy)benzoaldehyde oxime(25.9g, 96%).
1H-NMR (CDCl3, 400MHz): δ8.41 (s, 1H), 7.89-7.87 (dd, 1H), 7.47-7.41 (m, 1H), 7.38-7.26 (m, 2H).
Step 2 : Preparation of N -hydroxy-2-(trrifluoromethoxy)benzamidoyl chloride
This compound was made using the procedure described for Intermediate 1(Step 2). Thus, the intermediate compound(Step 1)(25.9g, 140mmol) was reacted with N-chlorosuccinimide(NCS, 18.4g, 140mmol) to afford the intermediate compound N-hydroxy-2-(trifluoromethoxy)benzamidoyl chloride(29g) and used without further purification.
1H-NMR (CDCl3, 400MHz): δ 8.79 (s, 1H), 7.62-7.59 (m, 1H), 7.51-7.47 (m, 1H), 7.40-7.33 (m, 2H).
Step 3 : Preparation of ethyl 5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl) isoxazol-4-carboxylate
This compound was made using the procedure described for Intermediate 1(Step 1). Thus, the intermediate compound(Step 2)(29g, 129mmol) was reacted with ethyl 3-cyclopropyl-3-oxopropanoate(25ml, 194mmol) and triethylamine(150ml) to afford the intermediate compound 5-cyclopropyl-3-(2-(trifluoromethoxy) phenyl)isoxazol-4-carboxylate(22.37g, 56%).
1H-NMR (CDCl3, 400MHz): δ 7.54-7.48 (m, 2H), 7.41-7.33 (m, 2H), 3.77 (s, 3H), 2.05-2.01 (m, 1H), 1.14-1.10 (m, 2H), 0.99-0.94 (m, 2H).
Step 4 : Preparation of (5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol -4-yl)methanol
This compound was made using the procedure described for Intermediate 1(Step 4). Thus, the intermediate compound(Step 3)(22.37g, 71.7mmol) was reacted with 1M diisobutylaluminium hydride in THF(DIBAL-H, 144ml, 144mmol) to afford the intermediate compound (5-cyclopropyl-3-(2-(trifluoromethoxy) phenyl)isoxazol-4-yl)methanol(12.2g, 60%).
1H-NMR (CDCl3, 400MHz): δ 7.58-7.50 (m, 2H), 7.42-7.38 (m, 2H), 4.50 (s, 2H), 2.21-2.16 (m, 1H), 1.27-1.22 (m, 2H), 1.15-1.11 (m, 2H).
Step 5 : Preparation of 4-(bromomethyl)-5-cyclopropyl-3-(2- (trifluoromethoxy)phenyl)isoxazole
This compound was made using the procedure described for Intermediate 1(Step 5). Thus, the intermediate compound(Step 4)(12.2g, 43.02mmol) was reacted with triphenyl phosphite(TPP, 16.9g, 64.53mmol), tetrabromomethane(21.4g, 64.53mmol) to afford the intermediate compound 4-(bromomethyl)-5- cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole(13.44g, 90%).
1H-NMR (CDCl3, 400MHz): δ 7.60-7.53 (m, 2H), 7.45-7.40 (m, 2H), 4.33 (s, 2H), 2.15 (m, 1H), 1.29-1.26 (m, 2H), 1.25-1.20 (m, 2H).
Step 6 : Preparation of 4-((3- chloro -4- ethynylphenoxy )methyl)-5- cyclopropyl -3-(2-(trifluoromethoxy)phenyl)isoxazole
This compound was made using the procedure described for example 1(Step 4). Thus, the intermediate compound(Step 5)(7.59g, 21.9mmol) was reacted with 3-chloro-4-((trimethylsilyl)ethynyl)phenol(Step 3 of Example 5)(4.92g, 21.9mmol) and potassium carbonate(4.54g, 32.9mmol) to afford the intermediate compound 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2- (trifluoromethoxy)phenyl)isoxazole(7.15g, 78%).
1H-NMR (CDCl3, 400MHz): δ 7.41-7.30 (m, 4H), 6.83 (d, 1H), 6.66 (dd, 1H), 4.80 (s, 2H), 3.26 (s, 1H), 2.17-2.10 (m, 1H), 1.31-1.27 (m, 2H), 1.23-1.17 (m, 2H).
Step 7 : Preparation of methyl 3-((2- chloro -4-((5- cyclopropyl -3-(2- (trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 6)(128mg, 0.31mmol) was reacted with methyl 3-iodobenzoate(80mg, 0.31mmol), bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 22mg, 0.03mmol), copper(I) iodide(5.8mg, 0.03mmol) and triethylamine(0.052ml, 0.37mmol) to afford the intermediate compound methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoate(107mg, 63%).
1H-NMR (CDCl3, 400MHz): δ 8.20 (s, 1H), 8.00-7.98 (m, 1H), 7.72-7.69 (m, 1H), 7.45-7.37 (m, 4H), 4.88 (s, 2H), 3.93 (s, 3H), 2.16-2.11 (m, 1H), 1.28-1.24 (m, 2H), 1.14-1.13 (m, 2H).
Step 8 : Preparation of 3-((2- chloro -4-((5- cyclopropyl -3-(2-( trifluoro methoxy )phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzoic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 7)(107mg, 0.20mmol) was reacted with lithium hydroxide(84mg, 2.0mmol) to afford the title compound(92.5mg, 86%).
1H-NMR (DMSO, 400MHz): δ 13.6 (s, 1H), 8.02 (s, 1H), 7.97-7.95 (d, 1H) 7.78-7.76 (d, 1H), 7.69-.51 (m, 6H), 7.15 (d, 1H), 6.90-6.88 (dd, 1H), 5.02 (s, 2H), 2.47-2.42 (m, 1H), 1.20-1.15 (m, 2H), 1.14-1.11 (m, 2H).
<Example 89> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indazole-6-carboxylic acid; (I-89)
Step 1 : Preparation of 1-( tert -butyl) 6-methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1 H -indazole-1,6-dicarboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(176mg, 0.422mmol) was reacted with 1-(tert-butyl) 6-methyl 4-bromo-1H-indazole-1,6-dicarboxylate(100mgg, 0.281mmol), copper(I) iodide(5.3mg, 0.028mmol) and bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 39.5g, 0.056mmol) to afford the intermediate compound 1-(tert-butyl) 6-methyl-4-((2-chloro-4- ((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl) ethynyl)-1H-indazole-1,6-dicarboxylate (107mg, 55%).
1H-NMR (CDCl3, 400MHz): δ 8.70 (s, 1H), 8.62 (s, 1H), 8.17-8.16 (d, 1H), 7.45-7.39 (m, 4H), 7.36-7.32 (m, 1H), 6.89 (d, 1H), 6.73-6.70 (dd, 1H), 4.83 (s, 2H), 4.04 (s, 3H), 2.19-2.13 (m, 1H), 1.74 (s, 9H), 1.33-1.29 (m, 2H), 1.20-1.18 (m, 2H).
Step 2 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indazole-6-carboxylate
Trifluoroacetic acid(0.15ml) was added to a solution of intermediate compound(Step1)(98mg, 0.140mmol) in dichloromethane(3ml) and stirred for 3 days at room temperature. The reaction mixture was concentrated in vacuum, added ethyl acetate and washed with water. The combined organic layers were dried over MgSO4, filtered, evaporated in vacuum and purified using silica chromatography to afford the intermediate compound methyl 4-((2-chloro-4- ((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indazole-6-carboxylate (24mg, 28%).
1H-NMR (CDCl3, 400MHz): δ 10.47 (s, 1H), 8.59 (s, 1H), 8.08 (d, 1H), 7.87 (s, 1H), 7.45-7.40 (m, 3H), 7.35-7.31 (m, 1H), 6.89-6.88 (d, 1H), 6.72-6.69 (dd, 1H), 4.83 (s, 1H), 4.09 (s, 3H), 2.18-2.13 (m, 1H), 1.32-1.26 (m, 2H), 1.20-1.16 (m, 2H).
Step 3 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indazole-6-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 2)(24mg, 0.04mmol) was reacted with lithium hydroxide(17mg, 0.405mmol) to afford the title compound(20mg, 86%).
1H-NMR (CDCl3, 400MHz): δ8.62 (s, 1H), 8.11 (s, 1H), 7.90 (s, 1H), 7.45-7.41 (m, 3H), 7.36-7.32 (m, 1H), 6.89-6.88 (d, 1H), 6.72-6.69 (dd, 1H), 4.83 (s, 2H), 2.02-2.12 (m, 1H), 1.32-1.19 (m, 4H).
<Example 90> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1H-benzo[d]imidazole-6-carboxylic acid; (I-90)
Step 1 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -benzo[d]imidazole-6-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Eample 5)(101mg, 0.24mmol) was reacted with 1-(tert-butyl) 6-methyl-4-bromo-1H-benzo[d]imidazole-1,6-dicarboxylate(71mg, 0.20 mmol), bis(triphenylphosphine)palladium(II) dichloride((PdCl2(PPh3)2, 7mg, 0.01mmol), Copper(I) iodide(2mg, 0.01mmol) and triethylamine(2mg, 0.01mmol) to afford the intermediate compound methyl 4-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-benzo[d]imidazole-6-carboxylate(57mg, 48%).
1H-NMR (CDCl3, 400MHz): δ 8.19 (s, 1H), 8.02 (s, 1H), 7.69-7.32 (m, 5H), 7.00 (m, 1H), 6.70 (m, 1H), 4.84 (s, 2H), 3.96 (s, 3H), 2.17 (m, 1H), 1.32-1.28 (m, 2H), 1.20-1.15 (m, 2H).
Step 2 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1H-benzo[d]imidazole-6-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(30mg, 0.05mmol) was reacted with lithium hydroxide(50mg, 1.2mmol) to afford the title compound(15mg, 52%).
1H-NMR (DMSO, 400MHz): δ 8.39 (s, 1H), 8.18 (s, 1H), 7.97 (s, 1H), 7.64 (m, 2H), 7.56 (m, 2H), 7.10 (d, 1H), 6.87 (dd, 1H), 5.00 (s, 2H), 3.16 (m, 2H), 1.23-1.13 (m, 4H).
<Example 91> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indole-6-carboxylic acid; (I-91)
Step 1 : Preparation of 1-( tert -butyl) 6-methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1 H -indole-1,6-dicarboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(236mg, 0.56mmol) was reacted with 1-(tert-butyl) 6-methyl 4-bromo-1H-indole-1,6-dicarboxylate(200mg, 0.56mmol), bis( triphenylphosphine)palladium(II) dichloride((PdCl2(PPh3)2, 79mg, 0.11mmol), copper(I) iodide(11mg, 0.06mmol) and triethylamine(0.39ml, 2.82mmol) to afford the intermediate compound 1-(tert-butyl) 6-methyl 4-((2-chloro-4-((5- cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indole-1,6-dicarboxylate(141mg, 36%).
1H-NMR (CDCl3, 400MHz): δ 8.83 (s, 1H), 8.12 (d, 1H), 7.97 (d, 1H), 7.48-7.32 (m, 5H), 6.92-6.90 (m, 2H), 6.73 (dd, 1H), 4.83 (s, 2H), 3.95 (s, 3H), 2.18-2.14 (m, 1H), 1.70 (s, 9H), 1.32-1.28 (m, 2H), 1.20-1.16 (m, 2H).
Step 2 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indole-6-carboxylate
This compound was made using the procedure described for example 89(Step 2). Thus, the intermediate compound(Step 1)(141mg, 0.2mmol) was reacted with trifluoroacetic acid(0.28ml, 3.8mmol) to afford the intermediate compound methyl 4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)-1H-indole-6-carboxylate(49mg, 41%).
1H-NMR (CDCl3, 400MHz): δ8.52 (s, 1H), 8.14 (t, 1H), 8.03 (d, 1H), 7.52-7.32 (m, 5H), 6.91-6.89 (dd, 2H), 6.73 (dd, 1H), 4.83 (s, 2H), 3.95 (s, 3H), 2.19-2.14 (m, 1H), 1.33-1.29 (m, 2H), 1.20-1.16 (m, 2H).
Step 3 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indole-6-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 2)(49mg, 0.08mmol) was reacted with lithium hydroxide(33mg, 0.8mmol) to afford the title compound(45mg, 98%).
1H-NMR (DMSO, 400MHz): δ 11.77 (s, 1H), 8.09 (s, 1H), 7.77 (d, 1H), 7.72 (t, 1H), 7.65-7.61 (m, 3H), 7.58 (dd, 1H), 7.11 (d, 1H), 6.86 (dd, 1H), 6.70 (s, 1H), 4.99 (s, 2H), 2.48 (m, 1H), 1.24-1.21 (m, 2H), 1.17-1.12 (m, 2H).
<Example 92> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2-(dimethylamino)ethyl)-1 H -indole-6-carboxylic acid; (I-92)
Step 1 : Preparation of 1-( tert -butyl) 6-methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-(dimethylamino)ethyl)-1 H -indole-6-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(41.87mg, 0.10mmol) was reacted with 1-(tert-butyl) 6-methyl 4-bromo-1H-indole-1,6-dicarboxylate(32.52mg, 0.10mmol), bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 7.7mg, 0.011mmol), copper(I) iodide(2mg, 0.011mmol) and triethylamine(42ul, 0.30mmol) to afford the intermediate compound 1-(tert-butyl) 6-methyl 4-((2- chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indole-1,6-dicarboxylate(67mg, 68%).
1H-NMR (CDCl3, 400MHz): δ 8.12 (s, 1H), 8.03 (d, 1H), 7.50-7.34 (m, 5H), 6.92 (d, 1H), 6.84-6.83 (d, 1H), 6.74-6.71 (dd, 1H), 4.85 (s, 2H), 4.33-4.29 (t, 2H), 3.97 (s, 3H), 2.75-2.71 (t, 2H), 2.31 (s, 6H), 2.20-2.17 (m, 1H), 1.34-1.30 (m, 2H), 1.22-1.19 (m, 2H).
Step 2 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2-(dimethylamino)ethyl)-1 H -indole-6-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(46mg, 0.069mmol) was reacted with lithium hydroxide(29mg, 0.694mmol) to afford the title compound(0.014g, 31%).
1H-NMR (DMSO, 400MHz): δ 12.85 (s, 1H), 8.16 (s, 1H), 7.78 (d, 1H), 7.74-7.73 (d, 1H), 7.65-7.61 (m, 3H), 7.58-7.54 (m, 1H), 7.12-7.11 (d, 1H), 6.86-6.83 (m, 1H), 6.68 (d, 1H), 4.99 (s, 2H), 4.4-4.36 (t, 2H), 2.64-2.60 (t, 2H), 2.18 (s, 6H), 1.23-1.18 (m, 2H), 1.16-1.14 (m, 2H).
<Example 93> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(3-(isopropylamino)propyl)-1H-indole-6-carboxylic acid; (I-93)
Step 1 : Preparation of methyl 1-(3-(( tert - butoxycarbonyl )(isopropyl)amino) propyl )-4-((2- chloro -4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indole-6-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(200mg, 0.52mmol) was reacted with methyl 4-bromo-1-(3-((tert-butoxycarbonyl)(isopropyl)amino)propyl)-1H-indole-6- carboxylate(235mg, 0.52mmol), bis(triphenylphosphine)palladium(II) dichloride (PdCl2(PPh3)2, 42mg, 0.0.6mmol), copper(I) iodide(11.4mg, 0.06mmol)and 1,8-Diazabicyclo[5.4.0]undec-7-ene(DBU, 0.4ml, 2.6mmol) to afford the intermediate compound methyl 1-(3-((tert-butoxycarbonyl)(isopropyl)amino) propyl)-4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indole-6-carboxylate(165mg, 38%).
1H-NMR (CDCl3, 400MHz): δ 8.07 (s, 1H), 8.01 (s, 1H), 7.47 (d, 1H), 7.42-7.31 (m, 4H), 6.90 (d, 1H), 6.83 (d, 1H), 6.72-6.69 (dd, 1H), 4.82 (s, 2H), 4.21 (q, 2H), 3.95 (s, 3H), 3.12 (br, 2H), 2.16-2.04 (m, 3H), 1.52 (br, 1H), 1.45 (s, 9H), 1.31-1.27 (m, 2H), 1.86-1.15 (m, 2H), 1.05 (s, 3H), 1.03 (s, 3H).
Step 2 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(3-(isopropylamino)propyl)-1H-indole-6-carboxylate
This compound was made using the procedure described for example 89(Step 2). Thus, this intermediate compound(Step 1)(165mg, 0.20mmol) was reacted with trifluoroacetic acid(0.2ml, 2.0mmol) to afford the intermediate compound methyl 4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)-1-(3-(isopropylamino)propyl)-1H-indole-6-carboxylate(85.7mg, 62%).
1H-NMR (CDCl3, 400MHz): δ 8.07 (s, 1H), 8.01 (s, 1H), 7.47 (d, 1H), 7.42-7.31 (m, 4H), 6.90 (d, 1H), 6.83 (d, 1H), 6.72-6.69 (dd, 1H), 4.82 (s, 2H), 4.21 (q, 2H), 3.95 (s, 3H), 3.12 (br, 2H), 2.16-2.04 (m, 3H), 1.52 (br, 1H), 1.31-1.27 (m, 2H), 1.86-1.15 (m, 2H), 1.05 (s, 3H), 1.03 (s, 3H).
Step 3 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(3-(isopropylamino)propyl)-1H-indole-6-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 2)(85.7mg, 0.12mmol)was reacted with lithium hydroxide(50mg, 1.2mmol) to afford the title compound(32mg, 39%).
1H-NMR (DMSO, 400MHz): δ 8.14 (s, 1H), 7.08 (s, 1H), 7.71 (d, 1H), 7.65-7.53 (m, 5H), 7.11 (d, 1H), 6.86-6.83 (dd, 1H), 6.68 (d, 1H), 4.90 (s, 2H), 4.30 (q, 2H), 3.06 (br, 2H), 2.46 (m, 2H), 1.48 (m, 1H), 1.22-1.12 (m, 4H), 1.01 (s, 3H), 1.00 (s, 3H).
<Example 94> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(pyridin-4-ylmethyl)-1 H -indole-6-carboxylic acid; (I-94)
Step 1 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(pyridin-4-ylmethyl)-1 H -indole-6-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.239mmol) was reacted with methyl 4-bromo-1-(pyridin-4-ylmethyl)-1H-indole-6-carboxylate(82.5mg, 0.287 mmol), bis(triphenylphosphine)palladium(II) dichloride(21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate compound methyl 4-((2-chloro-4-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(pyridin-4-ylmethyl)-1H-indole-6-carboxylate(78mg, 48%).
1H-NMR (CDCl3, 400MHz): δ 8.54-8.53 (d, 2H), 8.04 (s, 1H), 7.95 (s, 1H), 7.49-7.47 (d, 1H), 7.43 (d, 2H), 7.41-7.34 (m, 2H), 6.95-6.91 (m, 4H), 6.74-6.71 (m, 1H), 5.42 (s, 2H), 4.83 (s, 2H), 3.91 (s, 3H), 2.19-2.14 (m, 1H), 1.33-1.30 (m, 2H), 1.20-1.15 (m, 2H).
Step 2 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(pyridin-4-ylmethyl)-1 H -indole-6-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(78mg, 0.114mmol)와lithium hydroxide(47.8mg, 1.14mmol) to afford the title compound(72.4mg, 95%).
1H-NMR (DMSO, 400MHz): δ 12.88 (s, 1H), 8.50 (s, 2H), 8.06 (s, 1H), 7.89-7.88 (d, 1H), 7.80 (s, 1H), 7.65-7.54 (m, 4H), 7.13-7.12 (d, 1H),7.04-7.03 (d, 2H), 6.87-6.81 (m, 2H), 5.68 (s, 2H), 5.00 (s, 2H), 1.23-1.19 (m, 2H), 1.15 (m, 2H).
<Example 95> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2-morpholinoethyl)-1 H -indole-6-carboxylic acid hydrochloride; (I-95)
Step 1 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2-morpholineㅡethyl)-1 H -indole-6-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.239mmol) was reacted with methyl 4-bromo-1-(2-morpholinoethyl)-1H-indole-6-carboxylate(105mg, 0.287mmol), bis(triphenylphosphine)palladium(II) dichloride(21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate compoundmethyl 4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-morpholine-ethyl)-1H-indole-6-carboxylate(87.6mg, 52%).
1H-NMR (CDCl3, 400MHz): δ 8.12 (s, 1H), 8.01 (s, 1H), 7.48-7.31 (m, 5H), 6.90 (d, 1H), 6.82-6.81 (d, 1H), 6.72-6.69 (m, 1H), 4.83 (s, 2H), 4.32-4.28 (t, 2H), 3.95 (s, 3H), 3.69-3.37 (t, 3H), 2.77-2.74 (m, 2H), 2.48-2.46 (m, 4H), 2.18-2.12 (m, 1H), 1.32-1.29 (m, 2H), 1.19-1.15 (m, 2H).
Step 2 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2-morpholinoethyl)-1 H -indole-6-carboxylic acid hydrochloride
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(87.6mg, 0.124mmol) was reacted with lithium hydroxide(52mg, 1.24mmol) to afford the title compound (72.8mg, 85%).
1H-NMR (DMSO, 400MHz): δ 12.89 (s, 1H), 10.96 (s, 1H), 8.30 (s, 1H), 7.83-7.81 (m, 2H), 7.65-7.62 (m, 3H), 7.58-7.54 (m, 1H), 7.12 (d, 1H), 6.87-6.84 (dd, 1H), 6.78 (s, 1H), 5.00 (s, 2H), 4.79 (s, 2H), 4.00-3.90 (m, 2H), 3.75 (m, 2H), 3.57-3.56 (m, 2H), 3.47-3.44 (m, 2H), 3.15 (m, 2H), 1.23-1.17 (m, 2H), 1.15-1.12 (m, 2H).
<Example 96> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2,2-dimethoxyethyl)-1H-indole-6-carboxylic acid; (I-96)
Step 1 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2,2-dimethoxyethyl)-1H-indole-6-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6- dichloro phenyl)isoxazole(Example 5)(200mg, 0.52mmol)was reacted with methyl 4-bromo-1-(2,2-dimethoxyethyl)-1H-indole-6-carboxylate(178mg, 0.52mmol), bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 42mg, 0.0.6mmol), copper(I) iodide(11.4mg, 0.06mmol)and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.4ml, 2.6mmol) to afford the intermediate compound methyl 4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2,2-dimethoxyethyl)-1H-indole-6-carboxylate(205mg, 58%).
1H-NMR (CDCl3, 400MHz): δ8.13 (s, 1H), 8.02 (d, 1H), 7.48-7.31 (m, 6H), 6.90 (d, 1H), 6.84 (d, 1H), 6.72-6.70 (dd, 1H), 4.83 (s, 2H), 4.55 (m, 1H), 4.28 (d, 2H), 6.96 (s, 3H), 3.35 (s, 6H), 2.16 (m, 1H), 1.32-1.27 (m, 2H), 1.20-1.16 (m, 2H).
Step 2 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2,2-dimethoxyethyl)-1H-indole-6-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(205mg, 0.30mmol) was reacted with lithium hydroxide(126mg, 3.0mmol) to afford the title compound(115mg, 58%).
1H-NMR (DMSO 400MHz): δ 8.19 (s, 1H), 7.80 (s, 1H), 7.69 (d, 1H), 7.65-7.54 (m, 4H), 7.12 (d, 1H), 6.86-6.84 (dd, 1H), 6.71 (d, 1H), 6.99 (s, 2H), 4.62 (q, 1H), 4.01 (dd, 2H), 6.27 (s, 6H), 2.51 (m, 1H), 1.23-1.14(m, 4H).
<Example 97> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxyethyl)-1 H -indole-6-carboxylic acid; (I-97)
Step 1 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxyethyl)-1 H -indole-6-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.239mmol) was reacted with methyl 4-bromo-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-indole-6- carboxylate (118mg, 0.287mmol), bis(triphenylphosphine)palladium(II) dichloride(21mg, 0.03 mmol), copper(I) iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate compound methyl 4-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxyethyl)-1H-indole-6-carboxylate(48.6mg, 32%).
1H-NMR (CDCl3, 400MHz): δ 8.10 (s, 1H), 8.01 (d, 1H), 7.48-7.40 (m, 4H), 7.35-7.31 (m, 1H), 6.90 (d, 1H), 6.85-6.84 (d, 1H), 6.72-6.69 (m, 1H), 4.83 (s, 2H), 4.37-4.35 (t, 2H), 4.00-3.99 (d, 2H), 3.94 (s, 2H), 2.18-2.13 (m, 1H), 1.61 (s, 1H), 1.32-1.28 (m, 2H), 1.25-1.16 (m, 2H).
Step 2 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxyethyl)-1 H -indole-6-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(48.6mg, 0.076mmol) was reacted with lithium hydroxide(32mg, 0.76mmol) to afford the title compound(41.5mg, 88%).
1H-NMR (CDCl3, 400MHz): δ 8.18 (s, 1H), 8.08 (d, 1H), 7.49-7.40 (m, 4H), 7.36-7.32 (m, 1H), 6.91-6.90 (d, 1H), 6.87 (d, 1H), 6.73-6.70 (m, 1H), 4.83 (s, 2H), 4.40-4.37 (t, 2H), 4.02-4.00 (t, 2H), 2.18-2.17 (m, 1H), 1.32-1.27 (m, 2H), 1.20-1.16 (m, 2H).
<Example 98> 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxy-2-methylpropyl)-1 H -indole-6- carboxylic acid; (I-98)
Step 1 : Preparation of methyl 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxy-2-methylpropyl)-1 H -indole-6-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.239mmol) was reacted with methyl 4-bromo-1-(2-((tert-butyldimethylsilyl)oxy)-2-methylpropyl)-1H- indole-6-carboxylate(126mg, 0.287mmol), bis(triphenylphosphine)palladium(II) dichloride(21mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and triethylamine(0.2ml, 1.44mmol) to afford the intermediate compound methyl 4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxyethyl)-1H-indole-6-carboxylate(44.4mg, 28%).
1H-NMR (DMSO, 400MHz): δ 8.27 (s, 1H), 7.77 (d, 1H), 7.66-7.8 (m, 4H), 7.56-7.54 (t, 1H), 7.12-7.11 (d, 1H), 6.96(s, 3H), 6.68-6.84 (m, 1H), 6.70-6.69 (d, 1H), 4.99 (s, 2H), 4.74 (s, 1H), 4.19 (s, 2H), 1.23-1.14 (m, 4H), 1.09 (s, 6H).
Step 2 : Preparation of 4-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxy-2-methylpropyl)-1 H -indole-6-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus,the intermediate compound(Step 1)(44.4mg, 0.066mmol) was reacted with lithium hydroxide(27mg, 0.66mmol) to afford the title compound(39mg, 91%).
1H-NMR (DMSO, 400MHz): δ 8.27 (s, 1H), 7.77 (d, 1H), 7.66-7.8 (m, 4H), 7.56-7.54 (t, 1H), 7.12-7.11 (d, 1H), 6.68-6.84 (m, 1H), 6.70-6.69 (d, 1H), 4.99 (s, 2H), 4.74 (s, 1H), 4.19 (s, 2H), 1.23-1.14 (m, 4H), 1.09 (s, 6H).
<Example 99> 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indazole-4-carboxylic acid; (I-99)
Step 1 : Preparation of 1-( tert -butyl) 4-methyl 6-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1 H -indazole-1,4-dicarboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(118mg, 0.28mmol) was reacted with 1-(tert-butyl) 4-methyl 6-bromo-1H-indazole-1,4-dicarboxylate(100mg, 0.28mmol), bis(triphenylphosphine)palladium(II) dichloride((PdCl2(PPh3)2, 20mg, 0.028mmol), copper(I) iodide(2.6mg, 0.014mmol) and triethylamine(0.08ml, 0.56mmol) to afford the intermediate compound 1-(tert-butyl) 4-methyl 6-((2-chloro-4- ((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indazole-1,4-dicarboxylate(74mg, 38%).
1H-NMR (CDCl3, 400MHz): δ 8.63 (s, 1H), 8.55 (s, 1H), 8.09 (d, 1H), 7.37-7.33 (m, 3H), 7.29-7.25 (m, 1H), 6.82 (d, 1H), 6.65 (dd, 1H), 4.76 (s, 2H), 3.96 (s, 3H), 2.11-2.07 (m, 1H), 1.67 (s, 9H), 1.26-1.22 (m, 2H), 1.17-1.10 (m, 2H).
Step 2 : Preparation of methyl 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indazole-4-carboxylate
This compound was made using the procedure described for example 89(Step 2). Thus, the intermediate compound(Step 1)(74mg, 0.11mmol) was reacted with trifluoroacetic acid(0.2ml, 2.7mmol) to afford the intermediate compound methyl 6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)-1H-indazole-4-carboxylate(36mg, 55%).
1H-NMR (CDCl3, 400MHz): δ 8.62 (s, 1H), 8.11 (s, 1H), 7.90 (s, 1H), 7.50-7.34 (m, 4H), 6.91 (d, 1H), 6.74 (dd, 1H), 4.85 (s, 2H), 4.06 (s, 3H), 2.20-2.14 (m, 1H), 1.35-1.30 (m, 2H), 1.22-1.17 (m, 2H).
Step 3 : Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indazole-4-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 1)(36mg, 0.06mmol) was reacted with lithium hydroxide(25mg, 0.6mmol) to afford the title compound(35mg, 100%).
1H-NMR (DMSO, 400MHz): δ 13.57 (s, 1H), 8.42 (s, 1H), 7.97 (s, 1H), 7.83 (d, 1H), 7.65-7.54 (m, 4H), 7.11 (d, 1H), 6.86 (dd, 1H), 4.99 (s, 2H), 2.46 (m, 1H), 1.30-1.21 (m, 2H), 1.16-1.12 (m, 2H).
<Example 100> 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2,3-dihydrobenzofuran-7-carboxylic acid; (I-100)
Step 1 : Preparation of methyl 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2,3-dihydrobenzofuran-7-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.23mmol) was reacted with methyl 3-bromo-2,3-dihydrobenzofuran-7-carboxylate(61mg, 0.23mmol), bis(triphenyl phosphine)palladium(II)dichloride(PdCl2(PPh3)2, 8mg, 0.01mmol), Copper(I) iodide(2.2.mg, 0.01mmol) and triethylamine(0.1ml, 0.71mmol) to afford the intermediatecompound methyl 5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethyl)-2,3-dihydrobenzofuran-7-carboxylate(50mg, 37%).
1H-NMR (CDCl3, 400MHz): δ 7.93 (s, 1H), 7.76-7.71 (m, 1H), 7.52-7.50 (m, 1H), 7.44-7.33 (m, 5H), 6.99 (s, 1H), 6.69 (dd, 1H), 4.81 (s, 2H), 4.78 (t, 2H), 3.91 (s, 3H), 3.26 (t, 2H), 2.17-2.13 (m, 1H), 1.32-1.28 (m, 2H), 1.19-1.14 (m, 2H).
Step 2 : Preparation of 5-((2- chloro -4-((5- cyclopropyl - 3,( 2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2,3-dihydrobenzofuran-7-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(50mg, 0.08mmol) was reacted with lithium hydroxide(35mg, 0.84mmol) to afford the title compound(27mg, 56%).
1H-NMR (DMSO, 400MHz): δ 7.95 (s, 1H), 7.70-7.48 (m, 5H), 7.09 (s, 1H), 6.82 (dd, 1H), 4.97 (s, 2H), 4.67 (t, 2H), 3.26-3.14 (t, 3H), 1.24-1.12 (m, 2H), 0.87-0.84 (m, 2H).
<Example 101> 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indole-4-carboxylic acid; (I-101)
Step 1 : Preparation of 1-( tert -butyl) 4-methyl 6-((2- chloro -4-((5- cyclopropyl -3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1 H -indole-1,4-dicarboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(354mg, 0.846mmol) was reacted with 1-(tert-butyl) 4-methyl 6-bromo-1H-indole-1,4-dicarboxylate(100mg, 0.282mmol) was reacted with copper(I) iodide(5.3mg, 0.028mmol), bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 40mg, 0.056mmol) and triethylamine(0.2ml, 1.411mmol) to afford the intermediate compound 1-(tert-butyl) 4-methyl 6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indole-1,4-dicarboxylate(74mg, 38%).
1H-NMR (CDCl3, 400MHz): δ 8.18 (d, 1H), 8.32 (s, 1H), 7.48-7.45 (m, 4H), 7.42-7.38 (m, 1H), 7.16 (s, 1H), 6.89 (d, 1H), 6.72-6.69 m, 1H), 4.83 (s, 2H), 3.94 (s, 3H), 2.20-2.15 (m, 1H), 1.62 (s, 9H), 1.33-1.31 (m, 2H), 1.20-1.17 (m, 2H).
Step 2 : Preparation of methyl 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indole-4-carboxylate
This compound was made using the procedure described for example 89(Step 2). Thus, the intermediate compound(Step 1)(74mg, 0.108mmol) was reacted with trifluoroacetic acid(0.2ml) to afford the intermediate compound methyl 6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indole-4-carboxylate(29mg, 45%).
1H-NMR (CDCl3, 400MHz): δ 9.56 (s, 1H), 8.07 (d, 1H), 7.78 (s, 1H), 7.43-7.41 (m, 4H), 7.37-7.33 (m, 1H), 7.15 (s, 1H), 6.88 (d, 1H), 6.71-6.68 (m, 1H), 4.83 (s, 2H), 3.99 (s, 3H), 2.19-2.15 (m, 1H), 1.32-1.28 (m, 2H), 1.20-1.15 (m, 2H).
Step 3 : Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-1 H -indole-4-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, the intermediate compound(Step 2)(29mg, 0.049mmol) was reacted with lithium hydroxide(20mg, 0.489mmol) to afford the title compound(19mg, 67%).
1H-NMR (CDCl3, 400MHz): δ 8.45 (s, 1H), 8.19 (d, 1H), 7.82 (s, 1H), 7.46-7.42 (m, 4H), 7.36-7.32 (m, 1H), 6.88 (d, 1H), 6.71-6.68 (dd, 1H), 4.82 (s, 1H), 2.18-2.14 (m, 1H), 2.32-1.24 (m, 4H).
<Example 102> 5- ((2-chloro-4-( (5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylic acid; (I-102)
Step 1 : Preparation of methyl 5- ((2-chloro-4-( (5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(127.2mg, 0.30mmol) was reacted with methyl 5-bromobenzo[d]oxazole-7-carboxylate(77.8mg, 0.30mmol), tetrakis(triphenyl phosphine)palladium(0)(Pd(PPh3)4, 34.7mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and N,N -diisopropylethylamine(63ul, 0.36mmol)to afford the intermediate compound methyl 5-((2-chloro-4-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylate(31mg, 17%).
1H-NMR (CDCl3, 400MHz): δ 8.24-8.22 (m, 2H), 8.14 (d, 1H), 7.74-7.40 (m, 2H), 7.36-7.31(m, 2H), 6.89 (d, 1H), 6.70 (dd, 1H), 4.83 (s, 2H), 4.04 (s, 3H), 2.18-2.14 (m, 1H), 1.33-1.26 (m, 2H), 1.24-1.15(m, 2H).
Step 2 : Preparation of 5- ((2-chloro-4-( (5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(31mg, 0.05mmol) was reacted with lithium hydroxide(22mg, 0.52mmol) to afford the title compound(20mg, 69%).
1H-NMR (MeOD4, 400MHz): δ 8.42 (s, 1H), 8.36 (s, 1H), 7.77 (s, 1H), 7.53-7.44 (m, 3H), 7.40-7.37(m, 1H), 6.88 (d, 1H), 6.73 (dd, 1H), 4.93 (s, 2H), 2.36-2.33(m, 1H), 1.34-1.20 (m, 4H).
<Example 103> 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-7-carboxylic acid; (I-103)
Step 1 : Preparation of methyl 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-7-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(100mg, 0.24mmol) was reacted with methyl 5-bromo-2-methylbenzo[d]oxazole-7-carboxylate(64mg, 0.24mmol), tetrakis (triphenylphosphine)palladium(0)(Pd(PPh3)4, 23mg, 0.02mmol), copper(I) iodide(3.8mg, 0.02mmol) and N,N -diisopropylethylamine(50ul, 0.28mmol) to afford the intermediate compound methyl 5-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-7-carboxylate(44.2mg, 30%).
1H-NMR (CDCl3, 400MHz): δ 8.24-8.22 (m, 2H), 8.14 (d, 1H), 7.74-7.40 (m, 2H), 7.36-7.31(m, 2H), 6.89 (d, 1H), 6.70 (dd, 1H), 4.83 (s, 2H), 4.04 (s, 3H), 2.18-2.14 (m, 1H), 1.33-1.26 (m, 2H), 1.24-1.15(m, 2H).
Step 2 : Preparation of 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-7-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(44mg, 0.073mmol) was reacted with lithium hydroxide(30.4mg, 0.73mmol) to afford the title compound(30mg, 69%).
1H-NMR (MeOD4, 400MHz): δ 8.42 (s, 1H), 8.36 (s, 1H), 7.77 (s, 1H), 7.53-7.44 (m, 3H), 7.40-7.37(m, 1H), 6.88 (d, 1H), 6.73 (dd, 1H), 4.93 (s, 2H), 2.36-2.33(m, 1H), 1.34-1.20 (m, 4H).
<Example 104> 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-7-carboxylic acid; (I-104)
Step 1 : Preparation of methyl 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-7-carboxylate
This compound was made using the procedure described for example 1(step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(143.7mg, 0.34mmol) was reacted with methyl 5-bromo-2-ethylbenzo[d]oxazole-7-carboxylate(97.5mg, 0.34mmol), tetrakis (triphenylphosphine)palladium(0)(Pd(PPh3)4, 34.7mg, 0.03mmol), copper (I) iodide(5.7mg, 0.03mmol) and N,N -diisopropylethylamine(71ul, 0.41mmol) to afford the intermediate compound methyl 5-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-7-carboxylate(45.9mg, 22%).
1H-NMR (CDCl3, 400MHz): δ 8.12 (s, 1H), 7.99 (s, 1H), 7.44-7.40 (m, 3H), 7.36-7.33(m, 1H), 6.86 (d, 1H), 6.68 (dd, 1H), 4.83 (s, 2H), 4.02 (s, 3H), 3.04 (q, 2H), 2.19-2.14 (m, 1H), 1.49 (t, 3H), 1.29-1.25 (m, 2H), 1.19-1.16 (m, 2H).
Step 2 : Preparation of 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-7-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(45mg, 0.07mmol) was reacted with lithium hydroxide(30.4mg, 0.72mmol) to afford the title compound(24mg, 56.3%).
1H-NMR (MeOD4, 400MHz): δ 8.05 (s, 1H), 7.96 (s, 1H), 7.56-7.53 (m, 2H), 7.50-7.46(m, 2H), 6.95 (s, 1H), 6.79 (d, 1H), 3.07 (q, 2H), 2.40-2.36(m, 1H), 1.48 (t, 3H), 1.26-1.23 (m, 4H).
<Example 105> 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-propylbenzo[d]oxazole-7-carboxylic acid; (I-105)
Step 1 : Preparation of methyl 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-propylbenzo[d]oxazole-7-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(130mg, 0.31mmol) was reacted with methyl 5-bromo-2-propylbenzo[d]oxazole-7-carboxylate(92.2mg, 0.31mmol), tetrakis (triphenylphosphine)palladium(0)(Pd(PPh3)4, 34.7mg, 0.03mmol), copper(I) iodide(5.7mg, 0.03mmol) and N,N -diisopropylethylamine(64.8ul, 0.37mmol) to afford the intermediate compound methyl 5-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-propylbenzo[d]oxazole-7-carboxylate(88.4mg, 45%).
1H-NMR (CDCl3, 400MHz): δ 8.11 (dd, 1H), 7.99 (dd, 1H), 7.44-7.40 (m, 3H), 7.36-7.32(m, 1H), 6.88 (d, 1H), 6.70 (dd, 1H), 4.83 (s, 2H), 4.02 (s, 3H), 3.01-2.96 (m, 2H), 2.20-2.14 (m, 1H), 2.13-1.91(m, 2H), 1.33-1.29 (m, 2H), 1.20-1.19 (m, 2H), 1.17 (t, 3H).
Step 2 : Preparation of 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-propylbenzo[d]oxazole-7-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(88mg, 0.14mmol) was reacted with lithium hydroxide(58mg, 1.4mmol) to afford the title compound(61mg, 70%).
1H-NMR (DMSO, 400MHz): δ 13.68 (br s, 1H), 8.08 (d, 1H), 7,93 (d, 1H), 7.65-7.63 (m, 2H), 7.59-7.54 (m, 2H), 7.11 (d, 1H), 6.85 (dd, 1H), 4.99 (s, 2H), 2.99 (t, 2H), 1.91-1.80 (m, 2H), 1.26-1.12 (m, 4H), 1.02 (t, 3H).
<Example 106> 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-isopropylbenzo[d]oxazole-7-carboxylic acid; (I-106)
Step 1 : Preparation of methyl 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-isopropylbenzo[d]oxazole-7-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(326mg, 0.78mmol) was reacted with methyl 5-bromo-2-isopropylbenzo[d]oxazole-7-carboxylate(232mg, 0.78mmol), tetrakis(triphenylphosphine)palladium(0)(Pd(PPh3)4, 92.4mg, 0.08mmol), copper(I) iodide(15.2mg, 0.08mmol) and N,N -diisopropylethylamine(0.16ml, 0.94mmol) to afford the intermediate compound methyl 5-((2-chloro-4-((5- cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl) ethynyl)-2-isopropylbenzo[d]oxazole-7-carboxylate(210mg, 64%).
1H-NMR (CDCl3, 400MHz): δ 7.44-7.39 (m, 4H), 7.36-7.31 (m, 2H), 6.88 (s, 1H), 6.66-6.64 (m, 1H), 4.82 (s, 2H), 4.02 (s, 3H), 3.35-3.31 (m, 1H), 2.16-2.13 (m, 1H), 1.50 (d, 6H), 1.31-1.24 (m, 2H), 1.99-1.16 (m, 2H).
Step 2 : Preparation of 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-isopropylbenzo[d]oxazole-7- carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(86mg, 0.14mmol) was reacted with lithium hydroxide(56.7mg, 1.4mmol) to afford the title compound(74mg, 85%).
1H-NMR (MeOD4, 400MHz): δ 7.91 (s, 1H), 7.77 (s, 1H), 7.40-7.30 (m, 4H), 6.79 (s, 1H), 6.64 (d, 1H), 4.84 (s, 2H), 3.25-3.22 (m, 1H), 2.24-2.23 (m, 1H), 1.36 (d, 6H), 1.17-1.10 (m, 4H).
<Example 107> 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-(hydroxymethyl)benzo[d]oxazole-7-carboxylic acid; (I-107)
Step 1 : Preparation of methyl 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-(methoxymethyl)benzo[d]oxazole-7-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(224mg, 0.53mmol) was reacted with methyl 5-bromo-2-(methoxymethyl)benzo[d]oxazole-7-carboxylate(145.9mg, 0.49mmol), bis(triphenylphosphine)palladium(II)dichloride(PdCl2(PPh3)2, 17.2mg, 0.025mmol), copper(I) iodide(4.8mg, 0.025mmol) and triethylamine(82.2ul, 0.59mmol) to afford the intermediate compound methyl 5-((2-chloro-4-((5- cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-(methoxymethyl)benzo[d]oxazole-7-carboxylate(108mg, 35%).
1H-NMR (CDCl3, 400MHz): δ 7.75 (s, 1H), 7.48 (s, 1H), 7.47-7.31 (m, 4H), 6.86 (s, 1H), 6.67 (dd, 1H), 4.81 (s, 2H), 4.66 (s, 2H), 3.92 (s, 3H), 3.89 (s, 3H), 2.22-2.10 (m, 1H), 1.54-1.29 (m, 2H), 1.19-1.15 (m, 2H).
Step 2 : Preparation of5 -((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-(hydroxymethyl)benzo[d]oxazole-7-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(50mg, 0.08mmol) was reacted with lithium hydroxide(32.9mg, 0.8mmol) to afford the title compound(35mg, 72%).
1H-NMR (DMSO, 400MHz): δ 13.17 (br, 1H), 7.65-7.62 (m, 2H), 7.57-7.53 (m, 2H), 7.43 (d, 1H), 7.13 (d, 1H), 7.09 (d, 1H), 6.82 (dd, 1H), 4.99 (s, 2H), 4.71 (s, 2H), 1.24-1.12 (m, 4H).
<Example 108> 7-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4- yl)methoxy)phenyl)ethynyl)quinoxaline-5-carboxylic acid; (I-108)
Step 1 : Preparation of methyl 7-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)quinoxaline-5- carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(200mg, 0.52mmol) was reacted with methyl 7-bromoquinoxaline-5-carboxylate(138mg, 0.52mmol), bis(triphenylphosphine) palladium(II) dichloride(PdCl2(PPh3)2, 42mg, 0.0.6mmol), copper(I) iodide(11.4mg, 0.06mmol)and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.4ml, 2.6mmol) to afford the intermediate compound methyl 7-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)quinoxaline-5-carboxylate(223mg, 71%).
1H-NMR (CDCl3, 400MHz): δ 8.95 (s, 1H), 8.91 (s, 1H), 8.38 (s, 1H), 8.24 (s, 1H), 7.48-7.23 (m, 4H), 6.91 (d, 1H), 6.73 (d, 1H), 4.84 (s, 2H), 4.06 (s, 3H), 2.18 (m, 1H), 1.27-1.20 (m, 2H), 1.19-1.15 (m, 2H).
Step 2 : Preparation of 7-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)quinoxaline-5-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(223mg, 0.37mmol) was reacted with lithium hydroxide(155mg, 3.7mmol) to afford the title compound(46mg, 21%).
1H-NMR (DMSO, 400MHz): δ 13.99 (s, 1H), 9.12 (s, 1H), 8.24 (s, 1H), 7.66-7.63 (m, 3H), 7.56-7.54 (m, 1H), 7.14 (d, 1H), 6.89 (d, 1H), 5.01 (s, 2H), 2.51 (m, 1H), 1.21-1.15 (m, 4H).
<Example 109> 7-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2,3-dimethylquinoxaline-5-carboxylic acid; (I-109)
Step 1 : Preparation of methyl 7-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2,3-dimethylquinoxaline-5-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(200mg, 0.52mmol) was reacted with methyl 7-bromo-2,3-dimethylquinoxaline-5-carboxylate(153mg, 0.52mmol), bis( triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 42mg, 0.0.6mmol), copper(I) iodide(11.4mg, 0.06mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.4ml, 2.6mmol) to afford the intermediate compound methyl 7-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2,3-dimethylquinoxaline-5-carboxylate(190mg, 65%).
1H-NMR (CDCl3, 400MHz): δ 8.24 (d, 1H), 8.11 (d, 1H), 7.45-7.32 (m, 4H), 6.89 (d, 1H), 6.72-6.70 (dd, 1H), 4.84 (s, 2H), 4.04 (s, 3H), 2.76 (s, 3H), 2.73 (s, 3H), 2.16 (m, 1H), 1.30-1.24 (m, 2H), 1.20-1.16 (m, 2H).
Step 2 : Preparation of 7-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2,3-dimethylquinoxaline-5-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(190mg, 0.31mmol) was reacted with lithium hydroxide(130mg, 3.1mmol) to afford the title compound(63mg, 33%).
1H-NMR (DMSO, 400MHz): δ 14.52 (s, 1H), 8.31 (d, 1H), 8.25 (d, 1H), 7.64-7.62 (m, 3H), 7.58-7.54 (m, 1H), 7.13 (d, 1H), 6.88 (m, 1H), 5.01 (s, 2H), 2.77 (s, 3H), 2.67 (s, 3H), 2.51(m, 1H), 1.21-1.14 (m, 2H).
<Example 110> 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-cyclopropylbenzo[d]oxazole-7-carboxylic acid; (I-110)
Step 1 : Preparation of methyl 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-cyclopropylbenzo[d]oxazole-7-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(182mg, 0.43mmol) was reacted with methyl 5-bromo-2-cyclopropylbenzo[d]oxazole-7-carboxylate(117mg, 0.40mmol), bis(triphenylphosphine)palladium(II)dichloride(PdCl2(PPh3)2, 14mg, 0.02mmol), copper(I) iodide(3.8mg, 0.02mmol) and triethylamine(67ul, 0.48mmol) to afford the intermediate compound methyl 5-((2-chloro-4-((5-cyclopropyl-3-(2,6- dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-cyclopropylbenzo[d]oxazole-7-carboxylate(121mg, 48%).
1H-NMR (CDCl3, 400MHz): δ 8.06 (d, 1H), 7.90 (d, 1H), 7.43-7.40 (m, 3H), 7.36-7.31 (m, 1H), 6.88 (d, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 4.00 (s, 3H), 2.32-2.24 (m, 1H), 2.20-2.12 (m, 1H), 1.38-1.33 (m, 2H), 1.32-1.27 (m, 2H), 1.26-1.23 (m, 2H), 1.19-1.15 (m, 2H).
Step 2 : Preparation of 5-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-cyclopropylbenzo[d]oxazole-7-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(120mg, 0.19mmol)was reacted with lithium hydroxide(79.4mg, 1.9mmol) to afford the title compound(102mg, 87.4%).
1H-NMR (DMSO, 400MHz): δ 13.6 (br s, 1H), 7.99 (d, 1H), 7.97 (d, 1H), 7.87-7.62 (m, 2H), 7.57-7.55 (m, 2H), 7.09 (d, 1H), 6.83 (dd, 1H), 4.98 (s, 2H), 2.39-2.30 (m, 1H), 1.26-1.12 (m, 8H).
<Example 111> 2-butyl-5- ((2-chloro-4-( (5- cyclopropyl -3-(2,6- dichloro phenyl) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylic acid; (I-111)
Step 1 : Preparation of methyl 2-butyl-5- ((2-chloro-4-( (5- cyclopropyl -3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(339.3mg, 0.81mmol) was reacted with methyl 5-bromo-2-butylbenzo[d]oxazole-7-carboxylate(230mg, 0.74mmol), bis( triphenylphosphine)palladium(II)dichloride(PdCl2(PPh3)2, 26mg, 0.037mmol), copper(I) iodide(7mg, 0.037mmol) and triethylamine(0.12ml, 0.89mmol) to afford the intermediate compound methyl 2-butyl-5-((2-chloro-4-((5-cyclopropyl-3- (2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylate(260mg, 54%).
1H-NMR (CDCl3, 400MHz): δ 8.11 (d, 1H), 7.98 (d, 1H), 7.44-7.40 (m, 3H), 7.36-7.32 (m, 1H), 6.88 (s, 1H), 6.69 (dd, 1H), 4.82 (s, 2H), 4.02 (s, 3H), 3.01 (t, 2H), 2.16-2.14 (m, 1H), 1.93-1.89 (m, 2H), 1.55-1.40 (m, 2H), 1.31-1.22 (m, 2H), 1.20-1.11 (m, 2H), 1.61 (t, 3H).
Step 2 : Preparation of 2-butyl-5- ((2-chloro-4-( (5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(260mg, 0.40mmol)was reacted with lithium hydroxide(167.9mg, 4mmol) to afford the title compound(203mg, 80%).
1H-NMR (DMSO, 400MHz): δ 13.67 (br s, 1H), 8.06(d, 1H), 7,91 (d, 1H), 7.68-7.61(m, 2H), 7.59-7.54 (m, 2H), 7.09 (d, 1H), 6.85 (dd, 1H), 4.80(s, 2H), 2.99 (t, 2H), 2.10-2.04 (m, 1H), 1.91-1.88 (m, 2H), 1.52-1.38 (m, 2H), 1.21-1.17 (m, 2H), 1.17-1.13 (m, 2H), 1.01 (t, 3H).
<Example 112> 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-4-carboxylic acid; (I-112)
Step 1 : Preparation of methyl 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-4-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(200mg, 0.52mmol) was reacted with methyl 6-bromo-2-methylbenzo[d]oxazole-4-carboxylate(140mg, 0.52mmol), bis (triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 42mg, 0.0.6mmol), copper(I) iodide(11.4mg, 0.06mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.4ml, 2.6mmol) to afford the intermediate compound methyl 6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-4-carboxylate(164mg, 52%).
1H-NMR (CDCl3, 400MHz): δ 8.15 (d, 1H), 7.81 (d, 1H), 7.81-7.26 (m, 4H), 6.89 (d, 1H), 6.72-6.69 (dd, 1H), 4.83 (s, 2H), 4.04 (s, 3H), 3.09-3.04 (m, 3H), 2.14-2.04 (m, 1H), 1.32-1.17 (m, 4H).
Step 2 : Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-4-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(164mg, 0.27mmol)was reacted with lithium hydroxide(113mg, 2.7mmol) to afford the title compound(34mg, 21%).
1H-NMR (DMSO, 400MHz): δ 13.33 (s, 1H), 8.11 (d, 1H), 7.93 (d, 1H), 7.64-7.52 (m, 4H), 7.10 (d, 1H), 6.86-6.83 (dd, 1H), 5.02 (s, 2H), 3.06-3.00 (m, 3H), 1.23-1.08 (m, 4H).
<Example 113> 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-4-carboxylic acid; (I-113)
Step 1 : Preparation of methyl 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-4-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(200mg, 0.52mmol) was reacted with methyl 6-bromo-2-ethylbenzo[d]oxazole-4-carboxylate(148mg, 0.52mmol), bis( triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 42mg, 0.0.6mmol), copper(I) iodide(11.4mg, 0.06mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.4ml, 2.6mmol) to afford the intermediate compound methyl6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl) methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-4-carboxylate(200mg, 62%).
1H-NMR (CDCl3, 400MHz): δ 8.15 (d, 1H), 7.81 (d, 1H), 7.81-7.26 (m, 4H), 6.89 (d, 1H), 6.72-6.69 (dd, 1H), 4.83 (s, 2H), 4.04 (s, 3H), 3.09-3.04 (m, 2H), 2.14-2.04 (m, 1H), 1.47 (q, 3H), 1.32-1.17 (m, 4H).
Step 2 : Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-4-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(200mg, 0.32mmol)was reacted with lithium hydroxide(134mg, 3.2mmol) to afford the title compound(35mg, 18%).
1H-NMR (DMSO, 400MHz): δ 13.33 (s, 1H), 8.11 (d, 1H), 7.93 (d, 1H), 7.64-7.52 (m, 4H), 7.10 (d, 1H), 6.86-6.83 (dd, 1H), 5.02 (s, 2H), 3.06-3.00 (m, 2H), 1.38-1.14 (q, 3H), 1.23-1.08 (m, 4H).
<Example 114> 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-propylbenzo[d]oxazole-4-carboxylic acid; (I-114)
Step 1 : Preparation of methyl 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-propylbenzo[d]oxazole-4-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(200mg, 0.52mmol) was reacted with methyl 6-bromo-2-propylbenzo[d]oxazole-4-carboxylate(155mg, 0.52mmol), bis(triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 42mg, 0.0.6mmol), copper(I) iodide(11.4mg, 0.06mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.4ml, 2.6mmol) to afford the intermediate compound methyl 6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy) phenyl)ethynyl)-2-propylbenzo[d]oxazole-4-carboxylate(191mg, 58%).
1H-NMR (CDCl3, 400MHz): δ 8.15 (d, 1H), 7.81 (d, 1H), 7.43-7.26 (m, 4H), 6.89 (d, 1H), 6.71-6.69 (dd, 1H), 4.83 (s, 2H), 4.03 (s, 3H), 3.01 (q, 2H), 2.18-2.14 (m, 1H), 1.97-1.91 (m, 2H), 1.32-1.19 (m, 4H), 1.20-1.17 (m, 3H).
Step 2 : Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-propylbenzo[d]oxazole-4-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(191mg, 0.30mmol) was reacted with lithium hydroxide(130mg, 3.0mmol) to afford the title compound(37mg, 20%).
1H-NMR (DMSO, 400MHz): δ 13.34 (s, 1H), 8.11 (d, 1H), 7.94 (d, 1H), 7.64-7.53 (m, 4H), 7.11 (d, 1H), 6.86-6.83 (dd, 1H), 4.99 (s, 2H), 2.98 (q, 2H), 1.87-1.81 (m, 2H), 1.23-1.13 (m, 4H), 1.01 (q, 3H).
<Example 115> 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-isopropylbenzo[d]oxazole-4-carboxylic acid; (I-115)
Step 1 : Preparation of methyl 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-isopropylbenzo[d]oxazole-4-carboxylate
This compound was made using the procedure described for example 1(Step 5). Thus, 4-((3-chloro-4-ethynylphenoxy)methyl)-5-cyclopropyl-3-(2,6-dichloro phenyl)isoxazole(Example 5)(200mg, 0.52mmol) was reacted with methyl 6-bromo-2-isopropylbenzo[d]oxazole-4-carboxylate(148mg, 0.52mmol), bis( triphenylphosphine)palladium(II) dichloride(PdCl2(PPh3)2, 42mg, 0.0.6mmol), copper(I) iodide(11.4mg, 0.06mmol) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.4ml, 2.6mmol) to afford the intermediate compound methyl 6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-isopropylbenzo[d]oxazole-4-carboxylate(158mg, 48%).
1H-NMR (CDCl3, 400MHz): δ 8.15 (d, 1H), 7.81 (d, 1H), 7.43-7.26 (m, 4H), 6.89 (d, 1H), 6.71-6.69 (dd, 1H), 4.83 (s, 2H), 4.03 (s, 3H), 2.18-2.14 (m, 2H), 1.32-1.19 (m, 8H).
Step 2 : Preparation of 6-((2- chloro -4-((5- cyclopropyl -3-(2,6- dichlorophenyl ) isoxazol -4-yl)methoxy)phenyl)ethynyl)-2-isopropylbenzo[d]oxazole-4-carboxylic acid
This compound was made using the procedure described for example 1(Step 6). Thus, this intermediate compound(Step 1)(158mg, 0.25mmol)was reacted with lithium hydroxide(105mg, 2.5mmol) to afford the title compound(37mg, 24%).
1H-NMR (DMSO, 400MHz): δ 13.34 (s, 1H), 8.11 (d, 1H), 7.94 (d, 1H), 7.64-7.53 (m, 4H), 7.11 (d, 1H), 6.86-6.83 (dd, 1H), 4.99 (s, 2H), 2.49 (m, 2H), 1.23-1.13 (m, 8H).
<Experiment 1> In vitro test for FXR activity
To evaluate the in vitro test, the invented compounds(from I-1 to I-115) were determined as follows and showed table 1.
1. Determination of Cellular FXR activities
FXR reporter assay was performed to measure cellular FXR activities of the compounds in the present invention. FXR reporter cells with high expression level of human FXR were seeded into 96-well cell culture plates, and incubated for 1~2 hours at 37℃ under 5% CO2 atmosphere. The invented compounds diluted in DMSO with various concentrations were added to the 96-well cell culture plates, and they were incubated for 24 hours at 37℃ under 5% CO2 atmosphere. After incubation, we calculate EC50 by using luciferase substrate. Emax of the compounds in the present invention was calculated where the Emaxof GW-4064, a full FXR agonist, is 100%.
Compound Experiment Compound Experiment
Reporter CellEC50(nM) Emax(%) (GW4064 Emax =100%) Reporter CellEC50(nM) Emax(%) (GW4064 Emax =100%)
WO2000037077GW4064 C 100 I-56 A 96
WO2011020615A1Example 12 D 90 I-58 E 75
WO2009012125A1Example 32 B 89 I-59 D 90
I-1 E >100 I-60 B 98
I-2 E >100 I-61 C 95
I-3 D >100 I-62 C >100
I-4 C 91 I-63 C 78
I-5 D 84 I-64 B >100
I-7 E 85 I-65 C 92
I-8 E 98 I-66 C 92
I-11 E 90 I-67 B >100
I-12 D >100 I-68 E 96
I-13 D 90 I-69 D >100
I-14 D 96 I-70 C >100
I-15 C 82 I-71 D >100
I-16 C 91 I-72 D >100
I-17 D 89 I-73 D >100
I-18 D 87 I-74 A >100
I-19 A 99 I-75 B 93
I-20 C 94 I-76 A >100
I-21 A 92 I-77 A 100
I-22 C 93 I-78 B 89
I-23 C >100 I-81 D >100
I-24 B >100 I-83 B 89
I-25 C 97 I-84 D 98
I-26 D >100 I-86 C 100
I-27 B 91 I-87 D >100
I-28 C 91 I-88 D 97
I-29 C 93 I-89 B 88
I-30 B 92 I-90 D 75
I-31 B >100 I-91 A >100
I-32 C 94 I-92 B 87
I-33 C 99 I-93 D 82
I-34 C 100 I-94 C >100
I-35 D 86 I-95 B >100
I-36 C 93 I-96 A 98
I-37 C 94 I-97 A 94
I-38 C 92 I-98 B >100
I-39 D 85 I-99 C 86
I-40 B 83 I-100 C >100
I-41 B >100 I-101 A 97
I-42 B >100 I-102 D >100
I-43 C >100 I-103 A >100
I-44 D >100 I-104 A 94
I-45 D 88 I-105 A >100
I-46 C 99 I-106 B 96
I-48 D 81 I-107 E >100
I-49 B >100 I-108 B 98
I-50 B >100 I-109 B 100
I-51 D 75 I-110 A 92
I-52 B >100 I-111 B 98
I-53 A 93 I-113 B 96
I-54 A >100 I-114 B >100
I-55 B >100 I-115 B 97
Range A: EC50 ≤ 20
Range B: 20 ＜ EC50 ≤ 60
Range C: 60 ＜ EC50 ≤ 200
Range D: 200 ＜ EC50 ≤ 1,000
Range E: 1,000 ＜ EC50
According to the above table 1, we confirmed that the compounds in the present invention were FXR agonists by cell-based assay. The compounds with enhanced cellular FXR activities exhibited better activity than GW-4064, a full FXR agonist.
<Experiment 2> Mouse Pharmacokinetics
To evaluate the pharmacokinetics test, the invented 18 compounds of examples were determined as follows. Blood samples are collected at 15, 30, 60, 120, 240, 480, 1140 min. Quantification is by using a LC-MS/MS method specific to the selected compound. Pharmarcokinetics parameters are calculated using WinNonLinnon compartmental analysis software.
Compound AUC[ng/mL*hr] Compound AUC[ng/mL*hr] Compound AUC[ng/mL*hr]
WO2000037077GW4064 253.31 I-20 438.46 I-54 934.16
WO2011020615A1Example 12 352.09 I-21 6139.28 I-63 11876.91
WO2009012125A1Example 32 85.29 I-25 722.38 I-77 1006.29
I-2 277.37 I-28 1778.58 I-89 270.97
I-3 759.60 I-30 680.21 I-91 543.65
I-15 521.09 I-38 1000.33 I-99 205.49
I-16 2246.42 I-52 3309.52 I-106 2246.42
As can be seen from table 2, The selected compounds showed significant pharmacokinetics in Balb/c male mice.

Claims (8)

  1. A compound represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
    [Formula I]
    Figure PCTKR2018004277-appb-I000207
    In the present Formula I,
    Y is carbon or nitrogen,
    R1 and R2 are each independently hydrogen, halo or trifluoromethyl,
    Z is
    Figure PCTKR2018004277-appb-I000208
    or
    Figure PCTKR2018004277-appb-I000209
    ,
    n is 0, 1 or 2,
    X1, X2 and X3 are each independently carbon or nitrogen,
    R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
    Figure PCTKR2018004277-appb-I000210
    ,
    Figure PCTKR2018004277-appb-I000211
    ,
    Figure PCTKR2018004277-appb-I000212
    ,
    Figure PCTKR2018004277-appb-I000213
    , CONRa1Ra2, NRa1Ra2, CH2NRa1Ra2, CH2Rc3, CORa3, ORa3, NRa4CORa3, NRa4CO2Ra3, NHCONHRa3, NHSO2Ra3 or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
    wherein, m is 1 or 2,
    Ra1 and Ra2 are each independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
    Figure PCTKR2018004277-appb-I000214
    or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
    Ra3 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl,
    Figure PCTKR2018004277-appb-I000215
    ,
    Figure PCTKR2018004277-appb-I000216
    ,
    Figure PCTKR2018004277-appb-I000217
    or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
    Ra4 is hydrogen or C1-6 alkyl,
    R5 is hydrogen,
    Figure PCTKR2018004277-appb-I000218
    ,
    Figure PCTKR2018004277-appb-I000219
    ,
    Figure PCTKR2018004277-appb-I000220
    ,
    Figure PCTKR2018004277-appb-I000221
    ,
    Figure PCTKR2018004277-appb-I000222
    or
    Figure PCTKR2018004277-appb-I000223
    ,
    R6 and R7 are each independently hydrogen, halo, trifluoromethyl or trifluoromethoxy,
    Rc3 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl,
    W1, W2 and W3 are each independently oxygen, nitrogen, CHRw1, CRw1, NRw1 or CO,
    wherein, Rw1 is hydrogen, halo, C1-6 alkyl, C3-6 cycloalkyl, halo C1-6 alkyl, C1-6 alkylamine, C1-6 alkyl alcohol,
    Figure PCTKR2018004277-appb-I000224
    ,
    Figure PCTKR2018004277-appb-I000225
    (CH2)p heteroaryl or (CH2)p aryl, wherein, p is 1, 2 or 3.
  2. The compound according to claim 1,
    R3 and R4 are each independently hydrogen, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, trifluoromethyl,
    Figure PCTKR2018004277-appb-I000226
    ,
    Figure PCTKR2018004277-appb-I000227
    ,
    Figure PCTKR2018004277-appb-I000228
    ,
    Figure PCTKR2018004277-appb-I000229
    , NRa1Ra2, CH2NRa1Ra2, ORa3,
    Figure PCTKR2018004277-appb-I000230
    , NRa4CO2Ra3,
    Figure PCTKR2018004277-appb-I000231
    ,
    Figure PCTKR2018004277-appb-I000232
    or 3- or 8- membered heterocycles containing one or two oxygen or nitrogen atom(s) therein,
    wherein, m is 1 or 2,
    Ra1 and Ra2 are each independently hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, trifluoroethyl,
    Figure PCTKR2018004277-appb-I000233
    , azetidine or piperidine,
    Ra3 is hydrogen, methyl, ethyl, propyl, tert-butyl, cyclopropyl, trifluoromethyl,
    Figure PCTKR2018004277-appb-I000234
    ,
    Figure PCTKR2018004277-appb-I000235
    ,
    Figure PCTKR2018004277-appb-I000236
    , azetidine, piperidine, piperazine or morpholine,
    Ra4 is hydrogen or methyl,
    Rc3 is hydrogen or methyl,
    Rw1 is hydrogen, methyl, ethyl, propyl, cyclopropyl,
    Figure PCTKR2018004277-appb-I000237
    ,
    Figure PCTKR2018004277-appb-I000238
    ,
    Figure PCTKR2018004277-appb-I000239
    ,
    Figure PCTKR2018004277-appb-I000240
    ,
    Figure PCTKR2018004277-appb-I000241
    ,
    Figure PCTKR2018004277-appb-I000242
    ,
    Figure PCTKR2018004277-appb-I000243
    or
    Figure PCTKR2018004277-appb-I000244
    , Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
  3. The compound according to claim 1,
    R1 and R2 are each independently hydrogen, chloro or trifluoromethyl,
    wherein, when the Z is
    Figure PCTKR2018004277-appb-I000245
    ,
    R3 and R4 are each independently hydrogen, chloro, fluoro, iodo, cyano, methyl, ethyl, isopropyl, cyclopropyl, trifluoromethyl,
    Figure PCTKR2018004277-appb-I000246
    ,
    Figure PCTKR2018004277-appb-I000247
    ,
    Figure PCTKR2018004277-appb-I000248
    ,
    Figure PCTKR2018004277-appb-I000249
    , NRa1Ra2, CH2NRa1Ra2, NRa4CO2Ra3, azetidine, piperazine or pyrrolidine,
    wherein, Ra1 and Ra2 are each independently hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, trifluoroethyl,
    Figure PCTKR2018004277-appb-I000250
    , azetidine, piperidine or oxetane,
    Ra3 is hydrogen, methyl, ethyl, tert-butyl, cyclopropyl, trifluoromethyl,
    Figure PCTKR2018004277-appb-I000251
    ,
    Figure PCTKR2018004277-appb-I000252
    ,
    Figure PCTKR2018004277-appb-I000253
    , azetidine, piperidine, piperazine or morpholine,
    Ra4 is hydrogen, methyl or ethyl, Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
  4. The compound according to claim 1, R1 and R2 are each independently hydrogen, chloro or fluoro,
    wherein, when the Z is
    Figure PCTKR2018004277-appb-I000254
    ,
    n is 0 or 1,
    R5 is
    Figure PCTKR2018004277-appb-I000255
    ,
    W1, W2 and W3 are each independently oxygen, nitrogen, CRw1 or NRw1,
    wherein, Rw1 is hydrogen, methyl, ethyl, isopropyl, cyclopropyl,
    Figure PCTKR2018004277-appb-I000256
    ,
    Figure PCTKR2018004277-appb-I000257
    ,
    Figure PCTKR2018004277-appb-I000258
    ,
    Figure PCTKR2018004277-appb-I000259
    ,
    Figure PCTKR2018004277-appb-I000260
    or
    Figure PCTKR2018004277-appb-I000261
    , Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
  5. The compound according to claim 1, wherein, the compound represented by Formula I is selected from the group consisting of following compounds and by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof:
    4-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid;
    4-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid;
    4-((4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)phenyl)ethynyl)benzoic acid;
    4-((3-chloro-4-(phenylethynyl)phenoxy)methyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole;
    methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)phenyl)ethynyl)benzoate;
    methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoate;
    methyl 3-((tert-butoxycarbonyl)amino)-5-((2-chloro-4-((5-cyclopropyl- 3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoate;
    methyl 3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)(methyl)amino)benzoate;
    ethyl (3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol- 4-yl)methoxy)phenyl)ethynyl)phenyl)carbamate;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzenesulfonamide;
    N-(3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)phenyl)methanesulfonamide;
    N-(3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)phenyl)sulfamide;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)nicotinic acid;
    2-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)isonicotinic acid;
    6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)picolinic acid;
    5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)nicotinic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(dimethylamino)benzoic acid;
    6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)picolinic acid;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-(dimethylamino)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(diethylamino)benzoic acid;
    3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-(dimethylamino)benzoic acid;
    3-chloro-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    4-chloro-3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    2-chloro-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-fluorobenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-ethynylbenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-cyanobenzoic acid;
    3-((2,6-dichloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    2-chloro-3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoic acid;
    5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-fluorobenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-fluorobenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(trifluoromethoxy)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-methoxybenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-formylbenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropylamino)methyl)benzoic acid;
    3-(azetidin-1-ylmethyl)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((methylamino)methyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((ethylamino)methyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(((2,2,2-trifluoroethyl)amino)methyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((isopropylamino)methyl)benzoic acid;
    3-((tert-butylamino)methyl)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((dimethylamino)methyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(morpholinomethyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((oxetan-3-ylamino)methyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methylamino)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(ethylamino)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(isopropylamino)benzoic acid;
    3-(azetidin-1-yl)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(pyrrolidin-1-yl)benzoic acid;
    3-(azetidin-3-ylamino)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid hydrochloride;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(piperidin-4-ylamino)benzoic acid hydrochloride;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(piperazin-1-yl)benzoic acid hydrochloride;
    3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-methylbenzoic acid;
    3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-4-methoxybenzoic acid;
    3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methoxybenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-methylbenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-cyclopropylbenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-ethylbenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-isopropylbenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-iodobenzoic acid;
    3-((2,5-dichloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2,3-dichloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-6-fluorophenyl)ethynyl)benzoic acid;
    3-amino-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methylbenzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(3-ethylureido)benzoic acid;
    3-acetamido-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)amino)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((ethoxycarbonyl)(methyl)amino)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-((cyclopropoxycarbonyl)amino)benzoic acid;
    3-((tert-butoxycarbonyl)amino)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((tert-butoxycarbonyl)(methyl)amino)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(((cyclopropylmethoxy)carbonyl)amino)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(((2-cyclopropylethoxy)carbonyl)amino)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(((2-hydroxyethoxy)carbonyl)amino)benzoic acid;
    3-(((azetidin-3-yloxy)carbonyl)amino)-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(2-oxooxazolidin-3-yl)benzoic acid;
    5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)isophthalic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(piperazine-1-carbonyl)benzoic acid hydrochloride;
    3-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-5-(methylsulfonamido)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    3-((2-chloro-4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzoic acid;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indazole-6-carboxylic acid;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-benzo[d]imidazole-6-carboxylic acid;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indole-6-carboxylic acid;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-(dimethylamino)ethyl)-1H-indole-6-carboxylic acid;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(3-(isopropylamino)propyl)-1H-indole-6-carboxylic acid;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(pyridin-4-ylmethyl)-1H-indole-6-carboxylic acid;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-morpholinoethyl)-1H-indole-6-carboxylic acid hydrochloride;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2,2-dimethoxyethyl)-1H-indole-6-carboxylic acid;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxyethyl)-1H-indole-6-carboxylic acid;
    4-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1-(2-hydroxy-2-methylpropyl)-1H-indole-6-carboxylic acid;
    6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indazole-4-carboxylic acid;
    6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indazole-4-carboxylic acid;
    6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-1H-indole-4-carboxylic acid;
    5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylic acid;
    5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-7-carboxylic acid;
    5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-7-carboxylic acid;
    5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-propylbenzo[d]oxazole-7-carboxylic acid;
    5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-isopropylbenzo[d]oxazole-7-carboxylic acid;
    5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-(hydroxymethyl)benzo[d]oxazole-7-carboxylic acid;
    7-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)quinoxaline-5-carboxylic acid;
    7-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2,3-dimethylquinoxaline-5-carboxylic acid;
    5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-cyclopropylbenzo[d]oxazole-7-carboxylic acid;
    2-butyl-5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)benzo[d]oxazole-7-carboxylic acid;
    6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-methylbenzo[d]oxazole-4-carboxylic acid;
    6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-ethylbenzo[d]oxazole-4-carboxylic acid;
    6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-propylbenzo[d]oxazole-4-carboxylic acid; and
    6-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)ethynyl)-2-isopropylbenzo[d]oxazole-4-carboxylic acid.
  6. A pharmaceutical composition for the treatment, prevention, or amelioration of metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis comprising the compound according to any one of claims 1-5 and represented by Formula I, racemic, enantiomer, diastereoisomer thereof, or pharmaceutically acceptable salt thereof.
  7. The pharmaceutical composition according to claim 6,
    wherein, the metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis are treated, prevented, or ameliorated by activation of FXR receptors.
  8. The pharmaceutical composition according to claim 6,
    wherein, the metabolic diseases, cholestatic Liver Diseases and Organ Fibrosis are selected from the group consisting of hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, dyslipidemia, lipodystrophy, cholestasis/fibrosis, cholesterol gallstone disease, gastrointestinal disease or condition, hyperglycemia, diabetes, insulin resistance, metabolic inflexibility, nephropathy, liver diseases, atherosclerosis, cancer, inflammatory disorders, osteoporosis and skin aging.
PCT/KR2018/004277 2017-04-12 2018-04-12 An isoxazole derivatives as nuclear receptor agonists and used thereof Ceased WO2018190643A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
DK18785171.2T DK3612520T3 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
AU2018252880A AU2018252880B2 (en) 2017-04-12 2018-04-12 An isoxazole derivatives as nuclear receptor agonists and used thereof
ES18785171T ES2904294T3 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
SG11201908235R SG11201908235RA (en) 2017-04-12 2018-04-12 An isoxazole derivatives as nuclear receptor agonists and used thereof
US16/604,180 US10988449B2 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
CA3059869A CA3059869C (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
LTEPPCT/KR2018/004277T LT3612520T (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
MX2019012167A MX394743B (en) 2017-04-12 2018-04-12 ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND THEIR USES
RS20211546A RS62711B1 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
SI201830504T SI3612520T1 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
CN201880024769.3A CN110678450B (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
JP2020506694A JP6886074B2 (en) 2017-04-12 2018-04-12 Isoxazole derivatives that are nuclear receptor efficacy agents and their uses
EP18785171.2A EP3612520B1 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
IL269896A IL269896B (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
BR112019021320-1A BR112019021320B1 (en) 2017-04-12 2018-04-12 COMPOUND AND PHARMACEUTICAL COMPOSITION
HRP20220026TT HRP20220026T1 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
PL18785171T PL3612520T3 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
SM20220175T SMT202200175T1 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
MYPI2019006047A MY198265A (en) 2017-04-12 2018-04-12 Isoxazole Derivatives as Nuclear Receptor Agonists and uses Thereof
RU2019132135A RU2741306C1 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and use thereof
NZ758117A NZ758117A (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
PE2019002025A PE20191792A1 (en) 2017-04-12 2018-04-12 ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES OF THEM
ZA2019/06541A ZA201906541B (en) 2017-04-12 2019-10-04 Isoxazole derivatives as nuclear receptor agonists and uses thereof
PH12019502326A PH12019502326A1 (en) 2017-04-12 2019-10-11 An isoxazole derivatives as nuclear receptor agonists and used thereof
US17/191,806 US11912674B2 (en) 2017-04-12 2021-03-04 Isoxazole derivatives as nuclear receptor agonists and uses thereof
CY20221100082T CY1124936T1 (en) 2017-04-12 2022-02-01 ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGENTS AND USES THEREOF
US18/420,478 US20240262799A1 (en) 2017-04-12 2024-01-23 Isoxazole derivatives as nuclear receptor agonists and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0047393 2017-04-12
KR20170047393 2017-04-12
KR10-2018-0042545 2018-04-12
KR1020180042545A KR102168543B1 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonist and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/604,180 A-371-Of-International US10988449B2 (en) 2017-04-12 2018-04-12 Isoxazole derivatives as nuclear receptor agonists and uses thereof
US17/191,806 Continuation US11912674B2 (en) 2017-04-12 2021-03-04 Isoxazole derivatives as nuclear receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
WO2018190643A1 true WO2018190643A1 (en) 2018-10-18

Family

ID=63792982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/004277 Ceased WO2018190643A1 (en) 2017-04-12 2018-04-12 An isoxazole derivatives as nuclear receptor agonists and used thereof

Country Status (1)

Country Link
WO (1) WO2018190643A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329286B2 (en) 2016-06-13 2019-06-25 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US10421730B2 (en) 2016-06-13 2019-09-24 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US10450306B2 (en) 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2021009332A1 (en) 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
WO2021014350A1 (en) 2019-07-23 2021-01-28 Novartis Ag Combination treatment of liver diseases using fxr agonists
WO2021014349A1 (en) 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
WO2021044287A1 (en) 2019-09-03 2021-03-11 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists
WO2021053618A1 (en) 2019-09-19 2021-03-25 Novartis Ag Treatment comprising fxr agonists
WO2021064575A1 (en) 2019-09-30 2021-04-08 Novartis Ag Treatment comprising the use of fxr agonists
WO2021109712A1 (en) 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd. Compounds for modulating activity of fxr and uses thereof
WO2021127466A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
US11225473B2 (en) 2019-01-15 2022-01-18 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
WO2022152770A1 (en) 2021-01-14 2022-07-21 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
KR20230072437A (en) 2021-11-17 2023-05-24 일동제약(주) Preparation method of isoxazole derivatives and intermediates thereof
KR20230072438A (en) 2021-11-17 2023-05-24 일동제약(주) Preparation method of isoxazole derivatives and intermediates thereof
WO2023090859A1 (en) * 2021-11-17 2023-05-25 일동제약(주) Method for preparing isoxazole derivative, and novel intermediate therefor
WO2023090858A1 (en) * 2021-11-17 2023-05-25 일동제약(주) Method for preparing isoxazole derivative, and intermediate thereof
US11833150B2 (en) 2017-03-28 2023-12-05 Gilead Sciences, Inc. Methods of treating liver disease
US11958879B2 (en) 2015-03-31 2024-04-16 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007230909A (en) * 2006-03-01 2007-09-13 Univ Of Tokyo Substituted isoxazole derivatives
WO2009005998A1 (en) * 2007-07-02 2009-01-08 Smithkline Beecham Corporation Farnesoid x receptor agonists
WO2011020615A1 (en) * 2009-08-19 2011-02-24 Phenex Pharmaceuticals Ag Novel fxr (nr1h4 ) binding and activity modulating compounds
KR20130109210A (en) * 2010-12-20 2013-10-07 아이알엠 엘엘씨 Compositions and methods for modulating fxr

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007230909A (en) * 2006-03-01 2007-09-13 Univ Of Tokyo Substituted isoxazole derivatives
WO2009005998A1 (en) * 2007-07-02 2009-01-08 Smithkline Beecham Corporation Farnesoid x receptor agonists
WO2011020615A1 (en) * 2009-08-19 2011-02-24 Phenex Pharmaceuticals Ag Novel fxr (nr1h4 ) binding and activity modulating compounds
KR20130109210A (en) * 2010-12-20 2013-10-07 아이알엠 엘엘씨 Compositions and methods for modulating fxr

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BASS, J. Y. ET AL.: "Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064", BIOORGANIC & MEDICINAL , CHEMISTRY LETTERS, vol. 19, no. 11, 1 June 2009 (2009-06-01), pages 2969 - 2973, XP029439814, Retrieved from the Internet <URL:doi:10.1016/j.bmcl.2009.04.047> *
KAINUMA, M. ET AL.: "Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 15, no. 7, 1 April 2007 (2007-04-01), pages 2587 - 2600, XP005922449, Retrieved from the Internet <URL:https://doi.org/10.1016/j.bmc.2007.01.046> *
See also references of EP3612520A4 *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11958879B2 (en) 2015-03-31 2024-04-16 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10421730B2 (en) 2016-06-13 2019-09-24 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US10774054B2 (en) 2016-06-13 2020-09-15 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US11739065B2 (en) 2016-06-13 2023-08-29 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US10981881B2 (en) 2016-06-13 2021-04-20 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US12358903B2 (en) 2016-06-13 2025-07-15 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US10329286B2 (en) 2016-06-13 2019-06-25 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US11247986B2 (en) 2016-06-13 2022-02-15 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US10450306B2 (en) 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US11034684B2 (en) 2016-10-04 2021-06-15 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
US11833150B2 (en) 2017-03-28 2023-12-05 Gilead Sciences, Inc. Methods of treating liver disease
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US11225473B2 (en) 2019-01-15 2022-01-18 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US12102625B2 (en) 2019-02-19 2024-10-01 Gilead Sciences, Inc. Solid forms of FXR agonists
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2021009332A1 (en) 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
WO2021014349A1 (en) 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
WO2021014350A1 (en) 2019-07-23 2021-01-28 Novartis Ag Combination treatment of liver diseases using fxr agonists
WO2021044287A1 (en) 2019-09-03 2021-03-11 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists
WO2021053618A1 (en) 2019-09-19 2021-03-25 Novartis Ag Treatment comprising fxr agonists
WO2021064575A1 (en) 2019-09-30 2021-04-08 Novartis Ag Treatment comprising the use of fxr agonists
WO2021109712A1 (en) 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd. Compounds for modulating activity of fxr and uses thereof
JP7611916B2 (en) 2019-12-03 2025-01-10 ガンネックス ファーマ カンパニー リミテッド Compounds for the Modulation of FXR and Uses Thereof - Patent application
JP2023505205A (en) * 2019-12-03 2023-02-08 ガンネックス ファーマ カンパニー リミテッド Compounds and uses thereof for modulating activity of FXR
EP4073070A4 (en) * 2019-12-03 2023-10-18 Gannex Pharma Co., Ltd. COMPOUNDS FOR MODULATING FXR ACTIVITY AND THEIR USES
WO2021127466A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
WO2022152770A1 (en) 2021-01-14 2022-07-21 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
WO2023090858A1 (en) * 2021-11-17 2023-05-25 일동제약(주) Method for preparing isoxazole derivative, and intermediate thereof
WO2023090859A1 (en) * 2021-11-17 2023-05-25 일동제약(주) Method for preparing isoxazole derivative, and novel intermediate therefor
KR20230072438A (en) 2021-11-17 2023-05-24 일동제약(주) Preparation method of isoxazole derivatives and intermediates thereof
KR20230072437A (en) 2021-11-17 2023-05-24 일동제약(주) Preparation method of isoxazole derivatives and intermediates thereof
TWI833451B (en) * 2021-11-17 2024-02-21 南韓商日東製藥股份有限公司 Preparation method of isoxazole derivatives and intermediates thereof
TWI838964B (en) * 2021-11-17 2024-04-11 南韓商日東製藥股份有限公司 Preparation method of isoxazole derivatives and intermediates thereof

Similar Documents

Publication Publication Date Title
WO2018190643A1 (en) An isoxazole derivatives as nuclear receptor agonists and used thereof
EP3612520A1 (en) An isoxazole derivatives as nuclear receptor agonists and used thereof
WO2021187886A1 (en) Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
WO2010093191A2 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
WO2017018804A1 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
WO2011043568A2 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
EP3362445A1 (en) Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3116859A1 (en) Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
WO2009145456A2 (en) Heterocyclic derivatives
WO2013081400A2 (en) Novel benzamide derivative and use thereof
EP2906558A1 (en) Sodium channel blockers, preparation method thereof and use thereof
WO2020096372A1 (en) Novel piperidine-2,6-dione derivative and use of same
WO2021137665A1 (en) 1, 2, 3-triazole derivative compound as hsp90 inhibitor, and use thereof
WO2021086038A1 (en) Novel compound and pharmaceutical composition for prevention or treatment of cancer comprising same
WO2015102426A1 (en) Novel indole derivative compound and pharmaceutical composition comprising the same
WO2021172887A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP2943474A1 (en) Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
EP3060549A1 (en) Novel antifungal oxodihydropyridinecarbohydrazide derivative
WO2013165140A1 (en) Benzyl derivative compound containing activated vinyl group capable of being used for preventing and treating neurological disorders through nitric oxide generation inhibition and nrf2 activation, and pharmaceutical composition thereof
EP4110780A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2023080652A1 (en) Androgen receptor degraders for the treatment of castration-resistant prostate cancer and use thereof
WO2015016511A1 (en) Novel biphenyl derivative and method for preparing same
WO2011102660A2 (en) A novel 5-membered heterocycle derivatives and manufacturing process thereof
WO2021210857A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2025034034A1 (en) Novel compound, and pharmaceutical composition for prevention or treatment of cancer or tumors comprising same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18785171

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3059869

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020506694

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018252880

Country of ref document: AU

Date of ref document: 20180412

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019021320

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018785171

Country of ref document: EP

Effective date: 20191112

ENP Entry into the national phase

Ref document number: 112019021320

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20191010